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Abstract of Thesis 
Creutzfeldt-Jakob disease (CJD) is the commonest form of human prion disease and 
occurs in sporadic, genetic and acquired forms. The causative agents (prions) appear 
to be composed entirely of a modified host protein, the prion protein, which 
undergoes misfolding to a disease-associated isoform closely associated with 
infectivity that is resistant to conventional methods of decontamination. Prions can 
be transmitted from one individual to another by medical and surgical procedures, 
resulting in iatrogenic CJD (iCJD). The commonest cause of iCJD is the inoculation 
of cadaveric pituitary-derived human growth hormone (hGH) to treat growth 
hormone deficiency in children; this form of treatment was abandoned in 1985 after 
the first UK case of iCJD in a hGH recipient was identified.  Seventy-eight cases of 
iCJD have since occurred in the UK cohort of 1849 hGH recipients, including a case 
in 2016.  
This thesis describes a comprehensive tissue-based and molecular genetic analysis of 
the largest series (35 cases) of UK hGH-iCJD cases reported to date, including in 
vitro kinetic molecular modelling of genotypic factors influencing prion 
transmission. The results show that the polymorphism at codon 129 of the prion 
protein gene strongly influences the disease incubation period in hGH-iCJD (from 
7.8-32.3 years in this series) and interacts with the infectious prion strain to govern 
the molecular and pathological characteristics of iCJD. The findings are consistent 
with the hypothesis that the UK hGH-iCJD epidemic resulted from transmission of 
the V2 human prion strain, which is found in the second most common form of 
sporadic CJD.  
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The investigation also found accumulation of the amyloid beta (A) protein 
associated with Alzheimer’s disease (AD) in the brains and cerebral blood vessels in 
18/35 hGH-iCJD patients and 5/12 control patients who had been treated with hGH, 
but died from causes other than iCJD. In contrast, A accumulation was markedly 
less prevalent in age-matched patients who died from sporadic CJD (1/15 cases) and 
variant CJD (2/33 cases). These results are consistent with the hypothesis that A, 
which can accumulate in the pituitary gland, was present in the inoculated hGH 
preparations and seeded into the brains of around 50% of all hGH recipients, 
producing AD-like neuropathology and cerebral amyloid angiopathy (CAA). This 
provides further evidence of the prion-like properties of A and gives insight into the 
potential for possible transmission of AD/CAA. It is uncertain whether any A 
seeding within the brains of surviving patients in the UK hGH recipient cohort will 
ultimately result in clinical AD; however, the CAA in these patients may be 
complicated by intracerebral haemorrhage resulting from rupture of the blood vessels 













Creutzfeldt-Jakob disease (CJD) is a rare fatal neurological disease that can occur by 
chance, or within a family, or be acquired by accidental transmission from one 
individual to another. The transmissible agents in CJD are known as prions, which 
are composed of an abnormal form of the human prion protein that has undergone a 
change in its shape and become infectious. Prions are very resistant to standard 
cleaning and decontamination processes. Accidental transmission of CJD can occur 
after certain medical or surgical procedures. The commonest procedure resulting in 
accidental transmission of CJD is treatment with injections of human growth 
hormone (GH) obtained from the pituitary gland (at the base of the brain) obtained 
from deceased individuals at autopsy. This hormone was used to treat children with 
short stature who were deficient in growth hormone, starting in the 1960s. In 1985, a 
case of acquired CJD was identified in a UK patient who had been treated with GH, 
after which this form of treatment was stopped. However, cases of acquired CJD 
continue to occur in the group of 1849 UK patients treated with GH, most recently in 
2016, indicating that incubation periods for this disease can be very long indeed.  
This project investigates a group of 35 UK patients with acquired CJD following GH 
treatment. We have performed genetic studies, showing that the incubation period for 
acquired CJD is strongly influenced by a variable part of the gene that produces the 
prion protein. This gene also interacts with the prions causing acquired CJD and 
influences the patterns of brain damage that occur in these patients. We have 
conducted experiments to study how these genetic influences work, which suggest 
that a particular strain of prions (known as the V2 strain) is likely to have caused the 
acquired CJD in this group of patients.  
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We also investigated another protein, amyloid beta (A), which accumulates in the 
brain in a commoner fatal neurological disease, Alzheimer’s disease (AD). A can 
also accumulate in the pituitary gland, and could have been present in the GH 
preparations used to treat the groups of patients in our study. We observed A 
accumulation in the brain and in blood vessels around the brain in around half of all 
the patients we examined with acquired CJD, and also in around half of a smaller 
group of patients who were treated with GH, but died from causes other than CJD. 
These findings suggest that A from the GH injections can spread in the body and 
“seed” in the brain and its blood vessels.  We are not sure if this means that any of 
the surviving group of UK GH recipients might develop AD in the future. However, 
they might be at increased risk of a haemorrhage in the brain from blood vessels that 
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1. Introduction 
1.1. Introduction to prion diseases 
Prion diseases (also known as the transmissible spongiform encephalopathies or TSEs) 
are a group of fatal neurodegenerative disorders that affect both animals and humans 
and are associated with spongiform degeneration of the grey matter of the central 
nervous system (CNS) (Table 1.1). The CNS is the target system for prion diseases, 
within which high levels of infectivity (over 108 intracerebral Ld50/g) are reached 
during the clinical disease (Robinson et al., 1990). Unlike commoner human 
neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s 
disease (PD), human prion diseases are transmissible between individuals, with 
incubation periods measuring up to several decades (Ironside, 1998). The naturally 
occurring animal prion diseases are similarly transmissible; one of these diseases, 
bovine spongiform encephalopathy (BSE), has not only transmitted to a wide range of 
animal species (Table 1.1), but has also spread as a zoonotic infection to humans, 
resulting in variant Creutzfeldt-Jakob disease (vCJD) (Will et al., 1996).  
 
1.1.1. A brief history of prions 
Scrapie is the archetypal prion disease, described in the 18th century (Brown & Bradley 
1998), but not demonstrated to be transmissible until 1936 (Cuillé & Chelle, 1936). 
Cuillé & Chelle assumed that some type of virus was the most likely causative agent 
and the term “slow virus infection” was proposed by Sigurdsson in 1954 because of 
the prolonged incubation periods associated with scrapie transmission (Sigurdsson, 
1954). This assumption was challenged by subsequent studies of the scrapie agent, 
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Table 1.1.  
Classification of human and animal prion diseases 
 
Human prion diseases 
Idiopathic Sporadic Creutzfeldt-Jakob disease 
 Sporadic fatal insomnia 
 Variably protease-sensitive prionopathy 
Genetic  Familial Creutzfeldt-Jakob disease 
 Gerstmann-Sträussler-Scheinker syndrome 
 Fatal familial insomnia 
 Prion protein cerebral amyloid angiopathy 
Acquired  
Human origin: Kuru 
 Iatrogenic Creutzfeldt-Jakob disease  
Bovine origin:  Variant Creutzfeldt-Jakob disease 
 
Animal prion diseases 
Acquired  Scrapie (sheep, goats, mouflon) – classical 
 and atypical forms (e.g. Nor 98) 
 Chronic wasting disease (white-tailed deer, 
 mule deer, elk, caribou, moose) 
 Transmissible mink encephalopathy  
 Bovine spongiform encephalopathy (domestic 
cattle) – classical and atypical forms  
 Novel prion diseases related to bovine 
 spongiform encephalopathy occur as : 
 (a) Feline spongiform encephalopathy in 
domestic cats and Asian golden cat, cheetah, 
lion, ocelot, puma, tiger  
(b) exotic ungulate encephalopathy in zoo 
animals (American bison, Ankole cow, Arabian 
oryx, eland, gemsbok, greater kudu, nyala, 
scimitar-horned oryx) 
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which was found to be of remarkably small size and resistant to conventional methods 
of pathogen inactivation, including high temperatures, treatment with nucleases and 
ionising radiation (reviewed in Alper et al., 1978). Furthermore, no virus particles or 
nucleic acids were identified and no evidence of a host immune response to the scrapie 
agent could be found. These results led to the suggestions that the scrapie agent did 
not depend upon nucleic acid for replication (Alper et al., 1967) and that the agent 
might be composed only of protein (Griffith, 1967), which were received with 
considerable scepticism.  
 
Subsequent work on rodent-passaged scrapie brain homogenates identified a 
glycoprotein that was the main constituent of the most highly infective brain 
homogenate fractions and accumulated in the brains of infected animals, sometimes 
forming amyloid structures (Prusiner et al., 1978). Prusiner published the prion 
hypothesis in 1982: the term prion (from proteinaceous infectious particle) was 
proposed to distinguish the infectious scrapie pathogen from viruses or viroids 
(Prusiner, 1982). Prions were defined as “small proteinaceous infectious particles that 
resist inactivation by procedures which modify nucleic acids”. The gene encoding the 
prion protein was identified in 1985 (Oechs et al., 1985), and its product, the cellular 
prion protein (PrPC) was found to have the same amino acid sequence as the disease-
associated prion protein (PrPSc), but with a different structure and physicochemical 
properties (see below) (Borchelt et al., 1990; Caughey & Raymond, 1991) (Figure 1.1). 
 
Since the publication of this initially controversial hypothesis, a substantial body of 
experimental evidence has been published to support the prion hypothesis, although 
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contrary (but increasingly solitary) views persist (Botsios & Manuelidis, 2016). In 
particular, a range of novel synthetic prion strains has been generated from misfolded 
recombinant prion protein in vitro, some with high titres of infectivity that cause 
disease in wild-type mice (Legname et al., 2004; Kim et al., 2010; Makarava et al., 
2010). Another approach to the de novo in vitro generation of prion strains has 
employed protein misfolding cyclical amplification (PMCA) methodology (see 
below), in which manipulation of the conditions under which the reaction occurs can 
influence the biological properties of the prion strains generated (Castilla et al., 2005; 
Barria et al., 2009). 
 
1.2. Prion biology 
1.2.1. PrPC  
The normal (cellular) form of the prion protein, PrPC, has a three-exon structure in 
most species and is encoded by a single copy gene. The human prion protein gene 
(PRNP) is located on human chromosome 20p12-pterminus (Sparkes et al., 1986), 
with the final exon encoding the entire open reading frame of PrPC. However, although 
PRNP contains a large exon 2-like sequence, the second exon is not spliced into the 
final mRNA sequence (unlike most other species apart from hamsters) (Lee et al., 
1998). The other exons contain untranslated sequences including the promoter and 
termination sites, and intron 1 has been identified as essential for full promoter activity 
(Mahal et al., 2001).  PRNP is developmentally regulated (Mobley et al., 1988), with 
expression increasing to a steady level in the CNS from 10–20 days post conception 
in the hamster embryo (McKinley et al., 1987) and 13.5 days post conception in the 
mouse (Manson et al., 1992). More recently, PrPC has been shown in vitro to control 
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the differentiation of human embryonic stem cells towards neurone-, oligodendrocyte-, 
and astrocyte-committed lineages and is therefore likely to be involved in the 
differentiation of uncommitted neural progenitor cells in the developing CNS (Lee & 
Baskakov, 2014). 
 
PrPC is highly conserved in many species and is expressed at highest levels in the CNS 
by neurones (enriched at synapses), with lower levels of expression in astrocytes and 
in a wide range of non-CNS tissues including skeletal muscle, heart, lung and platelets 
(Herms et al., 1999). It is a copper-binding glycoprotein that is bound to the outer 
leaflet of the cell membrane by a glycosylphosphatidylinositol (GPI) anchor in lipid 
raft microdomains (Harris et al., 2004) (Figure 1.1). Nascent PrPC is 253 amino acids 
in length, with an unstructured N-terminal region and a structured C-terminal domain 
consisting of 3  helices, a small  sheet region and a signal sequence for the 
attachment of the GP anchor (Alfonso et al., 2007; Linden et al., 2008) (Figure 1.1). 
PrPC undergoes a number of post-translational modifications, which are initiated by 
the removal of the N- and C-terminal signal peptides and importation into the 
endoplasmic reticulum, followed by the attachment of the GPI anchor, attachment of 
2 N-linked glycans and the formation of a disulphide bond between Cys178 and 
Cys213 (Mangé et al., 2004; Hooper, 2005) (Figure 1.2).  
 
A complete loss of PrPC function in prion protein gene “knock-out” transgenic animals 
does not adversely affect the lifespan and reproductive capacity of such animals, 
although a range of other minor phenotypic features have been reported that vary 
according to the transgenic model studied (reviewed in del Rio & Gavin, 2016). PrP 
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null mice are resistant to prion infection (even following intracerebral inoculation), 
emphasising the importance of the conversion of PrPC to nascent PrPSc in the disease 
process; PrPSc when introduced into the CNS by inoculation is not neurotoxic in the 
absence of PrPC (Brandner et al., 1996a, 1996b). PrP null mice and cell lines have also 
been explored closely for evidence of the function of PrPC, sometimes with variable 
and apparently contradictory findings depending on the model system used (reviewed 
in Sakudo & Onodera 2015; del Rio & Gavin, 2016) 
 
The function of PrPC is still incompletely understood; in addition to its metal binding 
properties (Brown et al., 1997), a range of proposed CNS functions include cell 
signalling, neuronal growth and differentiation, synaptic plasticity and 
neuroprotection, particularly against oxidative stress (reviewed in Linden et al., 2008; 
Biasini et al., 2012; Atkinson et al., 2016). In peripheral nerves, PrPC promotes myelin 
homeostasis through flexible tail-mediated Gpr126 agonism (Küffer et al., 2016). In 
other tissues, proposed roles for PrPC include roles in the development, activation and 
proliferation of T lymphocytes, and in modulating macrophage phagocytosis (Mattei 
et al., 2004; de Almeida et al., 2005). Potential roles in cancer development, 
progression and multi-drug resistance have also been proposed (Zhao et al., 2002: 
Antonagopoulou et al., 2008, 2010) and apparently conflicting roles in both the 
removal of Aβ from the brain and transduction of the toxic actions of Aβ in AD are 








Figure 1.1  




















Cartoon of the 3-dimensional structure of human PrPC (residues 23-230). The helices 
are red, the  strands are cyan and the flexibly disordered C terminal region is 
represented by yellow dots (b) Schematic of PrPC (residues 93-31) in its glycosylated 
form attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. 
The  helices are red, the short anti-parallel  sheet region is blue. The glycans and 
the carbohydrate component of the GPI anchor are orange. The lipid component of the 
GPI anchor and the cell membrane are green. (c) The structure of PrPC contains mostly 
 helical structures (3 red ribbons) and a small portion of  sheet (blue arrows). The 
increase in a sheet (blue arrows) on conversion to PrPSc is depicted in (d). This 
theoretical structure shows the C-terminal -helices to be preserved and (as in PrPC) 
are linked by a disulphide bridge (yellow), but with more extensive -sheet structures 
wound into what has been termed as a -helix. 
Abbreviations: PrPC: cellular prion protein; PrPSc: disease-associated prion protein.   
(a) Courtesy of Professor Kurt Wuthrich, Zurich, Switzerland; (b) Courtesy of Dr Mark Wormald and 
Professors Pauline Rudd and Raymond Dwek, Oxford, UK; (c ,d) Courtesy of Professor Fred Cohen, 







The human prion diseases (Table 1.1) are all characterised by the deposition of disease-
associated PrPSc in the brain. The structure of PrPSc is markedly different from that of 
PrPC and is closely associated with prion infectivity, but PrPSc has the same amino acid 
sequence and undergoes the same post-translational modifications as PrPC (reviewed 
in Silva et al., 2015). PrPC is readily soluble in non-denaturing detergent solutions and 
sensitive to digestion by proteinase K (PK) (Prusiner, 1998a). In contrast, PrPSc has an 
increased β-pleated sheet content, decreased solubility and increased protease-
resistance compared with PrPC, probably as a result of refolding of the central and N-
terminal regions of the protein and self-aggregation (Figure 1.1). PrPSc and PrPC are 
conformational isoforms (Figure 1.1); denaturation of PrPSc results in loss of its 
associated infectivity (Colby & Prusiner, 2011b). 
 
The de novo formation of PrPSc is central to the pathogenesis of prion disease. This 
results from the conversion of PrPC to PrPSc, which is thought to involve other co-
factors (e.g. a hypothesised “protein X”) (Telling et al., 1995); polyanions (RNA and 
glycosaminoglycans) and lipids have been implicated as likely cofactors (reviewed in 
Gill et al., 2010). Although the site of this conversion process is not fully established, 
PrPC molecules on the cell surface of scrapie-infected cells may re-enter the cells 
through cholesterol-rich caveolae domains (Taraboulos et al., 1995). GPI-anchored 
PrPC can then be converted into PrPSc by a templating process in which PrPC refolds 
into a structure with an increased -sheet content without further cleavage or 
alterations in glycosylation (Peters et al., 2003) (Figure 1.1). 
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Despite intensive investigation, the structure of PrPSc is still uncertain; it is difficult to 
obtain in large quantities, insoluble in non-denaturing detergents and has not been 
crystallised. Limited proteolysis by PK has therefore been used to explore the structure 
of PrPSc, which has also been examined by cryo-electron microscopy, X-ray 
diffraction, mass spectrometry and epitope analysis using panels of anti-PrP antibodies 
(reviewed in Silva et al., 2015). Recent molecular modelling studies have suggested 
that each PrPSc monomer is likely to be stacked as a 4-rung  solenoid, with areas of 
high resistance to PK in the  strands, with areas of higher PK sensitivity in turns and 
loops (Vazquez-Fernandez et al., 2012). In this model, the upper and lower  solenoids 
could template an unfolded PrPC molecule, creating additional  solenoid rungs that 
can also participate in the process of templating (Silva et al., 2015). The process of 
PrPC conversion is likely to include an intermediate stage in which the partially 
refolded molecule still retains PK sensitivity (Daude et al., 1997). The presence of 
such molecules (designated senPrPSc) in human prion diseases has been investigated 
by conformation-dependent immunoassay studies on brain biopsy samples (Safar et 
al., 2005). 
 
Partially refolded PrP can form soluble, low molecular weight oligomers that are 
partially resistant to PK, neurotoxic in vitro on primary cultures of neurons and in vivo 
after subcortical stereotaxic injection into the brain (Silveira et al., 2005; Simoneau et 
al., 2007). Antibody rescue studies have shown that exposure of the hydrophobic 
stretch of PrP at the oligomeric surface is necessary for toxicity (Simoneau et al., 2007). 
Monomeric PrPSc was not toxic under these conditions and insoluble, fibrillar forms 
of PrPSc exhibited no toxicity in vitro and were less toxic than their oligomeric 
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counterparts in vivo. These findings suggest that oligomeric species of PrPSc are the 
most toxic forms of the molecule (Aguzzi & Falsig, 2012), as appears to be the case 
for other amyloidogenic proteins in neurodegenerative diseases, e.g. A in AD 
(Salahuddin et al., 2016). Our understanding of the complex processes resulting in 
neuronal neurotoxicity in prion diseases is incomplete.  Suggested mechanisms 
included early impairment of the ubiquitin-proteasome system (McKinnon et al., 
2016), activation of complex cell stress pathways involving the endoplasmic reticulum, 
NAD+ depletion and the RESET pathway (Zhou et al., 2015; Mays & Soto, 2016), 
altered mitochondrial function, protein synthesis machinery and purine metabolism 
(Ansoleaga et al., 2016), or sustained translational repression by elF2-P (Moreno et 
al., 2012). 
 
However, the classical neuropathological changes prion diseases (spongiform change, 
neuronal loss, gliosis and amyloid plaques) may develop in the CNS in some animal 
models in the apparent absence of detectable PrPSc (Lasmezas et al., 1997), although 
these models have not been fully explored for the presence of senPrPSc. Conversely, 
small amounts of insoluble aggregated PrP species (designated iPrPC) can be detected 
in human brains without either clinical or neuropathological evidence of a prion 
disease (Yuan et al., 2006). This finding is of uncertain significance; a role for iPrPC 
in binding to A species has been suggested, potentially increasing A toxicity at 
neuronal synapses in aging and in AD (Xiao et al., 2012).   
 
1.2.3. Prion strains 
Serial passage of sheep scrapie in mice by intracerebral inoculation has identified  
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distinct strains of the transmissible agent on the basis of individual biological 
properties that become stable on serial passage (Bruce et al., 1993). These properties 
include the disease incubation period and neuropathological phenotype, particularly 
the distribution and severity of spongiform change in the brain (Bruce, 2003). In the 
absence of any nucleic acid associated with the transmissible agent, these variations in 
strain properties have been accounted for by conformational variability in PrPSc that is 
self-propagating (Prusiner, 1998a). This concept was reinforced by the discovery of 
distinct strains (“hyper” and “drowsy”) of transmissible mink encephalopathy that are 
associated with different isoforms of PrPSc (Bessen & Marsh, 1994). More recent 
structural studies of synthetic prion strains derived from recombinant mouse prion 
protein also support this concept (Colby and Prusiner, 2011a). 
 
The mouse prion protein gene (Prnp) (first identified as the sinc (scrapie incubation) 
gene) also exerts an effect on disease incubation period and phenotype (Moore et al., 
1998). The primary transmission of sheep or bovine prions to mice is often inefficient, 
with only a proportion of the inoculated animals succumbing to disease with variable 
and sometimes protracted incubation periods, a phenomenon often referred to as the 
“species barrier” (Bruce et al., 1994). Serial passage in mice results in shortening and 
stabilisation of both the incubation period and the disease phenotype (Bessen and 
Marsh, 1994; Beringue et al., 2008). The underlying basis of the species barrier is not 
fully understood, but appears to be influenced by the degree of structural similarity 
between the prion proteins of the two species involved and the Prnp sequence 
similarities between these species (reviewed in Caughey, 2003; Beringue et al., 2008). 
The concept of prion strains has also been investigated in human prion diseases. The 
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prion strain causing vCJD appears distinct from those causing sporadic Creutzfeldt-
Jakob disease (sCJD), and closely resembles the BSE strain, providing evidence that 
vCJD results from human exposure to BSE (Bruce et al., 1997, Scott et al., 1999). 
However, the number of strains occurring in sCJD and other human prion diseases is 
still a subject of debate (see below). 
 
Conformational differences in the PrPSc in different prion strains can be assessed 
indirectly by examining the size of the core fragment of PrPSc after proteolytic 
degradation (PrPres) using Western blotting (Parchi et al., 1996). Two major 
conformational variants of PrPres occur in human prion diseases, which in the most 
commonly used nomenclature are termed type 1 and type 2 (Parchi et al., 1996) (Figure 
1.2). Type 1 PrPres is a core fragment with an N-terminus at glycine 82 with a molecular 
weight of around 21kDa. Type 2 PrPres is more extensively digested, resulting in a core 
fragment with an N-terminus at serine 97 and a molecular weight of around 19kDa 
(Parchi et al., 2000). Western blots also demonstrate the proportion  
of the three possible glycoforms of PrP (di-, mono, and non-glycosylated); the suffix 
A is used when the mono- or unglycosylated bands of PrPres predominate and the suffix 
B is used when the diglycosylated band predominates (Parchi et al., 1997). The PrPres 
type nomenclature employed throughout this thesis is that used by Parchi et al. and the 
vast majority of workers in this field (reviewed in Gambetti et al., 2003). Typical 
examples of the PrPres isoforms found on Western blot (WB) examination of the brain 





Figure 1.2.  
Molecular typing of abnormal prion protein found in the brain in different forms of 




  Courtesy of Dr Mark W Head, Edinburgh, UK. 
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Legend to Figure 1.2. 
(A) Diagram showing the normal cellular prion protein (PrPC) and the protease 
resistant fragments of the disease-associated isoform (PrPres). The polypeptide 
backbone is shown as a blue cylinder and the two N-linked glycans and the 
glycosylphosphatidylinositol (GPI) anchor are shown in green, with the lipid 
component of the GPI anchor shown as blue lines. The N-terminal endoplasmic 
reticulum signal sequence and the C-terminal GPI anchor sequence are shown cleaved 
as light blue short cylinders. The diagram shows the protease resistant core fragments 
of the prion protein (PrPres) remaining after digestion with proteinase K. Three major 
PrPres fragments occur that differ in the extent of N-terminal digestion and whether or 
not C-terminal digestions occurs. The 21kDa type 1 and 19kDa type 2 forms contain 
the two N-linked glycosylation sites, whereas the 8kDa PrPres fragment does not. (B) 
The combination of PrPres fragment sizes (type 1, type 2 and 8kDa) and the variable 
occupancy of two potential glycosylation sites produce distinct banding patters when 
protease digested human prion disease brain homogenates are analysed by Western 
blotting using antibodies such as 3F4 that bind to the central region of the prion protein. 
The glycoform pattern is designated A when the middle (monoglycosylated) band 
predominates, B when the top (diglycosylated) band predominates and A/B when the 
mono- and di-glycosylated bands predominate at the expense of the bottom (non-
glycosylated) band. Types 1A, 2A, 1+2(A) are characteristic of sCJD and iCJD. Type 
2B is associated with vCJD. Types 1B, 1A/B and 2A/B are often found in genetic CJD, 
GSS and FFI. The 8kDa pattern is characteristic of some cases of GSS and of VPSPr. 
The faint ladder of bands that sometimes accompanies the 8kDa band in VPSPr is 
shown in grey. (C) shows an example of a Western blot analysis of post-mortem brain 
samples from individuals with sCJD of two distinct subtypes (sCJD MM1 and sCJD 
VV2), vCJD and GSS. The approximate positions of molecular mass markers are 
indicated in (B) and (C) in kilodaltons. 
Abbreviations: CJD: Creutzfeldt-Jakob disease; FFI: fatal familial insomnia; GSS: Gerstmann-
Sträussler-Scheinker syndrome; i: iatrogenic; M: methionine; s:sporadic; v: variant; V: valine; VPSPr: 
variably protease-sensitive prionopathy  
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1.2.4. Prion genetics 
Studies of scrapie in sheep have identified three polymorphisms in the sheep Prnp 
gene (codon 136 A/V, codon 154 R/H and codon 171 Q/R) that have a major influence 
on both the disease incubation period and phenotype (Gonzalez et al, 2002; Baylis & 
Goldmann, 2004). The five major alleles VRQ, ARQ, ARH, AHQ and ARR show 
variable sensitivity to different scrapie strains; the ARR allele confers the greatest 
resistance to classical scrapie (Hunter et al., 1997). Several polymorphisms have also 
been identified in PRNP, of which the methionine (M) / valine (V) polymorphism at 
codon 129 (Figure 1.3) has a powerful effect on the clinicopathological phenotype in 
idiopathic, genetic and acquired diseases and the incubation period in acquired human 
prion diseases (Parchi et al., 1996, 1999; Collinge et al., 2006). Genetic human prion 
diseases - familial Creutzfeldt-Jakob disease (fCJD), Gerstmann-Sträussler-Scheinker 
syndrome (GSS), fatal familial insomnia (FFI) and prion protein cerebral amyloid 
angiopathy - are all associated with missense, insertion, deletion or amber mutations 
in the open reading frame of PRNP, of which over 50 have been identified (reviewed 
in Schmitz et al., 2016) (Figure 1.3).  
 
1.3. In vitro models of prion disease 
Early experimental work on scrapie in the 20th century was greatly facilitated by the 
transmission of the scrapie agent to mice by Chandler in 1961 (Chandler, 1961) 
allowing small animals rather than sheep or goats to be used as disease models and 
promoting the intensive studies of the scrapie agent from the 1960s onwards. Despite 






Diagrammatic representation of the human prion protein gene open reading frame 
(codons 1-235) with the structural landmarks of the encoded prion protein marked 
(with permission from Taylor and Francis, UK) 
 
The positions of pathogenic mutations are superimposed using codon number and 
single letter amino acid codes. The mutations are colour coded with respect to the 
disease phenotype and are place above or below the schematic to indicate the 
haplotype with respect to the codon 129 polymorphism of the mutated allele. The 
position of the codon 129 polymorphism (methionine (M)/valine(V)) is also indicated. 
An asterix (*) indicates a currently unknown haplotype. 
 
Abbreviations: CJD: Creutzfeldt-Jakob disease; CAA: cerebral amyloid angiopathy; FFI: fatal 
familial insomnia; GSS: Gerstmann-Sträussler-Scheinker syndrome; PrP: prion protein.  
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and logistical and financial limits to the numbers used for experimental study. A 
suitable cell culture system to support the replication of the scrapie agent and to study 
its cell biology was therefore sought. This proved difficult as different sources and 
strains of scrapie and other prion diseases appeared to have their own unique 
requirements in vitro. Consequently, most cell culture work on scrapie has been 
performed with a mouse neuroblastoma cell line that can infected with scrapie (Butler 
et al., 1988) and has been used in a wide range of applications including the study of 
PrPSc conversion, subcellular localisation, pathophysiology and species barrier 
determinants (Solassol et al., 2003).  More recently, other cell lines that support scrapie 
replication have been developed, and advances in molecular genetics have contributed 
to the increasing range of cell lines now available for work with animal prions and 
synthetic prions (Solassol et al., 2003; Klohn et al., 2003; van der Merwe et al., 2015). 
However, there remains a lack of cell culture systems suitable for research on human 
prions. Self-renewing populations of human embryonic stem cells were challenged 
with sCJD, vCJD and BSE and rapidly took up PrPSc. However, when the infectious 
source was removed, the intracellular levels of PrPSc fell rapidly (Krejciova et al., 
2011). This work has been invaluable in helping determine how exogenous prions are 
dealt with by cultured cells, but the challenge of developing a cell line that can be 
infected with (and hopefully cured of) human prions still remains. 
 
In contrast, cell free in vitro conversion systems have more recently been developed 
to model PrPC conversion and other aspects of prion biology, to study transmission 
barriers and allow the sensitive detection of PrPSc. Work in this field began in the 1990s 
with the in vitro conversion assay, where samples of tissue (usually brain tissue) 
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containing PrPSc were incubated with a substrate containing radiolabelled PrPC 
(Kocisko et al., 1994; Raymond, et al., 1997). This approach has now been refined by 
the addition of a shaking step during the incubation process of the PrPSc seed with a 
substrate, now termed quaking induced conversion (QuIC) (Orru et al., 2009). A recent 
development of this technique is to incorporate thioflavin T (ThT) into the reaction, 
which binds to the amyloid structures generated by the PrP conversion process, 
causing a change in the ThT fluorescence emission spectrum that can be measured in 
real time (RT-QuIC) (Atarashi et al., 2011) (Figure 1.4A). RT-QuIC allows the rapid 
and sensitive detection of PrPSc generated from a variety of recombinant PrP substrates, 
including truncated PrP substrates (Zanusso et al., 2016). This technique is now being 
applied in clinical diagnosis, particularly in the detection of PrPSc in CSF samples from 
sCJD patients with very high sensitivity and specificity (McGuire et al., 2016). 
 
Another cell free in vitro conversion assay to be developed recently is the protein 
misfolding cyclical amplification (PMCA) assay (Saborio et al., 2001). This also uses 
PrPSc seeds and PrPC substrates (e.g. normal brain homogenates or recombinant PrP ) 
in sequential rounds of incubation and sonication to promote PrPC conversion to PrPSc, 
which is then detected by Western blotting at the end of the reaction as PrPres (Castilla 
et al., 2006) (Figure 1.4B). The ability to undertake numerous sequential rounds of 
PMCA conversion allows the amplification and ultrasensitive detection of PrPSc in 
tissues, fluids and the environment (reviewed in Saa & Cervenakova, 2014). PMCA 
can also be used to investigate the conversion potential of various combinations of 






Schematic representation of real-time quaking-induced conversion (RT-QuIC) and 


















Legend to Figure 1.4.  
 
A: In RT-QuIC, a large excess of recombinant PrPC substrate is incubated with 
minimal quantities of PrPSc seed in the presence of Thioflavin T (ThT), followed by 
cycles of incubation and shaking. PrPC in the substrate is converted into PrPSc in -
sheet structures that grow, converting and incorporating further PrPC molecules. Each 
cycle of shaking and incubation (represented by arrows) breaks the nascent PrPSc 
aggregates, creating further seeds for PrPC conversion. Aggregate formation is 
monitored over time by plotting the increasing ThT fluorescence (when ThT binds -
sheet structures) as a graph.  
 
B: PMCA is comparable to RT-QuIC, except that mammalian brain PrPC is used a 
substrate and sonication is used to disrupt the nascent PrPSc aggregates. At the end of 
PMCA, the PrPSc generated in the amplification reaction is detected by western 
blotting as PrPres. Densitometry is used to assess the PrPres level in the amplified 
sample in comparison with the PrPres level in the non-amplified seed.  
 
Abbreviations: PMCA: protein misfolding cyclical amplification; PrPC: cellular prion protein; PrPres: 
















differing PRNP codon 129 genotypes (Jones et al., 2011) and cross-species PMCA to 
explore the zoonotic potential of different animal PrPSc seeds for differing human PrPC 
substrates (Barria et al., 2014). This method also has diagnostic applications, such as 
the detection of PrPSc in the urine and blood of patients with vCJD (Moda et al., 2014; 
Lacroux et al., 2014). The PMCA technique also amplifies infectivity in the seed for 
the reaction, thus supporting the prion hypothesis (reviewed in Morales et al, 2012). 
The exploration of factors influencing PrPC conversion indicates that currently 
unknown components present in normal brain homogenates have a positive influence, 
but polyanions (including short RNA sequences) also promote conversion (Deleault et 
al., 2003, 2007). Finally, repeated PMCA cycles in the absence of a PrPSc seed can 
result in the de novo generation of PrPSc and infectivity by apparently chance 
misfolding of the PrP substrate (Castilla et al., 2005; Barria et al., 2009). Modification 
of these PMCA reactions using defined substrate components (a “recipe for prions”) 
can influence the strain characteristics of the resulting prions, providing further 
evidence in support of the prion hypothesis (Lee & Caughey, 2007; Deleault et al., 
2007; Abid et al., 2010). 
 
1.4. Human prion diseases 
1.4.1. Introduction          
The expanding spectrum of human prion diseases includes idiopathic (sporadic), 
genetic (inherited) and acquired (infectious) disorders (Table 1.1). Human prion 
diseases are characterised clinically by progressive multifocal neurological signs and 
symptoms, including rapidly progressive cognitive decline with dementia, visual 
abnormalities, movement disorders, myoclonus and ataxia. The duration of the clinical 
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illness is variable, but ranges from a few months in sCJD to several years in some 
genetic prion disease. Prion diseases have characteristic neuropathological features 
that include spongiform change in the grey matter with variable neuronal loss, reactive 
gliosis and the accumulation of PrPSc in the brain, sometimes in the form of amyloid 
plaques. PrPSc can be detected biochemically in the CNS by WB examination (Figure 
1.2) and by other tissue-based investigations, including immunohistochemistry (IHC) 
and paraffin-embedded tissue (PET) blots (Ritchie et al., 2004).  
 
Neuropathological examination of the CNS is essential for a “definite” diagnosis of a 
human prion disease according to internationally accepted diagnostic criteria (see 
Tables 1.4, 1.5, 1.7 and 1.9 below). This is usually confined to autopsy brain 
examination, since brain biopsy in patients with prion diseases often results in 
subsequent clinical deterioration and the neurosurgical instruments coming into 
contact with the prion-infected brain have to be destroyed to prevent the risk of 
subsequent iatrogenic transmission (Advisory Committee on Dangerous Pathogens:  
www.gov.uk/ government/  uploads/ system/uploads/attachment_data /file/ 427854/ 
Infection _ control  v3.0.pdf). Brain biopsy is therefore usually confined to patients in 
whom the possibility of an alternative treatable condition exists, e.g. cerebral 
vasculitis. 
 
1.4.2. Historical background              
In the 1920s, Hans Creutzfeldt and Alfons Jakob separately reported 5 cases of an 
unusual fatal neurological disorder of unknown aetiology (Creutzfeldt, 1920; Jakob, 
1921a, 1921b, 1923). The term “Creutzfeldt-Jakob disease” (CJD) was introduced in 
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1922 (Spielmeyer, 1922) and was subsequently used to describe a range of 
neurological conditions, including the “amyotrophic form of CJD”, many of which are 
now considered not to be human prion diseases (Masters & Gajdusek, 1982).  
Subsequent neuropathological review of Creutzfeldt’s original case indicated that it is 
unlikely to be an example of a human prion disease, likewise for 3/5 of Jakob’s cases 
reported in 1921 and 1923 (Masters & Gajdusek, 1982). The term originally used by 
Jakob was ‘spastic pseudosclerosis’, since it clinically resembled some cases of 
multiple sclerosis, but had “remarkable anatomical findings” (Jakob, 1921a, 1921b, 
1923). Jakob experimentally inoculated rabbits in an attempt to demonstrate an 
infectious origin for CJD, which was unsuccessful; rabbits are now known to be 
relatively resistant to prion diseases (Collinge, 2005). Consequently, an infectious 
aetiology was not considered likely, particularly since there was no neuropathological 
evidence of an inflammatory reaction in the brain or other features indicating infection 
by any of the then known CNS pathogens. In the following years many different 
aetiologies were proposed for CJD, including neurodegenerative, vascular and 
metabolic disorders (Nevin et al., 1960). Familial forms of ‘spastic pseudosclerosis’ 
were identified as early as 1924 (Kirschbaum, 1924) and GSS was reported in 1936 as 
an inherited spinocerebellar ataxia with distinctive neuropathological features that did 
not appear to be related to CJD (Gerstmann et al., 1936). 
      
In the late 1950s, Gajdusek and Zigas reported an acute progressive degenerative CNS 
disorder that was endemic in a remote tribe in the Highlands of New Guinea, known 
as “kuru” in the native population (Gajdusek & Zigas, 1957, 1959). The aetiology of 
kuru was unknown; however, a detailed study of a series of kuru brains suggested that 
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there were similarities to the neuropathology of sCJD, which was not known at that 
time to be a transmissible disease (Klatzo et al, 1959). In the same year, on the basis 
of his observation that the neuropathology of kuru in humans resembled that of scrapie 
in sheep, Hadlow proposed an infectious aetiology for kuru (Hadlow, 1959). This led 
to the experimental transmission of kuru to chimpanzees in 1965 (Gajdusek et al., 
1966), followed by similar transmissions of sCJD and later GSS to chimpanzees 
(Gibbs et al., 1968; Masters et al., 1981).  
 
The genetic basis of GSS was reported in 1989, when a PRNP P102L mutation was 
identified in two affected kindreds (Hsiao et al., 1989); in the same year, a 144 bp 
insertional mutation in PRNP was identified in a UK kindred with familial CJD (Owen 
et al., 1989). Since then, many pathogenic mutations, non-pathogenic mutations and 
polymorphisms in PRNP have also been identified, including the polymorphisms at 
codon 129 (Table 1.2) and codon 219 that predispose to certain forms of human prion 
disease (Schmitz et al., 2016) (Figure 1.3). A human source of acquired CJD was 
reported in 1974, when iatrogenic transmission of CJD was identified in a corneal graft 
recipient (Duffy et al., 1974). Early epidemiological surveillance studies of sCJD in 
the UK attempted to identify possible sources of acquired infection and identified a 
series of 3 cases associated with transmission via neurosurgery (Will & Matthews, 
1982). The first cases of iatrogenic CJD in human growth hormone recipients were 
reported in 1985 from both the United States of America (USA) and the United 
Kingdom (UK) (Koch et al., 1985; Gibbs et al., 1985; Powell-Jackson et al., 1985).  
The genetic basis of fatal familial insomnia (a familial disease described over centuries 
in Italy with no similarities to CJD or GSS) was finally revealed when the D178N 
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mutation at codon 178 in PRNP with methionine at codon 129 was identified in 1992 
(Medori et al., 1992). The underlying genetic mutation in the family described by 
Kirschbaum in 1924 was identified in 1994 as the D178N mutation with valine at 
codon 129 (Brown et al., 1994). Variant CJD was identified in the UK in 1996 and 
attributed to oral infection from BSE in the foodchain (Will et al., 1996). The latest 
member of the ever-expanding group of human prion diseases, variably protease-
resistant prionopathy, was reported in the USA in 2008 (Gambetti et al., 2008). 
 
1.5. Overview of human prion diseases 
The subject of this thesis, iatrogenic CJD in human growth hormone recipients in the 
UK, has a likely origin from sCJD and can be compared with other acquired human 
prion diseases in the UK, including iatrogenic CJD acquired from human dura mater 
grafts and variant CJD. Accordingly, these forms of human prion disease will be the 
main subjects of this section, but the other forms of human prion disease are included 
more briefly for the sake of completeness. Animal prion diseases are discussed only in 
terms of their known relationships to human prion diseases. 
 
1.5.1. Sporadic CJD 
1.5.1.1. Epidemiology 
Sporadic CJD accounts for around 85% of all human prion diseases. It is a rare disorder 
with a worldwide incidence of around 1-2 cases per million per annum in most national 
surveys  (Ladogana et al., 2005). No good evidence exists to indicate an environmental 
source of infection (Cousens et al., 1997) and detailed  case-control studies have failed 
to demonstrate any other significant risk factors (Linsell et al., 2004; de Pedro Cuesta 
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et al., 2012). A history of surgery has been identified as a possible risk factor in some, 
but not all studies (Ward et al., 2002, de Pedro Cuesta et al., 2011). No occupational 
risk factors have been identified, including in medical or paramedical staff (Alcalde-
Cabero et al., 2012). No definitive evidence exists to suggest that sCJD is transmissible 
via blood transfusion (Dorsey et al., 2009; Puopolo et al., 2011). However, recent 
experimental transmission studies in transgenic mice overexpressing human prion 
protein with codon 129 MM has detected infectivity in plasma from a small series of 
sCJD patients (Douet et al., 2014). Sporadic CJD has been transmitted by 
contaminated neurosurgical instruments, intracerebral electrodes and inoculated tissue 
extracts, grafts and implants, resulting in iatrogenic CJD (see below). Since there is no 
persuasive evidence to indicate that sCJD is an acquired disease, it has been proposed 
that sCJD results either from the random conversion of PrPC to PrPSc in the CNS, or a 
somatic pathogenic mutation in PRNP, resulting in the self-replication and 
accumulation of PrPSc in the CNS and leading to neuronal dysfunction, the onset of 
clinical signs and symptoms and ultimately death (Prusiner, 1998b). 
 
1.5.1.2. Subgroups of sporadic CJD 
Studies of large cohorts of sCJD cases have identified some key factors influencing 
the disease phenotype, which helps explain the variable clinical presentations and 
disease course. Sporadic CJD can be divided into subgroups that are defined by the  
PRNP codon 129 polymorphism that encodes either methionine (M) or valine (V) 
(Table 1.2). The three possible genetic subgroups (MM, MV, VV) can be subdivided 
according to the PrPres isoform detected by WB analysis of brain tissue homogenates 
in each case: type 1 or type 2. This gives 6 possible subgroups - MM1, MM2, MV1, 
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MV2, VV1 and VV2; the MM1 and MV1 subtypes have a common phenotype 
(MM1/MV1) and the MM2 subtype is divided into the cortical and thalamic variants, 
with markedly different clinical features and neuropathology (Parchi et al., 1999). 
Table 1.3 summarizes the predominant clinical and neuropathological features of these 
sCJD subtypes. The MM2 thalamic subtype of sCJD is increasingly being referred to 
as sporadic fatal insomnia because of its clinical and neuropathological similarities to 
fatal familial insomnia (see below), in the absence of the PRNP haplotype associated 
with this genetic prion disease (Mastrianni et al., 1999).  Not all cases of sCJD cases 
exhibit the characteristic features summarized in Table 1.3 and atypical cases are 
increasingly being recognised in terms of both their clinical and neuropathological 




PRNP codon 129 polymorphisms in the normal population and in prion diseases 
    PRNP codon 129 polymorphisms (%) 
    MM  MV  VV 
Normal population1  39  50  11 
Sporadic CJD2  60  20  20 
Variant CJD3   99  1  -  
1Data pooled from five studies (http://www.cjd.ed.ac.uk/documents/report23.pdf). 
2UK deaths from sporadic CJD 1996-2014 for whom genetic data are available 
(n=856) (http://www.cjd.ed.ac.uk/documents/report23.pdf). 
3National CJD Research & Surveillance Unit 2016 (http://www.cjd.ed.ac.uk/ 
documents/worldfigs.pdf). 
 




 Major subtypes of sporadic CJD classified by PRNP codon 129 genotype and PrPres 


























































* Cases with mixed PrPres subtypes are not included 
 
Abbreviations: CJD: Creutzfeldt-Jakob disease; M: methionine: PrP: prion protein; PrPres: protease-
resistant prion protein; V: valine.  
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1.5.1.3. Clinical features 
Sporadic CJD occurs as a progressive neurological disorder affecting predominantly 
elderly patients, with an average age of around 65 years and an equal sex distribution. 
However, a wide age range can be affected, including rare cases in teenagers.  
Patients present most commonly with rapidly progressive dementia, ataxia, visual 
abnormalities and myoclonus  (Head et al., 2015). Early diagnosis is challenging as 
patients may present with isolated abnormalities such as cerebellar ataxia (particularly 
in the VV2 subtype) or cortical visual impairment (particularly in the MM1 subtype). 
Most patients with sCJD die within 4 months after the onset of neurological 
abnormalities, but there is a wide variation in the duration of illness, with some patients 
surviving for more than 2 years (particularly the MM2 subtype).  
 
The clinical diagnosis of sCJD and other human prion diseases is aided by specialised 
investigations, including electroencephalography (EEG), magnetic resonance imaging 
(MRI) of the brain and examination of the cerebrospinal fluid (CSF), which are all 
included in internationally accepted criteria for the clinical diagnosis of sCJD (Table 
1.4). Periodic triphasic EEG complexes are diagnostic of sCJD and occur commonly 
in the MM1/ MV1 subgroup, but do not occur in all other subgroups (Zerr et al., 2000). 
MRI shows increased signal in the caudate nucleus, putamen, and/or cerebral cortex 
(cortical “ribboning”) on diffusion-weighted imaging in up to 80% of cases (Meissner 
et al., 2009a). A positive CSF assay for 14-3-3 protein is not specific for sCJD per se, 
as this investigation can be positive in other conditions associated with rapid neuronal 
death, eg stroke or herpes simplex encephalitis, but is useful when other conditions 
potentially causing elevated CSF levels of 14-3-3 are excluded (Green et al., 2007). 
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RT-QuIC amplification of PrPSc in the CSF has a remarkably high sensitivity and 
specificity for sCJD and is now included in the diagnostic criteria (McGuire et al., 
2016). Olfactory mucosa biopsy combined with RT-QuIC amplification of PrPSc also 




Diagnostic criteria for sporadic Creutzfeldt-Jakob disease.  
(http://www.cjd.ed.ac.uk/documents/criteria.pdf) 
 
1. Sporadic CJD (from 1 January 2017) 
 
1.1 DEFINITE: 














1.2.1    I + 2 of II + III, OR 
 1.2.2  I + 2 of II + IV, OR 
 1.2.3   Possible + positive 14-3-3, OR 
1.2.4  Progressive neurological syndrome and positive RT-QuIC in CSF or 
other tissues 
 
1.3 POSSIBLE: I + two of II + duration < 2 years 
 
Abbreviations: CJD: Creutzfeldt-Jakob disease; EEG: electroencephalogram; MRI: magnetic resonance 
imaging 
I Rapidly progressive dementia 
 
II A   Myoclonus 
 B   Visual or cerebellar problems 
 C    Pyramidal or extrapyramidal features 
 D   Akinetic mutism 
 
III Typical EEG (generalised periodic complexes) 
 
IV    High signal in caudate/putamen on MRI brain 
scan or at least 2 cortical regions (temporal, 
parietal occipital) either on DWI or FLAIR 
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1.5.1.4. Neuropathology 
Macroscopic examination of the brain in sCJD usually shows only age-related changes, 
often with sparing of the hippocampus. Cerebellar atrophy, most evident in the 
superior vermis, is present in some cases of sCJD, particularly the VV2 subtype. 
Cerebral and cerebellar atrophy may occur in cases with a long duration of illness; 
severe cerebral atrophy is accompanied by secondary degeneration of the cerebral 
white matter, referred to as panencephalopathic CJD (Jansen et al., 2009).  
 
The microscopic neuropathology of sCJD is characterised by spongiform change, 
reactive gliosis involving microglia and astrocytes, and the accumulation of PrPSc , 
with amyloid plaque formation in the form of the kuru-type plaques that are 
characteristic of the MV2 subtype (Head et al., 2015). These features vary in their 
distribution and severity within a single brain, but characteristic readily identifiable 
pathological features have been described for each of the different sCJD subtypes 
(Parchi et al., 2012). Spongiform change comprises collections of rounded vacuoles in 
the grey matter of the brain. In the microvacuolar spongiform change found in the 
MM1/MV1 subtypes, the vacuoles vary from 2–20 m in diameter. Larger vacuoles 
occur in the confluent spongiform change in the cerebral cortex in the in the MM2 and 
MV2 sCJD subtypes (Parchi et al., 1999). Status spongiosis in the cerebral cortex 
occurs when there is severe neuronal loss and gliosis, collapse of the cortical 
cytoarchitecture and numerous large, coarse vacuoles are present. Although status 
spongiosis can occur in other disorders e.g. frontotemporal lobar degeneration and 
severe hypoxic brain damage, it is characteristic of panencephalopathic sCJD. 
Ultrastructural studies of sCJD have revealed tubulovesicular structures within 
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neurones, the origin of which is uncertain (Liberski et al., 1992). Although also present 
in many other forms of human prion disease, these structures do not label with 
antibodies to PrP (Liberski et al., 2005). 
 
PrPSc aggregates in various patterns in the grey matter in sCJD, including 
granular/synaptic deposits in the MM1/MV1 subtypes, perivacuolar accumulation in 
the MM2 cortical subtype, perineuronal and plaque-like accumulations in the VV2 
subtype, and kuru-type amyloid plaques in the MV2 subtype (Parchi et al., 1999). 
PrPSc may also be detected in extraneural tissues in sCJD, including the peripheral 
nervous system, pituitary gland and (rarely) in the spleen (Glatzel et al., 2003; Head 
et al., 2004b; Peden et al., 2006, 2007). The characteristic histological and 
immunohistochemical features of the six sCJD subtypes are illustrated in Figure 1.5. 
 
1.5.1.5. Molecular biology 
Western blot examination of different brain regions in sCJD has revealed that different 
PrPres types can occur in different brain regions. In some cases, the co-occurrence of 
PrPres types 1 and 2 has been identified in the same brain region (Head & Ironside, 
2012). These abnormalities appear to occur in approximately 30% of sCJD cases, 
resulting in a review of the classification system described above (Parchi et al., 2009); 
these abnormalities may provide further explanation for phenotypic variability in sCJD. 
It has been proposed that the different PrPres isoforms in CJD may also be linked to 
different causative prion strains, a concept referred to  as “molecular strain typing” 




Characteristic histological and immunohistochemical features of sCJD subtypes. 
(with permission from Taylor and Francis, UK) 
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Legend to Figure 1.5. 
 
The MM1/MV1 subtype of sCJD shows widespread microvacuolar change in the 
frontal cortex (a) with a predominantly granular/synaptic pattern of PrP accumulation 
(b).  
 
The MM2C subtype of sCJD shows widespread confluent spongiform change in the 
temporal cortex (c), with intense perivacuolar immunoreactivity for PrP (d). 
 
The VV1 subtype of sCJD shows widespread microvacuolar spongiform change in the 
temporal cortex (e), and synaptic and focal perineuronal positivity for PrP on 
immunohistochemistry (f). 
 
 The VV2 subtype of sCJD shows widespread vacuolation, neuronal loss and gliosis 
in the cerebellum (g), and a perineuronal and synaptic pattern of PrP immunoreactivity 
in the parietal cortex (h).  
 
The MV2 subtype of sCJD is characterised by kuru-type amyloid plaques in the 
cerebellum (arrow) (i), with both plaque and plaque-like immunoreactivity for PrP (j).  
 
Sporadic fatal insomnia (sCJD MM2T subtype) shows severe neuronal loss and gliosis 
in the anterior and medial thalamic nuclei, with little spongiform change (k).  Thalamic 
gliosis is demonstrated by immunohistochemistry for glial fibrillary acidic protein (l).   
 
(Sections a, c, e, g, i and k are stained with haematoxylin and eosin and sections b, d, 
f, h, j, and l are stained by immunohistochemistry for PrP using the KG9 antibody.) 
Scale bar=250m 
 





Experimental transmission studies have been performed to identify and characterise 
the strains of prions that cause sCJD (Bishop et al., 2010; Parchi et al., 2010; Gambetti 
et al., 2011; Moda et al., 2012). Overall, the results indicate that more than a single 
strain is responsible for this disorder, but there appears to be no direct correlation 
between the prion strains identified and the sCJD subtypes described in Table 1.3. 
Most researchers agree that at least five different prion strains can be identified in the 
different sCJD subtypes; these are provisionally designated the M1, M2C, M2T, V1 
and V2 strains (Haik et al., 2011). The M1 strain has been isolated from sCJDMM1 
and MV1 cases, the M2C strain from sCJDMM2 cortical cases and the M2T strain 
from sCJDMM2 thalamic cases; the V1 strain has been isolated in sCDVV1 cases only, 
but the V2 strain has been isolated from both sCJDVV2 and sCJDMV2 cases. Further 
work in characterising sCJD strains is in progress, using both experimental 
transmission studies and in vitro conversion/seeding studies, making it is highly likely 
that any further information on this topic will reveal increasing complexity (Chapuis 
et al., 2016). 
 
1.5.2. Variably protease-sensitive prionopathy 
Variably protease-sensitive prionopathy (VPSPr) was first described in the USA in 
2008 as a novel idopathic human prion disease with unique biochemical findings in 
the brain (Gambetti et al., 2008). Similar cases were subsequently identified in Europe 
(Head et al., 2013). No predisposing environmental cause for VPSPr has been reported 
and no mutations in the PRNP coding sequence have been identified to date. VPSPr 
occurs most commonly in the PRNP codon 129 VV genotype, followed by the MV 
and MM genotypes, in contrast to sCJD (Zou et al., 2010). As for sCJD, most VPSPr 
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patients are in the seventh decade or older, but the clinical history is lengthy (usually 
over 2 years) and includes movement disorders, extrapyramidal signs, cerebellar 
ataxia, and cognitive impairment. Rapidly progressive dementia is uncommon (Zou et 
al., 2010). No clinical diagnostic criteria for VPSPr have yet been defined; 
consequently, the precise incidence of this disorder is unknown. However, a 
retrospective review in the UK indicated that although it is underascertained, it appears 
to be much rarer than sCJD (Head et al., 2013).  
 
Microscopy of the brain shows irregular collections of vacuoles of intermediate size 
in the cerebral cortex, basal ganglia, thalamus, and cerebellar cortex (Gambetti et al., 
2008). The most striking neuropathological feature is the presence of microplaques, 
often arranged in a “target” pattern in the cerebellar molecular layer, particularly in the 
PRNP codon 129 VV genotype  (Zou et al., 2010). Microplaques may also be found 
in the thalamus, basal ganglia, hippocampus, and cerebral cortex, hippocampus, basal 
ganglia and thalamus, and are periodic acid/Schiff-(PAS) positive with intense 
labeling on immunohistochemistry for prion protein. Differential labelling of 
microplaques with panels of different anti-PrP antibodies is another characteristic 
feature of VPSPr (Head et al., 2013), which can readily be identified from the VV2 
and MV2 subtypes of  sCJD  (Parchi et al., 1999). The PRNP codon 129 genotype 
modifies the neuropathological phenotype of VPSPr, with larger plaques appearing in 
the MM genotype (Zou et al., 2010).  
 
VPSPr was so named because of the presence of PrPSc in the brain that is poorly 
resistant to PK digestion, yielding a characteristic 8-kDa N- and C-terminally truncated 
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band in Western blots (Figure 1.2). These are often accompanied by a faint “ladder” 
of bands extending into the 18–30 kDa range (Fig. 6) (Gambetti et al., 2008). Some 
recent cases of VPSPr have also contained a sCJD-like type 2A isoform in the 
cerebellum, suggesting a possible molecular overlap with sCJD (Head et al., 2013). 
Recent experimental transmission studies have shown that VPSPr is poorly 
transmissible to transgenic mice, with transmission characteristics markedly different 
from those of sCJD (Diack et al., 2014; Notari et al., 2014). 
 
1.5.3. Genetic prion diseases         
Genetic forms of human prion disease are thought to account for around 10-15% of all 
cases of human prion disease (Ladogana et al., 2005). They are inherited as autosomal 
dominant disorders, usually with almost complete penetrance and a markedly variable 
age at onset (Kong et al., 2004). A clear-cut family history of a neurological disorder 
is not always obtained (possibly due to spontaneous PRNP mutations), favouring the 
collective term of genetic prion disease to an alternative of familial prion disease 
(Kovacs et al., 2005). Historical clinical classification into different forms - familial 
Creutzfeldt-Jakob disease (fCJD), fatal familial insomnia (FFI) and GSS - is now 
accompanied by PRNP sequence analysis, which has found over 50 distinct point, 
amber, insertional and deletion mutations associated with disease (Schmitz et al., 
2016) (Figure 1.3). The internationally agreed diagnostic criteria for genetic prion 
diseases are summarised in Table 1.5. Phenotypic variation occurs within kindreds 
carrying an identical PRNP mutation; the polymorphic codons at 129 and 219 on both 
the mutant and non-mutated PRNP alleles are major influences in determining 
phenotypic variation in many forms of genetic prion diseases (Head et al., 2015). 
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Many, but not all, familial prion diseases have been transmitted experimentally; some 
of those transmitted more recently have used a transgenic mouse with a corresponding 
PRNP mutation to achieve transmission, since earlier attempts to transmit the disease 
to wild-type mice were unsuccessful (reviewed in Head et al., 2015). 
 
1.5.3.1. Principal disease subtypes 
Familial CJD is the commonest form of genetic prion disease and closely resembles 
sCJD in its clinical and neuropathological features, occasionally being identified only 
after PRNP sequencing in cases of apparently sporadic CJD, with no relevant family 
history. The PRNP mutation associated with most cases of familial CJD is E200K, 
which has been identified in many countries across the world, but numerous other 
PRNP mutations have been identified in association with this disorder (Head et al., 
2015) (Figure 1.3).  
 
GSS was first identified as a progressive spinocerebellar syndrome accompanied by 
other neurological features including pyramidal signs and progressive cognitive 
decline, which does not always result in dementia (Gerstmann et al., 1936). GSS 
patients in the past have been diagnosed with other inherited disorders, e.g. 
spinocerebellar ataxia, particularly if PRNP gene sequencing is not performed or 
neuropathological examination of the CNS is not carried out (Head et al., 2015). The 
P102L mutation was the first PRNP mutation to be identified in GSS (Hsiao et al., 
1989); an ever- increasing number of point mutations associated with GSS have since 
been identified (Figure 1.3). The neuropathology of GSS is characterised by the 
multicentric PrP-amyloid plaques in the cerebellar cortex and occasionally in other 










3.1.1 Definite TSE + definite or probable TSE in 1st degree relative     
            
3.1.2   Definite TSE with a pathogenic PRNP mutation (see box) 
 
(TSE: transmissible spongiform encephalopathy; PRNP: prion protein gene) 
               
3.2 PROBABLE 
  
3.2.1  Progressive neuropsychiatric disorder + definite or probable TSE in 1st 
degree relative 
 
3.2.2 Progressive neuropsychiatric disorder + pathogenic PRNP mutation 
(see box)     
  
• PRNP MUTATIONS ASSOCIATED WITH GSS NEUROPATHOLOGICAL 
PHENOTYPE 
 P102L,   P105L, A117V,  G131V,   F198S,   D202N,   Q212P,  Q217R,  M232T,  192 bpi 
• PRNP MUTATIONS ASSOCIATED WITH CJD NEUROPATHOLOGICAL 
PHENOTYPE 
 D178N-129V,  V180I,  V180I+M232R,  T183A, T188A, E196K,  E200K,  V203I,  
R208H,  V210I,  E211Q,  M232R,  96 bpi,  120 bpi,  144 bpi,  168 bpi,  48 bpdel 
• PRNP MUTATIONS ASSOCIATED WITH FFI NEUROPATHOLOGICAL 
PHENOTYPE    
D178N-129M 
• PRNP MUTATION ASSOCIATED WITH VASCULAR PrP AMYLOID    
Y145s 
• PRNP MUTATIONS ASSOCIATED WITH PROVEN BUT UNCLASSIFIED 
PRION DISEASE    
H187R,  216 bpi,   
• MUTATIONS ASSOCIATED WITH NEURO-PSYCHIATRIC DISORDER 
BUT NOT PROVEN PRION DISEASE 
 I138M,  G142S,  Q160S,  T188K,  M232R,  24 bpi,  48 bpi,  48 bpi + nucleotide 
substitution in other octapeptides 
• PRNP MUTATIONS WITHOUT CLINICAL AND NEUROPATHOLOGICAL 
DATA  
 T188R,  P238S 
• PRNP POLYMORPHISMS WITH ESTABLISHED INFLUENCE ON 
PHENOTYPE 
 M129V 
• PRNP POLYMORPHISMS WITH SUGGESTED INFLUENCE ON 
PHENOTYPE  
  N171S,  E219K,  24 bp deletion 
• PRNP POLYMORPHISMS WITHOUT ESTABLISHED INFLUENCE ON 
PHENOTYPE 
        P68P, A117A, G124G, V161V, N173N, H177H, T188T, D202D, Q212Q, R228R, S230S 
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variable in its severity and distribution. Some PRNP mutations, e.g. F198S, are 
associated with widespread neurofibrillary tangles in the cerebral cortex in addition to 
multicentric amyloid plaques (Ghetti et al., 1995). The presence of widespread 
amyloid plaques in GSS is frequently accompanied by a 8kDa PrPres band on Western 
blot examination of unfixed brain tissue (Piccardo et al., 1998).  
 
FFI is characterised clinically by sleep disturbance, dysautonomia, cognitive 
impairment and variable pyramidal signs (Medori et al., 1992). Neuropathological 
examination shows severe thalamic gliosis with marked neuronal loss, particularly in 
the anterior thalamic nuclei. The inferior olivary nuclei, the cerebral and cerebellar 
cortex exhibit more variable neuronal loss and gliosis. Spongiform change and PrPSc 
deposition in the brain are absent in most brain regions (including the thalamus), but 
may occasionally be found in the entorhinal cortex (Parchi et al., 1998). FFI is 
associated with the PRNP D178N-129M haplotype (Medori et al., 1992). The PRNP 
D178N mutation also occurs in some patients with familial CJD; however, these cases 
are associated with a D178N-129V haplotype (Goldfarb et al., 1992). Phenotypic 
variability in FFI is influenced by the PRNP codon 129 genotype on the wild-type 
allele (Harder et al., 1999).  
 
Some of the rarer forms of genetic prion diseases, particularly those caused by caused 
by PRNP insertional mutations, have in the past been misdiagnosed clinically as other 
neurodegenerative disorders, including AD and Huntington’s disease (Harder et al., 
1999; Mead et al., 2006). It is therefore likely that the frequency of these and other 
rarer forms of genetic prion disease is underestimated. However, a recent large-scale 
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genetic study has found that apparently pathogenic mutations in PRNP are at least 30 
times more common than expected in the general population on the basis of genetic 
prion disease prevalence (Minikel et al., 2016). Although this finding may be 
attributable to some benign genetic variants mistakenly being assigned as pathogenic, 
other variants have genuine effects on disease susceptibility, but confer lifetime risks 
ranging from <0.1 to ~100%. This study also found that truncating variants in PRNP 




Kuru was first reported in the 1950s as a common neurological disorder affecting 
particularly women and children in the isolated Fore tribe in the Eastern Highlands of 
Papua New Guinea (Gajdusek & Vigas, 1957, 1959). The main clinical features were 
a progressive ataxic syndrome with dysarthria, dysphagia, tremor, pyramidal and 
extrapyramidal motor dysfunction. Emotional lability occurred in the final stages of 
the illness, but cognitive decline and dementia were rare. The neuropathology was 
characterized by spongiform change in the grey matter of the CNS and the presence of 
large numbers rounded amyloid deposits with a solid core and radiating fibrils in the 
cerebellar cortex, referred to as “kuru plaques” (Klatzo et al., 1959).  
 
A number of causes for cause of kuru were suggested, including genetic, endocrine, 
nutritional and toxic causes, until the neuropathological changes were proposed to 
resemble those of scrapie, a disorder that was not apparently transmissible to human 
and had hitherto been largely ignored by medical science (Hadlow, 1959). This 
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observation led to the intracerebral inoculation of kuru to chimpanzees, which were 
kept under long term surveillance. In 1965, three of these animals developed a kuru-
like illness 18-21 months after inoculation, proving that kuru was a transmissible 
spongiform encephalopathy of humans (Gajdusek et al., 1966). 
 
Kuru occurred as an epidemic within the Fore tribe, transmitted by ritualistic 
endocannibalism of deceased tribe members, during which the brain was handled or 
consumed mainly by women and children ( reviewed in Liberski et al., 2012). The 
youngest recorded patient was 5 years old, while in the 1950s the mean age at death in 
the tribe was 49 years. After this ritual was discouraged in the tribe, the age at death 
of kuru patient increased. The final patients dying in the early 21st century were over 
60 years old, with incubation periods of over 40 years (Collinge et al., 2006). Kuru is 
now extinct; it had affected all PRNP codon 129 genotypes in the tribe; heterozygotes 
appear to have had significantly longer incubation periods than homozygotes, 
particularly the methionine homozygotes (Collinge et al., 2006). Genetic analysis of 
kuru patients and the New Guinea population has identified a novel PRNP 
polymorphism (G12V) that was found exclusively in inhabitants of the region in which 
kuru was prevalent.  It was present in half of the otherwise susceptible women from 
the region of highest kuru exposure and appears to represent an acquired resistance 
factor selected during the kuru epidemic (Mead et al., 2009). Kuru may have originated 
from the chance consumption of a tribe member who had died with sCJD; this 
possibility is supported by transmission studies of a few recent kuru cases, which found 
transmission characteristics similar to sporadic CJD, but different from variant CJD 
(Wadsworth et al., 2008).  
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Recent neuropathological re-examination of kuru brains confirms the earlier 
observations of a similarity to sCJD and demonstrates widespread accumulation of 
PrPSc, particularly in the form of kuru plaques (McLean et al., 1998). The 
neuropathological features appear to be influenced by the PRNP codon 129 genotype, 
with kuru-type plaques generally associated with the MV genotype. No evidence of 
PrPSc accumulation in lymphoid tissues was noted in a recent kuru case, in which the 
PrPres isoform in the brain resembled that of the type 2 isoform found in sCJD 
(Brandner et al., 2008). 
 
1.5.5. Variant CJD  
1.5.5.1. Variant CJD and BSE       
Variant CJD was identified in 1996 as a new form of human prion disease in the UK 
that might have resulted from human exposure to BSE by the consumption of 
contaminated meat products (Will et al., 1996). BSE occurred as an epizootic in the 
UK, with the first cases were reported in 1987 (Wells et al., 1987). However, it is 
highly likely that cattle were affected for several years prior to this date: 1980 is a 
generally accepted date for the beginning of the BSE epizootic, but BSE may have 
occurred before this estimated date of onset (Wells & Wilesmith, 1995).  
 
BSE appears to have been transmitted by the feeding of contaminated meat and bone 
meal animal feed produced from cattle carcasses to dairy cattle, which after death were 
then rendered and recycled for the production of meat and bone meal animal feed 
(Wells & Wilesmith, 1995). The origin of BSE remains unknown; possible sources of 
infection include scrapie from sheep that were also recycled for animal feed, a sporadic 
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case of BSE, or a mutation in the cattle Prnp gene resulting in a BSE-like illness in 
one or more cattle (Richt & Hall, 2008). BSE also spread to some other species fed 
with the same product, including exotic ungulates and domestic cats (Table 1.1) – 
interestingly, the case in a UK zoo nyala was identified in 1986 before the first cases 
of BSE in cattle were reported (Kirkwood & Cunningham, 1994). BSE also infected 
wild cats in UK zoos that were fed with contaminated cattle carcasses (Table 1.1). 
Although over 180,000 clinical cases of BSE were identified in the UK, the number of 
asymptomatic infected animals entering the human food chain is likely to have been 
much higher, possibly as many as 3 million up to 1996, when the reinforced animal 
feed ban to abolish the feeding of ruminant-derived proteins to cattle was introduced 
in the UK (Smith & Bradley 2003). The BSE epizootic reached its peak in 1992, since 
when it has declined markedly due to the effects of the 1996 reinforced animal feed 
ban, although isolated cases were still detected up to 2015, almost 20 years after the 
ban (Department of the Environment, Food and Rural Affairs, 2016). 
 
Transmission studies in wild-type and transgenic mice (Bruce et al., 1997; Scott et al., 
1999) have provided evidence that the transmissible agent in vCJD (but not sCJD) has 
similar strain characteristics to the BSE agent. vCJD most likely results from dietary 
consumption of high-titre BSE-infected tissues in the food chain (Ward et al., 2006). 
Concerns that there might be a large epidemic of vCJD in the UK have not yet 
materialised, since the numbers of new vCJD cases peaked in 2000 and have 
subsequently declined. Humans are likely to have a high species barrier to BSE and 
the infectious oral dose for transmission of BSE to humans also appears to be high 
(Lasmezas et al., 2005; Bishop et al., 2006). These factors are likely to have helped 
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restrict the UK vCJD epidemic to 175 primary cases to date. Three additional 
secondary vCJD cases have occurred in the UK as a likely consequence of 
transmission via transfusion of packed red blood cells from UK vCJD-infected donors 
(reviewed in Urwin et al., 2016) (Figure 1.6). 
 
1.5.5.2. Genetics 
All tested definite and probable UK cases of vCJD up to 2015 belong to the PRNP 
codon 129 MM subgroup, but a definite case in 2016 was identified in a PRNP codon 
129 MV patient (Table 1.2; Figure 1.6). This recent case raises the possibility of a 
further cases in this genotype, which is the commonest in the UK.  
 
The incubation period for vCJD is unknown, but a mean value of 16 years has been 
estimated (Valleron et al., 2001). The full extent of the vCJD epidemic cannot yet be 
determined, particularly because of the possibility of further cases in PRNP codon 129 
heterozygotes, which may have a more prolonged incubation period than the codon 
129 MM cases (Garske & Ghani, 2010). Smaller numbers of vCJD cases have been 
identified in other countries (Table 1.6), either as a result of local exposure to BSE-
contaminated meat products, or to exposure during a period of residence in the United 
Kingdom during 1980–1996, when dietary BSE exposure was likely. The number of 
new cases of vCJD in these countries has also declined, although a further case was 






Annual deaths from variant CJD in the United Kingdom. 
 
 
Numbers of variant CJD cases in the UK grouped by the year of death and the numbers 
of deaths per year. PRNP codon 129 genotype data is provided where known 
(unknown cases are indicated as untyped) and the three secondary variant CJD cases 
occurring as a result of infection via transfusion of packed red blood cells are also 
indicated. 
Abbreviations: CJD: Creutzfeldt-Jakob disease. M: methionine; PRNP: prion protein gene; V: valine 











TOTAL NUMBER OF 
PRIMARY CASES  
(NUMBER ALIVE)  




(NUMBER ALIVE)  
 
RESIDENCE 






UK  175 (0)  3 (0)  178§  
France  27 (0)  -  1  
Republic of Ireland  4 (0)  -  2  
Italy  3 (0)  -  0  
USA  4† (0)  -  2  
Canada  2 (0)  -  1  
Saudi Arabia  1 (0)  -  0  
Japan  1* (0)  -  0  
Netherlands  3 (0)  -  0  
Portugal  2 (0)  -  0  
Spain  5 (0)  -  0  
Taiwan  1 (0)  -  1  
 
 † The third US patient with variant CJD was born and raised in Saudi Arabia and has lived permanently 
in the United States since late 2005. According to the US case-report, the patient was most likely 
infected as a child when living in Saudi Arabia.  
The completed investigation of the fourth US patient did not support the patient’s having had extended 
travel to European countries, including the United Kingdom or travel to Saudi Arabia. It confirmed that 
the case was in a United States of America citizen born outside the Americas and indicated that his 
infection occurred before he moved to the United States; the patient had resided in Kuwait, Russia and 
Lebanon. (http://wwwnc.cdc.gov/eid/article/21/5/pdfs/14-2017.pdf ) 
 
* The case from Japan had resided in the UK for 24 days in the period 1980-1996.  
§ Case 178 from the UK was heterozygous (methionine/valine) at codon 129 of the PRNP gene  
 
Abbreviations: CJD: Creutzfeldt-Jakob disease; PRNP: prion protein gene. 
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1.5.5.3. Clinical features 
Variant CJD affects young patients with a mean age at death of 30 years and a median 
duration of illness of 14 months  (Heath et al., 2011). The youngest case had an onset 
at 11 years and was reported from Portugal (Barbot et al., 2010). The age distribution 
may be attributable to age-related differences in dietary BSE exposure (Cooper & Bird 
2002), or age-related disease susceptibility (Boelle et al., 2004). The presenting 
symptoms are nonspecific and usually psychiatric (anxiety, depression, personality 
change), often with painful sensory symptoms, for a mean of 6 months before the 
emergence of neurological signs and symptoms, including progressive ataxia, visual 
problems, cognitive decline and involuntary movements, including myoclonus, 
dystonia and chorea (Zeidler et al., 1997a, 1997b) (Table 1.7). The terminal stages are 
characterised by akinetic mutism, similar to sCJD. Death is usually due to intercurrent 
infection. Six UK vCJD cases over the age of 55 years  have been identified, of which 
only two were diagnosed in life, reinforcing the need for autopsy to provide a definitive 
diagnosis and for effective disease surveillance (el Tawil et al., 2015). Further similar 
cases can be predicted on the basis of epidemiological data and disease modelling 
(Valleron et al., 2001), implying that the full extent of the vCJD epidemic cannot yet 
be established. The internationally agreed diagnostic criteria for vCJD are summarised 
in Table 1.7. 
 
The EEG usually appears normal in vCJD; the periodic triphasic complexes 
characteristic of sCJD have only rarely been reported in the terminal stages of vCJD 
(Binelli et al., 2006; Yamada, 2006). CSF analysis of 14-3-3 is positive in around 50% 
of vCJD cases (Green et al., 2001), while the RT-QuiC test for PrPSc in CSF has been  
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Table 1.7. 




1A and neuropathological confirmation of variant Creutzfeldt-Jakob diseasee. 
 
4.2 PROBABLE 
 4.2.1   I and 4/5 of II and IIIA and IIIB 
 4.2.2   I and IV Ad 
 
4.3 POSSIBLE 


















Abbreviation: CJD: Creutzfeldt-Jakob disease. 
 
I    A   Progressive neuropsychiatric disorder 
      B   Duration of illness > 6 months 
      C   Routine investigations do not suggest an alternative diagnosis 
      D   No history of potential iatrogenic exposure 
      E   No evidence of a familial form of prion disease 
 
II   A   Early psychiatric symptomsa 
      B   Persistent painful sensory symptomsb 
      C   Ataxia 
      D   Myoclonus or chorea or dystonia 
      E   Dementia 
 
III   A   Electroencephalogram does not show the typical appearance of 
sporadic CJDc  in the early stages of illness 
        B   Bilateral pulvinar high signal on brain magnetic resonance 
imaging 
 
IV    A   Positive tonsil biopsyd 
_____________________ 
a   depression, anxiety, apathy, withdrawal, delusions. 
b   this includes both frank pain and/or dysaesthesia. 
c   the typical appearance of the electroencephalogram in sporadic CJD consists of 
generalised triphasic periodic complexes at approximately one per second.  These 
may occasionally be seen in the late stages of variant CJD. 
d  tonsil biopsy is not recommended routinely, nor in cases with 
electroencephalogram appearances typical of sporadic CJD, but may be useful in 
suspect cases in which the clinical features are compatible with variant CJD and 
magnetic resonance imaging does not show bilateral pulvinar high signal. 
e   spongiform change and extensive prion protein deposition with florid plaques 
throughout the cerebrum and cerebellum. 
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negative to date. MRI scans show high signal in the posterior thalamus (the so-called 
“pulvinar sign”) and in the periaqueductal region of the midbrain on fluid-attenuated 
inversion recovery (FLAIR) and/or diffusion-weighted imaging (DWI) sequences in 
over 90% of vCJD cases in PRNP codon 129 MM patients  (Collie et al., 2003) (Fig. 
9). The recent PRNP codon 129 heterozygote vCJD patient case had similar clinical 
features to previous cases, but the MRI scan showed features more in keeping with 
sporadic CJD. Tonsil biopsy in vCJD patients can demonstrate abnormal prion 
protein accumulation in the lymphoid follicles on IHC and PrPres on WB examination  
(Hill et al., 1999). However, this procedure is not without risk and is not 




In marked contrast to sCJD, the neuropathology of vCJD is stereotyped and 
characterised by the presence of large numbers of florid plaques in the cerebral cortex 
and cerebellar cortex, composed of a central eosinophilic amyloid core with radiating 
linear amyloid fibrils surrounded by a corona of spongiform change (Fig. 10) (Will et 
al., 1996). Spongiform change is present to a variable extent in the cerebral cortex and  
cerebellum, but is most marked in the caudate nucleus and putamen. The thalamus 
shows less spongiform change and amyloid plaque formation, but there is severe 
neuronal loss and gliosis in the posterior nuclei, particularly the pulvinar (Ironside et 
al., 2000). The distribution of these abnormalities corresponds to the abnormalities 
identified in this region of the brain on MRI (Collie et al., 2003). The brainstem and 
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spinal cord show no evidence of florid plaques and exhibit minimal spongiform 
change.  
 
Immunohistochemistry for prion protein shows intense labeling of the florid plaques 
in the cerebral and cerebellar cortex, and also demonstrate small amorphous “feathery” 
deposits of abnormal PrP around small capillaries and neurones, along with numerous 
smaller cluster plaques that are not present on routine stains (Fig. 9) (Ironside et al., 
2002). The characteristic histological and immunohistochemical features of vCJD are 
illustrated in Figure 1.7. The neuropathological features described above in large 
numbers of PRNP codon 129 MM patients were also present in the recently reported 
case of vCJD in a UK PRNP codon 129 MV patient (Professor S Brandner, personal 
communication, 2016). 
 
1.5.5.5. Peripheral pathogenesis 
Experimental oral transmission of scrapie and BSE to mice has established that the 
agent crosses the wall of the small intestine, most likely via M cells (Heppner et al.,  
2001; Donaldson et al., 2012) and replicates in the follicular dendritic cells in Peyer’s 
patches. It can then spread to replicate in other lymphoid tissues, including  
the spleen and lymph nodes, but can also spread retrogradely via the parasympathetic 
nerves in the gut via the vagus to the medulla (McBride et al., 2001). Centripetal spread 
from the spleen via the sympathetic nervous system to the spinal cord can also occur, 
followed by spread to the brain (Figure 1.8). Centrifugal spread from the CNS to 
sensory ganglia and muscles may also occur at a later stage in the disease (Beekes & 
McBride, 2007).  
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Figure 1.7. 
Characteristic histological and immunohistochemical features of vCJD  
(with permission from Taylor and Francis, UK) 
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Legend to Figure 1.7. 
 
Large rounded amyloid plaques are present in the frontal cortex in the form of florid 
plaques (a), and in the cerebellum as rounded plaques with little surrounding 
vacuolation in the granular layer (arrows) (c).  Immunohistochemistry for PrP shows 
intense labelling of these large plaques, and also demonstrates multiple smaller cluster 
plaques in addition to amorphous and pericellular PrP deposits in the frontal cortex (b) 
and in the cerebellar cortex (d).   
The caudate nucleus shows intense spongiform change, with little evidence of amyloid 
plaque formation (e). PrP accumulation in the caudate nucleus and other regions of the 
basal ganglia shows multiple small punctate deposits around neurones and also 
apparently around axons in a linear pattern (f).  
The pulvinar in vCJD shows extensive neuronal loss and gliosis with patchy 
spongiform change and little evidence of amyloid plaque formation (g).  The intense 
gliosis in the pulvinar is demonstrated on immunohistochemistry for glial fibrillary 
acidic protein (h).   
Peripheral pathology in vCJD. Immunohistochemistry shows evidence of PrP 
accumulation in: dorsal root ganglion cells (i); germinal centres within the tonsil (j) 
follicular dendritic cells in  small germinal centres in the spleen (PET blot) (k) a 
cervical lymph node in an asymptomatic patient who had received a blood transfusion 
from a donor who subsequently died from vCJD, providing evidence of asymptomatic 
infection at the time of death (l). 
(Sections a, c, e, and g are stained with haematoxylin and eosin, and sections b, d, f, i, 
j, and l are stained by immunohistochemistry for PrP using the KG9 antibody. The 3F4 
antibody was used in the PET blot in section k). 
Scale bar=250 m 
 








Spread of the scrapie agent from the gut along two distinct neuroanatomical pathways 
to the CNS (with permission from Taylor and Francis, UK) 
 
 
Following oral inoculation with scrapie, the agent crosses the gut mucosa and 
replicates in the gut-associated lymphoid tissues (GALT) and can then spread to other 
lymphoid organs, including the spleen. From the spleen, the agent can spread along 
sympathetic nerves from the splanchnic plexus to the intermediolateral (IML) column 
of the spinal cord and then to the brain. Direct spread from the gut to the CNS can also 
occur along parasympathetic fibres of the vagus nerve to the dorsal motor nucleus of 
the vagus (DMNV) within the medulla. (DRG: dorsal root ganglion) 
Courtesy of Professor Neil Mabbott, Edinburgh, UK. 
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Variant CJD is also characterised by the accumulation of PrPSc in follicular dendritic 
cells within follicles in lymphoid tissues throughout the body that is readily detected 
by immunohistochemistry, PET blot, or WB analysis (Head et al., 2004a; Ritchie et 
al., 2004). This finding has enabled the use of tonsil biopsy as a diagnostic tool for 
vCJD (see above). PrPSc has also been detected by these techniques in peripheral 
autonomic ganglia in vCJD (Haik et al., 2003). In a vCJD case from the United States 
with a lengthy clinical history, PrPSc was detected in a wider range of tissues using a 
high sensitivity WB technique, including skeletal muscle and skin, following autopsy 
(Notari et al., 2010).  
 
1.5.5.6. Molecular biology 
WB analysis of the brain in vCJD shows a uniform single PrPres type (type 2B) with 
predominance of the diglycosylated fragment, in contrast to sCJD and other forms of  
human prion diseases (Head & Ironside, 2012). A similar PrPres isoform is present in 
lymphoid tissues in vCJD, including tonsil, thymus, spleen, lymph nodes, and gut-
associated lymphoid tissues (Head et al., 2004b). The PrPres isoform in vCJD is also 
similar to that found in the CNS in cattle and in other species infected with BSE, 
including antelopes and cats (Collinge et al., 1996), supporting the concept of 
molecular strain typing. 
 
Significant levels of infectivity are present in lymphoid tissues in vCJD, although the 
levels are less than those in the CNS (Bruce et al., 2001). Concerns over possible 
infectivity also being present in blood led to the establishment of the UK Transfusion 
Medicine Epidemiology Review project, a lookback study that identified three patients 
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who died from vCJD after receiving non-leukodepleted packed red blood cell 
transfusions from asymptomatic donors who subsequently died from vCJD (reviewed 
in Urwin et al., 2016). The incubation period from transfusion to the onset of 
symptoms in recipients was 7–9 years and the period prior to clinical signs in the 
donors was 1–3 years. A further UK recipient of a similar transfusion died of an 
unrelated illness with no neurological signs or symptoms 5 years later. After autopsy, 
accumulation of PrPres  characteristic of vCJD was found by WB, IHC and PET blot 
in the spleen and a lymph node, indicating an asymptomatic vCJD infection (Peden et 
al., 2004), subsequently proven by experimental transmission  (Bishop et al., 2013). 
This individual was a PRNP codon 129 heterozygote. A UK patient with haemophilia, 
but no neurological signs or symptoms suggestive of vCJD, was also found to have 
PrPres characteristic of vCJD in an autopsy spleen sample, raising the possibility that 
UK plasma products may also transmit vCJD (Peden et al., 2010). The biological 
properties and the PrPres isoform of the vCJD prion strain in brain tissue from these 
UK patients with secondary transfusion-related vCJD and in spleen tissue from the 
individual with an asymptomatic transfusion-acquired vCJD infection have not altered 
significantly in experimental transmission studies  (Bishop et al., 2008), even 
following passage in the PRNP codon 129 heterozygous individual  (Bishop et al., 
2013). Transmission studies to transgenic mice overexpressing bovine prion protein 
have recently demonstrated infectivity in leucocytes, plasma and erythrocytes in vCJD 
patients (Douet et al., 2014). 
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1.5.5.7. Prevalence of asymptomatic vCJD infection 
To date, 231 cases of vCJD have been identified worldwide, with 178 occurring in the 
UK (Table 1.6). There is ongoing concern about the possible numbers of UK residents 
with asymptomatic vCJD infection, given the wide exposure of the UK population to 
BSE via the food chain in the 1980s and 1990s, and concerns over the safety of blood 
transfusion in the UK still remain (House of Commons Science and Technology 
Committee, 2014).  In the absence of a blood based screening test for vCJD (see below), 
several tissue-based studies using IHC to detect abnormal PrP accumulation in 
lymphoid tissues in appendix and tonsil specimens from UK patients have been 
undertaken to address these concerns, since abnormal prion protein can accumulate in 
the appendix before the onset of symptoms in vCJD (Hilton et al., 1998). Positive 
immunohistochemical labelling of follicular dendritic cells within lymphoid follicles 
is specific for vCJD (Hilton et al., 2004b). The patients in these large studies 
underwent surgery because of suspected appendicitis or tonsillitis, but were otherwise 
normal.  
 
The first study (Appendix I) in 2004 found 3/12,674  positive specimens, giving an 
estimated prevalence of asymptomatic vCJD infection of 237 per million, or 
approximately 1 in 4000 in the UK, with a wide confidence interval (Hilton et al., 
2004a). A subsequent study (Appendix II) examined 32,441 appendix samples from 
individuals born in birth cohorts from 1941–1960 and 1961–1985. 16 positive cases 
from both cohorts were identified, giving an estimated  prevalence of asymptomatic 
vCJD infection in the UK of 493 per million, or approximately 1 in 2000, also with a 
wide confidence interval (Gill et al., 2013). This difference between the results of these 
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two studies is not statistically significant (Gill et al., 2013). Genetic analysis found 2 
of the 3 positive cases in the first study  to have the PRNP codon 129 VV genotype  
(Ironside et al., 2006), and the 16 positive cases in the 2013 study comprised 8 VV, 4 
MV and 4 MM codon 129 genotypes (Gill et al., 2013). It therefore appears that all 
three PRNP codon 129 genotypes are susceptible to vCJD infection and may develop 
vCJD after an unknown and possibly lengthy incubation period. Preliminary results 
from the latest study (Appendix III) found 7/29516 appendix cases to be positive for 
prion protein (Public Health England, 2016). Of these, 2 were found in the 5,865 
appendices removed between 1977-79 and 5 positives were identified in the 14,824 
appendices removed between 2000-14 in patients born between 1996-2000, suggesting 
that dietary BSE exposure in the UK may have occurred over a wider time period than 
initially thought. 
 
At present, several groups are working on a blood test for vCJD, some with 
encouraging progress. However, none of the methods currently under development has 
been used to detect asymptomatic vCJD infection in humans, although this can be 
achieved in some animal models (Saa et al., 2006; Edgeworth et al., 2011; Lacroux et 
al., 2014; Sawyer et al., 2015; Concha-Marambio et al., in press). Further progress is 
required to refine the most recent estimates for the prevalence of asymptomatic vCJD 
infection from tissue-based studies and a protocol for the evaluation of a test for its 
suitability in the diagnosis of vCJD has been proposed (Cooper et al., 2013). Blood 
tests for vCJD could also be used in the screening of blood donations or individuals 
prior to surgery in the UK; such uses will first require detailed ethical consideration 
(Turner, 2006). 
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1.5.6. Iatrogenic CJD 
The first reported case of iatrogenic CJD (iCJD) was published in 1974 in a recipient 
of a corneal graft from a donor who had died from sCJD (Duffy et al., 1974). Since 
then hundreds of cases of iCJD have been identified in groups of patients exposed to 
human tissue grafts and implants, inoculated with tissue homogenates or operated on 
with instruments or electrodes previously used on the brains of patients with CJD, most 
likely sCJD (Table 1.8).  
 
The largest groups of iCJD cases have occurred in patients inoculated with human 
growth hormone (hGH) or human pituitary gonadotrophins, and patients who received 
an implant of human dura mater (hDM) during neurosurgery. Over 200 cases have 
occurred worldwide in each of these groups, and their numbers are still increasing with 
time, with incubation periods of up to 40 years in some cases  (Brown et al., 2012). 
There have also been a few cases of iCJD linked to contaminated neurosurgical 
instruments, intracerebral depth electrodes and corneal grafts (Table 1.8), but most of 
these causes are now historical. The internationally agreed diagnostic criteria for iCJD 
are summarised in Table 1.9. 
 
1.5.6.1. Epidemiology  
The incidence of hGH iCJD varies from country to country in general relation to the  
scale of the local hGH production process and the likelihood of prion contamination in 
the selection of autopsy cases for pituitary collection (Brown et al., 2012). The 
incidence of iCJD in human dura mater recipients reflects in general the frequency of 
use of Lyodura (a commercially processed lyophilised hDM product implicated in  
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Table 1.8. 
Worldwide cases of iatrogenic CJD, modified from Brown et al., 2012 
 
* An additional instance of subclinical vCJD infection in a PRNP codon 129 MV recipient (Peden 
et al., 2004). 
** A report of probable subclinical vCJD infection in a PRNP codon 129 MV recipient of Factor 
VIII (Peden et al., 2010).  
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2.2.1 Progressive predominant cerebellar syndrome in human pituitary 
hormone recipients 
 





 Possible CJD with a recognised risk factor 




RELEVANT EXPOSURE RISKS FOR THE CLASSIFICATION 
AS IATROGENIC CJD 
The relevance of any exposure to disease causation must take into 
account the timing of the exposure in relation to disease onset 
 
• Treatment with human pituitary growth hormone, human 
pituitary gonadotrophin or human dura mater graft. 
 
• Corneal graft in which the corneal donor has been classified as 
definite or probable human prion disease. 
 
• Exposure to neurosurgical instruments previously used in a case 
of definite or probable human prion disease. 
 
This list is provisional as previously unrecognised mechanisms of human 










almost all cases of iCJD in hDM graft recipients) in neurosurgical procedures, which 
was particularly high in Japan (Hamaguchi et al., 2013). These risks have been 
addressed by the use of recombinant pituitary hormones and synthetic or autologous 
dura mater grafts respectively, so future iatrogenic exposure to CJD through these 
treatments are unlikely to occur. 
 
The incubation periods in the worldwide cohort of iCJD cases are markedly variable, 
with the shortest incubation periods occurring in those exposed via surgical 
instruments or electrodes used on the CNS (1-2.3 years) and the longest occurring in 
human pituitary-derived hGH recipients (5-42 years) (Brown et al., 2012) (Table 1.8). 
Only 4 cases of iCJD in human gonadotrophin recipients have occurred, all in Australia 
(Table 1.8); one of these patients died in the UK (Figure 2.1). Estimation of incubation 
periods in human pituitary hormone recipients is difficult, since the patients are often 
treated over a period of years; the time period from the mid-point 
of pituitary hormone treatment to the onset of clinical symptoms of iCJD is often used 
as an estimate for the incubation period (Swerdlow et al., 2003). 
 
1.5.6.2. Clinical features 
The clinical features of iCJD appear to vary according to the route of exposure. The 
introduction of iatrogenic infection in, on, or adjacent to the brain through 
contaminated neurosurgical instruments or hDM grafts leads to an illness similar to 
sCJD, with rapidly progressive dementia associated with ataxia and myoclonus. 
Accordingly, the duration of illness is similar to sCJD, often measured in a few months. 
Following peripheral exposure through intramuscular injections of hGH a progressive 
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ataxic syndrome develops accompanied by limb dysaesthesiae and followed by other 
cerebellar signs and symptoms, often with cognitive impairment at a relatively late 
stage in the illness, if at all (Rudge et al., 2015). The duration of illness in hGH-iCJD 
is longer than that for centrally acquired forms of iCJD and is often around 14 months 
(Rudge et al., 2015). Although there is relatively limited data, the clinical 
investigations in iCJD patients, including EEG, MR, and CSF 14-3-3, have a similar 
sensitivity and specificity as in sCJD (Meissner et al., 2009b; Rudge et al., 2015). The 
diagnostic criteria for iCJD depend on the identification of a potential risk factor for 
iatrogenic exposure in suspected cases of CJD or in relatively young individuals 
presenting with a progressive ataxic syndrome.  
 
1.5.6.3. Neuropathology 
Since the sCJD agent is the likely source of infection in most cases of iCJD, it is  
perhaps to be expected that, as for sCJD, the pathological phenotype in iCJD appears 
to be influenced by the patient’s PRNP codon 129 genotype and the PrPres type 
identified on WB of brain homogenates  (Meissner et al., 2009b). However, some 
differences occur:there is a subgroup of hDM-iCJD PRNP codon 129 MM cases in 
Japan that contain amyloid plaques in the brain, which resemble kuru plaques  
(Yamada et al., 2009). In the UK, cases of hDM-iCJD occurred in PRNP codon 129 
MM patients with type 1 PrPres in the brain and no evidence of amyloid plaques  (Heath 
et al., 2006).  
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1.5.7. Precautions to avoid future cases of iatrogenic CJD 
1.5.7.1. Control measures 
Control measures to reduce the risk of human-human transmission of prion diseases 
have been produced by the World Health Organisation (WHO), Geneva 
(http://www.who.int/ entity/ csr/resources/publications/bse/whocdscsraph2003.pdf) 
and in the UK by the Advisory Committee on Dangerous Pathogens 
(https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/ 
427854/Infection_controlv3.0.pdf). Similar guidelines have appeared more recently 
(Brown et al., 2012; Brown & Farrell, 2015; Bonda et al., 2016), including an audit of 
the work of the CJD Incidents Panel in the UK, which was set up to deal with any 
event in the UK healthcare system that might have the potential to result in the 
iatrogenic transmission of prion diseases (Hall et al., 2014).  In the absence of a rapid 
and reliable test to detect asymptomatic infection with any form of human prion 
disease, the risk of human-to-human transmission of prions, either via contaminated 
surgical instruments, tissue-derived implants or injections, blood transfusion or organs 
donation, cannot be eliminated completely.  Several strategies have been employed to 
help manage these risks: 
1) Identification of symptomatic patients with any form of prion disease and 
asymptomatic individuals at increased risk of developing any form of prion 
disease and implementing a process of donor deferral for organs or tissues for 
transplantation, blood for transfusion (particularly for those at increased risk for 
vCJD) or tissues used in the manufacture of biological products. 
2) Classification of tissues by their likely level of prion infectivity in human prion 
diseases. CNS tissues (brain, spinal cord, cranial nerves and cranial ganglia), 
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pituitary gland and the posterior eye (retina, retinal pigment epithelium, choroid, 
posterior hyaloid face, subretinal fluid and optic nerve) are considered to have the 
highest levels of infectivity, particularly in symptomatic patients. Spinal ganglia 
and olfactory epithelium are considered to have medium levels of infectivity in all 
forms of human prion disease, but in vCJD all lymphoid tissues (spleen, tonsil, 
lymph nodes, gut, appendix and thymus) and the adrenal gland are also considered 
to be medium infectivity tissues. All other tissues (including blood and CSF) are 
classified as low infectivity in all forms of human prion diseases 
(https://www.gov.uk/government/uploads/system/uploads/ attachment_ data/file/ 
444243/Annex_A1_update.pdf). 
3)  Use of dedicated or single-use surgical instruments in these individuals, 
especially for those instruments coming into contact with high-infectivity tissues 
(CNS and retina), or quarantining such instruments in symptomatic patients in 
whom a diagnosis of CJD is being investigated, to be re-evaluated once the results 
of the additional investigations become available. 
4) Inclusion of steps in the sterilization of certain neurosurgical and ophthalmic 
surgical instruments and the processing of therapeutic tissues and fluids that are 
designed to reduce or eliminate any potential prion infectivity. 
5) Avoidance of human-derived hormones and other biological products and their 
replacement by recombinant equivalents whenever possible, e.g. Factor VIII.  
The groups of individuals deemed to be at increased risk of CJD in the UK are 
summarised in Table 1.10. While the categories including the recipients of human dura 
mater grafts, human pituitary-derived hormones and those at a genetic risk of CJD are 




Categorisation of individuals at increased risk of human prion disease in the UK 
1. Symptomatic patients: 
a. Patients who fulfil the diagnostic criteria for definite, probable or possible CJD 
(see Tables 1.4, 1.5, 1.7 and 1.9 for diagnostic criteria)  
b. Patients with neurological disease of unknown aetiology, who do not fit the 
criteria for possible CJD, but where the diagnosis of CJD is being actively 
considered 
 
2. Patients at increased risk of genetic forms of human prion disease: 
a. Individuals who have been shown by specific genetic testing to be at significant 
risk of developing CJD 
b. Individuals who have a blood relative known to have a genetic mutation 
indicative of genetic CJD 
c. Individuals who have or have had two or more blood relatives affected by CJD 
or other prion disease  
 
3. Patients identified as “at increased risk” of vCJD through receipt of blood 
from a donor who later developed vCJD: 
a. Individuals who have received labile blood components (whole blood, red cells, 
white cells or platelets) from a donor who later went on to develop vCJD 
 
4. Patients identified as “at increased risk” of CJD through iatrogenic 
exposures: 
a. Recipients of hormone derived from human pituitary glands, e.g. growth 
hormone, gonadotrophin, are “at increased risk” of transmission of sporadic 
CJD  
b. Individuals who underwent intradural brain or intradural spinal surgery before 
August 1992 who received (or might have received) a graft of human-derived 
dura mater are “at increased risk” of transmission of sporadic CJD (unless 
evidence can be provided that human-derived dura mater was not used)  
c. Individuals who have had surgery using instruments that had been used on 
someone who went on to develop CJD, or was “at increased risk” of CJD 
d. Individuals who have received an organ or tissue from a donor infected with 
CJD or “at increased risk” of CJD  
e. Individuals who have been identified as having received blood or blood 
components from 300 or more donors since January 1990;  
f. Individuals who have given blood to someone who went on to develop vCJD; 
g. Individuals who have received blood from someone who has also given blood 
to a patient who went on to develop vCJD 
h. Individuals who have been treated with certain implicated UK sourced plasma 
products between 1990 and 2001 
 
Abbreviations: CJD: Creutzfeldt-Jakob disease; UK: United Kingdom. 
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is of special concern for the UK, particularly when the incidence of asymptomatic 
vCJD infection in the UK population is estimated to be as high as 1 in 2000 
individuals (Gill et al., 2013). 
 
1.5.7.2. Risk reduction 
Risk reduction steps to reduce or remove prion infectivity are often challenging to 
implement in both clinical and laboratory settings (https://www.gov.uk/government/ 
uploads/system/ uploads/attachment_data/ file /427855/Annex_C_v3.0.pdf): 
1. Sodium hypochlorite is considered effective at reducing infectivity, but only at 
concentrations (20,000ppm available chlorine for 1 hour at ambient 
temperature) that pose certain practical constraints, particularly in enclosed 
spaces. 
2. Sodium hydroxide (2M for 1 hour) has a substantial effect, and will reduce 
infectivity to an acceptable level when used at ambient temperature. An 
increase in temperature will increase effectiveness. 
3. Incineration is effective at removing the infectious agent and eliminating 
infectivity. Temperatures over 600ºC are likely to be practically effective, and 
850ºC is commonly used in practice. Temperatures ≥1000 ºC can produce 
sterility. 
4. The following autoclave methods will reduce infectivity, but cannot be relied 
upon to completely eliminate infectivity (either porous load or gravity 
displacement): 
a. 121°C for 15 minutes  
b. 134-137°C for 3 minutes  
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c. 134-137°C for 18 minutes  
d. Six successive cycles of 3 minutes  
5.  Chemical disinfectants commonly used for decontamination that are   
ineffective at reducing prion infectivity include acids, alcohols, formaldehyde 
and related compounds, and phenol solutions. 
Many of these methods are impractical for use on delicate or complex neurosurgical 
instruments. The decontamination of steel surfaces on surgical instruments is hindered 
by the fact that prions adhere avidly to stainless steel surfaces (Zobeley et al., 1999); 
furthermore, different strains of prions exhibit differential sensitivity to heat when used 
for inactivation (Fernie et al., 2007). However, on the basis of scenario modelling it 
has been suggested that after six cycles of neurosurgical instrument use with 
conventional cleaning and autoclaving following an index patient, subsequent patients 
on whom the instrument is used are highly unlikely to be at risk for iatrogenic CJD 
(Thomas et al., 2013). 
The challenges of removing prions from stainless steel surfaces have been addressed 
by a number of new technologies, including radio-frequency gas plasma treatment 
(Baxter et al., 2005), combinations of proteolytic enzymes and detergents (Jackson et 
al., 2005) and gaseous hydrogen peroxide (Fichet et al., 20007). None have yet been 
scaled up for use in a clinical setting, even for a trial period. This disappointing failure 
of translation must be overcome to ensure that an effective means of decontaminating 
neurosurgical and ophthalmological instruments used on patients with or at increased 
risk of prion diseases will be available in UK hospitals.  
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Leucodepletion alone appears to reduce vCJD infectivity inblood by a considerable 
extent (Lacroux et al., 2012), justifying its use in the UK. However, additional “prion 
filters” have been unsuccessful in completely removing prion infectivity in various 
experimental models, including a sheep model of BSE with endogenous infectivity in 
blood (Lacroux et al., 2012; McCutcheon et al., 2015).  
 
1.6. Treatment of human prion diseases 
Numerous compounds have been used over many decades in attempts to treat prion 
diseases, initially in animal models, but now including cell culture models and cell-
free prion conversion systems such as PMCA. The earliest investigations in animal 
models identified several compounds that appeared to have an effect in prolonging the 
disease incubation period, but only if administered before or at the same time as the 
experimental infection. None was capable of curing the disease. The background to 
these extensive studies has been reviewed in detail by Trevitt and Collinge (Trevitt & 
Collinge, 2006), who summarised the therapeutic approaches into five groups:  
1. Groups of chemical agents, e.g. heparin sulphate and its analogues, tetracyclic 
compounds, polyene antibiotics, amyloid-binding dyes, e.g. Congo Red.  
2. Immunological agents, e.g. antibodies, active and passive immunisation 
strategies.  
3. Approaches targeting PrPC expression, e.g. by RNA interference. 
4. Novel compounds identified by screening approaches in vitro (cell culture and 
in vitro screens).   
5. Other miscellaneous compounds including RNA aptamers and a range of 
unrelated compounds.  
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Since then, in silico systems have been employed to screen large numbers of 
compounds by a variety of modelling strategies including molecular docking to 
identify possible binding agents to inhibit the conversion of PrPC to PrPSc (Ferreira et 
al., 2014). Some of the aryl amide compounds currently under investigation can extend 
survival in some prion-infected mice, but have no effect on transgenic mice infected 
with human prions (Giles et al., 2016). The development of drug resistant prion strains 
appears to be a problem with some of these novel compounds, e.g. 2-aminothiazole 
compounds (Berry et al., 2013). Another potential therapeutic target is the unfolded 
protein response, which is activated in the brain in a range of neurodegenerative 
diseases associated with protein misfolding. Overactivation of the protein kinase 
RNA-like ER kinase (PERK) branch of the unfolded protein response results in a 
critical reduction in protein synthesis in neurones, leading to dysfunction and 
ultimately cell death (reviewed in Smith & Mallucci, 2016). PERK inhibition prevents 
neuronal loss, spongiform change and clinical disease in prion-infected mice, but this 
can result in toxicity in other organs (particularly in the pancreas), which can be 
overcome by the use of highly selective compounds (Halliday et al., 2015). 
 
1.6.1. Clinical trials 
One of the major challenges in developing and evaluating potential treatments for 
prion diseases in that they are rare disorders, difficult to diagnose in the early stages 
of disease and often show rapid clinical progression with death in a few weeks or 
months after the onset of the first symptoms of illness (Stewart et al., 2008). Any drug 
being considered for this purpose should ideally have the capability to cross the blood-
brain barrier rapidly in order to reach therapeutic levels in the CNS. A double-blind 
 75 
trial of flupirtine maleate, which protects neuronal cells from apoptosis following 
exposure to PrP fragments and A peptides, showed no significant effect on patient 
survival (Otto et al., 2004). Pentosan polysulphate, which binds to PrPC and may 
prevent its conversion to PrPSc, does not cross the blood-brain barrier and requires 
intraventricular infusion (Farquhar et al., 1999). This compound produced no 
discernible clinical improvement in small numbers of sCJD, genetic CJD, GSS, iCJD 
and vCJD patients (Tsuboi et al., 2009; Bone et al., 2008; Newman et al., 2014). A 
patient preference trial of quinacrine, which can delay PrPC conversion in vitro (Barret 
et al., 2003), produced no significant clinical benefits (Haik et al., 2004; Collinge et 
al., 2009); this was confirmed in a larger double-blind placebo-controlled trial 
(Geschwind et al., 2013). Although showing some beneficial effects in animal models, 
a recent clinical trial of doxycycline showed no effect on the disease course in both 
sCJD and genetic CJD (Haik et al., 2014). Despite this disappointing outcome, this 
study has demonstrated that a clinical trial in this group of rare diseases is possible 
through international collaboration, which can serve as a model system in which other 
potential treatments can be evaluated (Geschwind, 2014). In a recent preventative 
study, asymptomatic adult carriers of the FFI mutation will undergo long-term 
doxycycline treatment with monitoring of PrPSc levels in olfactory mucosal brushings 
as a biomarker for efficacy (Forloni et al., 2015; Zanusso et al., 2016).  
 
Improvements in early clinical diagnosis of human prion diseases will also be required 
if any new therapeutic agents are to be effectively evaluated in the setting of a clinical 
trial. In the absence of any effective curative agents, treatment of human prion diseases 
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currently remains symptomatic and aimed at providing as much relief and support to 
the patient and their families as possible, as for other fatal neurodegenerative disorders. 
 
1.7. Prion-like mechanisms in other human neurodegenerative disorders. 
The recognition that other neurodegenerative diseases are associated with the 
accumulation and propagation of misfolded proteins in the CNS has led to the proposal 
that prion-like mechanisms may also be responsible for these disorders, including AD, 
PD and motor neurone disease (MND) in both their sporadic and genetic forms (Jucker 
& Walker, 2013; Prusiner 2013). A common model of disease progression occurs in 
these disorders, in which abnormally folded isoforms of a disease-associated protein 
interact to form  sheet structures that aggregate to form a seed or nucleus that results 
in the formation of other abnormally folded isoforms, including neurotoxic isoforms, 
in a prion-like process (Goedert, 2015). In view of the lack of epidemiological 
evidence for disorders such as AD, PD and MND being infectious (Edgren et al., 2016), 
the term “propagon” rather than prion has been proposed for the group of proteins 
(including A, tau and -synuclein) that have the capacity to misfold and aggregate 
homotypic molecules without possessing infectivity (Eisele & Duyckaerts, 2016). 
Oligomeric species of these aggregates appear to have the greatest capacity for self-
propagation and also are the molecular species most likely to be associated with 
neurotoxicity (Silveira et al., 2005; Aguzzi & Lakkaraju, 2016). 
 
Histological examination of the brain in AD and PD has long established that the 
protein aggregates that are key components of the neuropathology – A plaques and 
neurofibrillary tangles composed of hyperphosphorylated tau in AD and Lewy bodies 
 77 
containing -synuclein in PD – appear to spread progressively with time through the 
brain in highly predictable synaptically-connected neuroanatomical pathways, often 
correlating with the nature and severity of clinical signs and symptoms prior to death 
(Alafuzoff et al., 2009a, 2009b). These observations have led to agreed histological 
classification schemes to denote the extent of the neuropathological changes in these 
disorders to facilitate clinicopathological correlation and research (Hyman et al., 2012). 
These patterns of spread imply cell-to-cell spread of protein aggregates in the CNS, 
leading to progressive disease and ultimately death. The underlying mechanisms of 
this cell-to-cell spread are uncertain, but a number of models have been proposed, 
including exosomes as vehicles to carry toxic proteinaceous seeds from an affected 
cell to an acceptor cell, nonconventional export via direct secretion, or exchange via 
tunneling nanotubes (Victoria & Zurzolo, 2015). 
 
1.7.1. Amyloid seeding 
There is no convincing epidemiological evidence to date to suggest that protein 
misfolding disorders affecting the CNS are infectious, apart from prion diseases 
(Mayeux & Stern, 2012; Edgren et al., 2016). However, there is an increasing body of 
evidence to indicate that the abnormal proteins involved can be seeded in vivo and in 
vitro, with accumulation of the seeded deposit over time (reviewed in Moreno-
Gonzalez & Soto, 2011). Intraperitoneal administration of A and tau aggregates in 
experimental models can result in accumulation of these proteins in the brain either by 
vascular spread (involving crossing the blood-brain barrier, or initial spread into the 
regions where no blood-brain barrier exists) or by retrograde axonal transport along 
peripheral nerves to the CNS (Eisele et al., 2010; Clavaguera et al., 2014). Furthermore, 
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different strains of A in AD and tau in a range of human tauopathies (AD, 
corticobasal degeneration, argyrophilic grain disease and frontotemporal lobar 
degeneration–tau) have been identified on the basis of their biological behaviour on 
experimental transmission, including the nature and distribution of the pathology and 
the timing of the appearance of the pathology in the brain (Sanders et al., 2014; Watts 
et al., 2014; Stohr et al., 2014). 
 
These prion-like properties have potentially wide-ranging implications for our 
understanding of human neurodegenerative diseases in terms of cell biology, 
mechanisms of toxicity and opportunities for intervention and treatment (Goedert, 
2015; Sanders et al., 2016). Another implication is the possibility of iatrogenic 
transmission of these disorders from one individual to another by routes known to 
result in iCJD. The possibility of iatrogenic transmission of A, tau and -synuclein 
in recipients of human growth hormone was raised by Irwin et al, (Irwin et al., 2013), 
since the pituitary gland can harbour deposits of A and tau in patients with AD and 
-synuclein in patients with PD, as well as PrPSc in CJD (Peden et al., 2007; 
Hashizume et al., 2013; Homma et al., 2014; Irwin et al., 2013; Jaunmuktane et al., 
2015). This possibility was reinforced by recent evidence of A seeding in the brains 
of 4/8 hGH recipients who died with iCJD (Jaunmuktane et al., 2015). However, this 
evidence has been questioned since the patients concerned all suffered from iCJD, with 
widespread accumulation of aggregated PrPSc in the brain that may have acted as an 
amyloid seed, resulting in co-localisation and aggregation of A in the CNS. 
Aseeding around PrPSc deposits has been reported in other forms of human prion 
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disease, particularly in genetic prion diseases associated with the formation of PrPSc 
amyloid plaques (Miyazono et al., 1992; Bugiani et al., 1993; Ikeda et al., 1994).  
 
Recently, further questions have been raised on the clinical background of the patients 
included in the study by Jaunmuktane et al., suggesting that the pre-existing and 
underlying conditions causing hGH deficiency in this patient cohort “could by 
themselves lead to A pathology and abnormal brain structure” (Feeney et al., 2016). 
In response, Collinge et al.  refuted this suggestion (Collinge et al., 2016), but both 
groups of authors acknowledged the need for further studies, including the 






2. Historical narrative on the production and use of hGH in the UK 
The information in this section of the thesis comes from a wide ranges of sources, 
inevitably including records of meetings, copies of correspondence and other 
documents that cannot be cited as references in the published literature. Every attempt 
has been made to include citable references whenever possible. 
 
2.1. Iatrogenic CJD in human growth hormone recipients in the UK 
2.1.1. Background  
One of the first attempts to isolate hGH from the human pituitary gland was in 1957, 
when Raben reported the extraction of hGH from a small series of pituitaries from 
humans, rhesus monkeys and pigs (Raben, 1957). Previous attempts to use animal-
derived growth hormone to treat growth hormone deficiency in humans had been 
generally unsuccessful (Blizzard, 2012). Raben described a method in which pituitary 
glands were stored in acetone after autopsy (no time intervals were specified) then air 
dried, homogenised, washed again in acetone and desiccated in a vacuum. hGH was 
extracted using glacial acetic acid followed by precipitation in ethyl alcohol. Raben 
commented that the chemical processing using acetone, ether and hot glacial acetic 
acid “provided strong bactericidal and viricidal action in the extraction of human 
pituitaries of indeterminate origin” and that the final product was “well suited for 
clinical use” (Raben, 1957). Raben reported the clinical use of the extracted hGH the 
following year in a male “pituitary dwarf” aged 17 years, who grew 2.6 inches per year 
on treatment, as compared with 0.5 inches for the 18 months prior to treatment. No 
complications were reported (Raben, 1958). 
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2.1.2. Production and use of hGH 
In 1959, a clinical trial on the use of pituitary-derived hGH in the treatment of primary 
growth hormone deficiency (either in isolation or as part of a deficiency of all anterior 
pituitary hormones) and secondary growth hormone deficiency (most often due to a 
craniopharyngioma) in the United Kingdom (UK) began under the auspices of a 
Medical Research Council (MRC) Working Party of the Pituitary Hormone 
Committee. The growth hormone was extracted from acetone-fixed pituitary glands in 
the Department of Biochemistry, University of Cambridge, initially using the Raben 
method, but later changing to a modified Wilhelmi method, which caused less 
degradation of hGH, gave higher hGH yields per gland and was less likely to cause 
anti-hGH antibody production (Mills et al., 1969). In 1975, an additional hGH 
extraction site was established at St Bartholomew’s Hospital, London to help meet the 
increasing clinical demand for hGH. This site collected frozen pituitary glands and 
used the Lowry method to extract hGH, with additional gel filtration and 
chromatographic steps for purification of the final pyrogen-free product (Jones et al., 
1979), and remained active until 1980.  
 
In 1977, UK hGH production was transferred to the Therapeutic Products Laboratory 
in the Public Health Laboratory Service Centre for Applied Microbiology in Porton 
Down, where both frozen and acetone-fixed pituitary glands were collected and the 
hGH product underwent purification using Sephadex G-100 gel filtration. As the MRC 
Clinical Trial of hGH had ended in 1976, the MRC Working Group was disbanded 
and responsibility for the hGH service was transferred to the Department of Health 
and Social Security (DHSS) Human Growth Hormone Committee in 1977, which was 
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later reconstituted as the Joint MRC/DHSS Committee for the National Pituitary 
Collection (Milner et al., 1979). The clinical trial was considered a success: “growth 
hormone treatment is one of the outstanding therapeutic successes in recent years” 
(Milner, 1979). 
 
2.1.3. CJD risks  
When the collection of pituitary glands for hGH extraction in the UK began in 1959, 
there was no evidence that sCJD or GSS were infectious diseases that could be 
transmitted from human to human. However, this situation changed in 1968 when 
sCJD was transmitted experimentally to primates, and was reinforced in 1974 when 
the first case of iatrogenic CJD was reported in the recipient of a corneal graft from a 
donor who had died from sCJD (Duffy et al, 1974). Prior to 1974, patients with 
neurological diseases were not specifically excluded as donors of pituitary glands in 
the UK; in 1974, this exclusion was introduced for donors of frozen pituitary glands 
only and expanded in 1976 to cover all frozen glands in the MRC collection. The 
possibility of a scrapie-like “slow virus” agent contaminating the hGH production 
process was raised by the Agricultural Research Council (Dr A Dickinson) in 1976; 
Dr Dickinson also suggested a series of measures that should be put into place to help 
reduce the risks of CJD in the hGH preparations, but not all of these were apparently 
acted upon (Green, 2000). In 1977, the only CNS disorders that were identified as 




Another report of accidental CJD transmission to 2 patients via contaminated brain 
depth electrodes was published in 1977 (Bernoulli et al., 1977); the electrodes in 
question subsequently transmitted CJD to a chimpanzee 18 months after intracerebral 
implantation (Gibbs et al., 1994). Following this event, recommended precautions in 
handling material from patients with CJD were published (Gajdusek et al., 1977).  
Advice was sought in 1978 from Dr Carlton Gajdusek in the USA concerning the 
collection of human pituitary glands in the UK; the advice received (no name was 
recorded) was that tissue from patients with CJD or any other form of dementia should 
not be used in the preparation of hGH for human use. In 1980 the exclusion criteria for 
pituitary gland collection were extended to include CJD and dementia, but it is 
uncertain as to how compliance was monitored, if at all. 
 
A MRC Working Group was then set up to investigate the establishment of 
epidemiological studies of CJD in the UK, particularly concerning the possibility that 
it was a naturally transmissible disease and, if so, by what means. This project was 
subsequently funded by MRC and awarded to Professor Bryan Matthews in the 
University of Oxford, who employed Dr RG Will as a Research Fellow. The first 
results of this retrospective study identified three cases of probable iatrogenic 
transmission of sCJD by contaminated neurosurgical instruments in the 1950s, along 
with a cluster of sCJD cases in Eastern England and the identification of a further sCJD 
case who had been in social contact with a patient suffering from familial CJD (Will 
& Matthews, 1982). In 1984, a retrospective study of CJD cases in England and Wales 
from 1970-79 described three main clinical phenotypes of sCJD, but no further 
evidence of person-to person transmission was reported (Will & Matthews, 1984).   
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2.1.4. Iatrogenic CJD and hGH 
In the winter of 1984, the first deaths from iCJD in recipients of hGH in the USA 
emerged. Three of these patients had died by 1985, and later in the year the death of 
the first UK hGH recipient, a 23-year old female, from iCJD was reported (Koch et 
al., 1985; Gibbs et al., 1985; Powell- Jackson et al., 1985). Administration of hGH in 
the UK was stopped and all other pituitary hormones were withdrawn from clinical 
use. All hGH recipients were flagged and a follow-up project for this cohort was 
undertaken by Professor Michael Preece, Institute of Child Health, London. Later in 
1985 a product licence for biosynthetic growth hormone (Somatonorm II) was granted 
to KabiVitrum and treatment of all hGH deficient patients in the UK was 
recommenced with this product. A publication from the groups of Dr A Dickinson and 
Dr P Lowry describing the preparation of hGH free from contamination with 
unconventional slow viruses (the recently-coined term “prion” was scrupulously 
avoided) appeared in the same edition of the Lancet in which the report of the first UK 
death from iCJD in a hGH recipient was reported (Taylor et al., 1985; Powell-Jackson 
et al., 1985). Later in 1985, an article warning of a potential epidemic of CJD from 
hGH therapy was published by the Gajdusek group (Brown et al., 1985). The presence 
of prion infectivity in hGH preparations in the USA was subsequently confirmed by 
experimental intracerebral inoculation of samples of pituitary-derived hGH into 
primates, which resulted in the onset of neurological symptoms in a squirrel monkey 
after an incubation period of over 5.5 years (Gibbs et al., 1993). Post mortem 
examination of the brain of this animal confirmed the presence of a spongiform 
encephalopathy. Further cases of hGH-iCJD have been recorded in other countries 
(Brown et al., 2012), with the largest numbers occurring in France (see below). 
 85 
2.1.4.1. Legal consequences 
In both the UK and France, legal proceedings were commenced against the bodies 
responsible for the administration of hGH that later resulted in cases of iCJD. In the 
UK, families of 8 hGH recipients who died from iCJD began a case in the High Court 
against the MRC and the Department of Health in 1996 (Dyer, 1996a). The judge, Mr 
Justice Moreland, ruled that the two bodies were negligent in not passing on concerns 
raised by scientists that would probably have led to suspension of hGH treatment from 
July 1977. This decision meant that only the families of patients dying from iCJD who 
started treatment after 1st July 1977 would be entitled to compensation (Dyer, 1996b). 
In France, an investigation began in 1993 into involuntary homicide and aggravated 
fraud charges on a six doctors and biochemists/pharmacists involved in the preparation 
and administration of hGH (Balter, 1993).  In 2009, three French judges acquitted the 
accused and an Appeal Court hearing in 2011 dismissed all the charges (Casassus, 
2009; News of the week (Science), 2011). 
 
2.1.5. Iatrogenic CJD in hGH recipients in the UK and France 
Overall, 1,849 patients from UK and Ireland were treated with hGH produced in the 
UK from 1959 until 1985 (Swerdlow et al., 2003). Over this period, it has been 
estimated that as many as 940,000 pituitary glands were collected for hGH extraction 
over this period (Dr P Adlard, personal communication), which were batched in groups 
of up to 35,000 for hGH extraction. The death rate for all forms of human prion disease 
is around 1 in 10,000 in the UK, so there was ample opportunity for at least one 
pituitary gland from a patient either with or incubating a prion disease (most likely 
sCJD) to be included in the collection for hGH extraction. Since 1985, 78 deaths from 
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iCJD have occurred in this cohort, the latest occurring in 2016 (Figure 2.1). It has been 
established that one form of UK pituitary-derived hGH (the modified Wilhelmi 
preparation) had been administered to all hGH recipients who had developed iCJD, 
albeit in varying quantities and over different time periods (Swerdlow et al., 2003; 
Rudge et al., 2015). Estimated incubation periods in the UK hGH-iCJD patients range 
from 7-40 years (Rudge et al., 2015); these prolonged incubation periods are 
reminiscent of those occurring in kuru, where incubation periods of over 40 years have 
been reported (Collinge et al., 2006). In contrast, only 8 cases of iCJD in hDM graft 
recipients have been reported in the UK, with incubation periods ranging from around 
4-15 years (Heath et al., 2006).    
 
Figure 2.1. 
Annual deaths from iatrogenic CJD in the United Kingdom  
 
Abbreviations: CJD: Creutzfeldt-Jakob disease; dura mater: human dura mater graft-associated 
iatrogenic CJD hGH: human pituitary growth hormone-associated iatrogenic CJD; hGNH : human 
pituitary gonadotrophin-associated iatrogenic CJD (this patient was treated in Australia, but died in 
UK). 
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In France, 119 cases of iCJD in 1443 hGH recipients have occurred between 1991 and 
2009, with no further deaths so far after this date (Brandel et al., 2013). The youngest 
patients died aged 10-11 years (Billette de Villemeur et al., 2012). All were 
treated between December 1983 and July 1985, which has been identified as a high- 
risk period for hGH in France, since treatment of hGH with 8M urea was introduced 
at this time as a risk reduction step for prions (Brandel et al., 2013). However, it is 
unlikely that this step would have completely eliminated any prion infectivity in the 
administered product.   
 
Incubation periods in prion diseases have been studied extensively under experimental 
conditions and appear to be significantly influenced by both recipient (host) genetic 
factors and the strain properties of the infectious agent (Head et al., 2015). The 
principal human genetic factor influencing this incubation period is the PRNP codon 
129 polymorphism of the recipient.  It has long been recognised that homozygosity at 
this locus may predispose to both iCJD and sporadic CJD (sCJD) (Collinge et al., 
1991; Palmer et al., 1991). However, differences in the frequency of the three PRNP 
codon 129 polymorphisms (MM, MV and VV) have been reported in hGH-iCJD 
cohorts in different countries; in particular, most cases of hGH-iCJD in France have 
belonged to the MM sub-group, whilst in the UK the VV and MV sub-groups 
predominate (Brandel et al., 2003).  These differences may also reflect the nature of 
the strain(s) of CJD (presumably sCJD) that were responsible for the iatrogenic disease 
transmission. The average incubation period in the French iCJD hGH cohort is 9-10 
years (Huillard d’Aignuax et al., 1999), with patients in the PRNP codon 129 MM 
subgroup having the shortest incubation periods (Brandel et al., 2003).  
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3. Objectives and Aims of the thesis: 
3.1. Unanswered questions on iCJD in UK hGH recipients 
Despite the fact that iCJD in hGH recipients has occurred in over 200 patients across 
the world, there have been very few detailed studies of the neuropathology, prion 
protein biochemistry and prion protein seeding activity in this form of human prion 
disease. There has been only a limited study of non-CNS tissues in these cases, which 
might inform understanding of the peripheral pathogenesis of this disease following 
inoculation of infected hGH preparations by intramuscular injection (Head et al., 
2004a). Most reports from the UK describe only small numbers of cases that are not 
necessarily representative of the cohort in question, particularly with respect to the 
year of diagnosis in relation to the evolving time period since iatrogenic exposure to 
contaminated hGH ceased (Markus et al., 1992; Cordery et al., 2003; Jaunmuktane et 
al., 2015).  
 
A previous smaller study of iCJD in predominantly US hGH recipients have proposed 
that the prions accumulating in the brain may show an increased propagation efficiency 
following the secondary transmission of sporadic CJD, in a manner analogous to the 
shortening of disease incubation periods after cross-species transmission of scrapie 
prions (Xiao et al., 2014). Further studies on hDM-iCJD cases in Japan have proposed 
that the cases in PRNP codon 129 MM patients with amyloid plaques in the brain 
exhibit a “traceback phenomenon”, that is to say the prions in the brain exhibit 
characteristics of the sCJD prion strain from which they originated, regardless of the 
PRNP codon 129 genotype of the secondary host. These characteristics will re-emerge 
on transmission or amplification from the secondary host to a new host with an 
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appropriate PRNP codon 129 genotype to allow the re-emergence and re-expression 
of these characteristics (Kobayachi et al., 2009, 2010). This phenomenon has been 
extensively investigated in sCJD and hDM-iCJD on transmission to transgenic mice, 
but has not yet been studied in cases of hGH-iCJD to investigate the possible sCJD 
strain of origin. 
 
These two proposals can be explored using in vitro PrPSc amplification techniques in 
UK hGH-iCJD cases:  
1. RT-QuIC will be used to measure the seeding activity of hGH-iCJD cases and to 
compare the findings with PRNP codon 129 genotype- and PrPSc isoform-matched 
cases of sCJD to establish whether there is evidence of increased seeding activity in 
the iCJD cases, corresponding to the proposed increased propagation efficiency in 
iCJD.  
2. PMCA will be used to measure the conversion activity of PrPSc seeds from hGH-
iCJD cases with PRNP codon 129 genotype- and PrPSc isoform-matched cases of sCJD 
in substrates containing PrPC of either MM, VV or MV genotypes, to identify any 
differences in conversion activity, substrate preference and the isoform of the PrPSc 
generated on WB analysis. This will give an indication of any trace-back phenomenon 
in the hGH-iCJD cases that reflects the characteristics of the strain(s) of sCJD 
responsible for these cases, and will also demonstrate any increased conversion 




3.2 Objectives of the thesis 
This thesis will examine the largest cohort yet collected of hGH-iCJD cases, with 
detailed characterisation of the PrPSc isoforms in the brain, correlation with genetic 
and pathological factors and an exploration of the in vitro PrP seeding activity present 
in different genetic sub-groups. These cases are compared with a smaller number of 
cases of hDM-iCJD in the UK, but also a very much larger group of sCJD cases drawn 
from the UK population over a similar time period.  Crucially, this thesis also examine 
brain tissue samples from UK hGH recipients who were treated over a similar period 
to the hGH-iCJD patients, but who died from other causes and did not develop iCJD. 
Information on the hGH-iCJD patients and non-iCJD hGH recipients (e.g. sex, date of 
birth, date of death, duration of treatment, types of hGH administered, estimated 
incubation period and some genetic data) will be kindly provided from the UK 
National Registry of hGH recipients by Dr Peter Adlard, Institute of Child Health, 
London. The detailed examination of these cohorts allows a unique opportunity to ask 
fundamental questions about person-to-person transmission of prion disease and the 
molecular mechanisms involved. 
 
3.3. Aims of the thesis 
1. Determine the pathological phenotype of hGH-iCJD in the UK.  
2. Explore whether the pathological phenotype is influenced by the PRNP codon 
129 genotype and the CNS PrPres isoform in the same way as in sCJD (Parchi 
et al., 1999). 
3. Investigate the peripheral pathogenesis of hGH-iCJD following intramuscular 
inoculation. 
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4. Characterise the causal agent strain in hGH-iCJD and establish whether it 
relates to any of the known sCJD strains (Haik et al., 2011). 
5. Seek evidence in hGH-iCJD and other non-iCJD hGH recipients for 
transmission/seeding of other neurotoxic proteins found in the pituitary gland 
- A, tau, -synuclein (Irwin et al., 2013; Jaunmuktane et al., 2015). 
 
3.4. Hypotheses to be tested: 
1. Disease phenotype: The clinicopathological phenotype of hGH-iCJD in the UK 
is determined by the PRNP codon 129 polymorphism of the patient and the 
PrPres isoform in the CNS. 
2. Increased propagation efficiency: The secondary transmission of sporadic CJD 
prions has led to the acquisition of greater propagation efficiency in hGH-iCJD 
prions (Xiao et al., 2014). 
3. Trace-back phenomenon: The origin of the prions in hGH-iCJD can be inferred 
by ready reversion to their original state when given an appropriate host 
(Kobayashi et al., 2009, 2010). 
4.  Origin: The origin of hGH-iCJD in the UK can be inferred by the molecular 
and genetic changes occurring in the disease over time. 
5. Co-pathology: Aseeding occurs in hGH recipients in the UK both with and 




4. Materials and Methods 
4.1. Cases 
All cases included in this study were of UK origin and were referred to the National 
CJD Research & Surveillance Unit (NCJDRSU) between 1991-2016 for 
neuropathological diagnosis and surveillance purposes (www.cjd.ed.ac.uk).  
Diagnoses were made according to the internationally accepted criteria for sCJD 
(Table 1.4), vCJD (Table 1.7) and acquired CJD (Table 1.9) on the basis of the clinical 
data and histological, immunohistochemical and (when unfixed frozen tissue was 
available) biochemical and genetic investigations. The clinical data (including the 
results of PRNP codon 129 genotype and full sequence analysis performed on blood 
samples taken in life) for sCJD, vCJD and iCJD were available from the clinical 
database in NCJDRSU with the kind help of Ms Jan Mackenzie, NCJDRSU co-
ordinator. The clinical histories and details of treatment with UK hGH were kindly 
provided by Dr Peter Adlard, Institute of Child Health, London, who leads the National 
Registry of hGH recipients in the UK.  
 
The inclusion criteria for the cases investigated in this thesis are: 
1. A definite diagnosis of sCJD, vCJD, hDM-iCJD and hGH-iCJD, or a 
documented history of treatment with UK hGH with no clinical or 
neuropathological evidence of a human prion disease.  
2. Appropriate consent/authorisation for use of autopsy tissues for research, or 
classification of autopsy tissues as Existing Holdings under the Human Tissue 
Act 2004 and the Human Tissue (Scotland) Act 2006. The MRC Edinburgh 
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Brain Bank has Research Ethics approval to provide these tissues (Edinburgh 
Brain Bank 16-ES-0084, IRAS project ID 199294).  
 
4.1.1. Cases of hGH-iCJD 
To date (2016) 78 cases of iCJD have occurred in the 1849 recipients of UK-produced 
hGH for whom records are available. Of these, 43 cases were referred to NCJDRSU 
for neuropathological diagnosis, three of which were brain biopsy samples in which 
insufficient paraffin-embedded tissue was available for research. Of the 40 autopsy 
cases, 35 fulfilled the inclusion criteria for research, but 2/35 had insufficient paraffin-
embedded tissue available for full pathological investigation. These comprised eight 
female (f) and 27 male (m) patients, 21 of which had frozen brain tissue available (5f, 
16m). The age at death in these 35 cases ranged from 20-46 years (y) (mean 31.2y, ± 
standard deviation (sd) 6.7y) (Figure 4.1). These 35 patients had been treated with 
hGH between 1970 and 1985 (see Appendix 1 for details of hGH treatment in this 
cohort). 
 
4.1.2. Control cases 
4.1.2.1. hGH control cases 
Twelve autopsy cases with a history of hGH treatment had been referred to NCJDRSU 
for neuropathological diagnosis between 1991-2016, in whom there was no clinical or 
pathological evidence of iCJD or any other form of human prion disease. These 
comprised 3f and 9m patients, all with paraffin-embedded tissue available for research; 
2m cases had frozen brain tissue available for research. The age at death ranged from 
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13-45y (mean 29.5y, ± sd 9.8y) (Figure 4.1). These patients had been treated with hGH 
between 1969 and 1985 (see Appendix 2 for details of hGH treatment in this cohort).  
 
4.1.2.2 hDM-iCJD cases 
Five autopsy cases of iCJD occurring in UK hDM graft recipients were referred to 
NCJDRSU for neuropathological diagnosis.  These comprised 2f and 3m patients, 
three cases of which (2f, 1m) were available for research, but 1/3 had insufficient 
paraffin-embedded tissue available for full pathological investigation. The age at death 
ranged from 27-47y (mean 36.8y, ± sd 8.9y) (Figure 4.1). Dura mater graft surgery 
was performed between 1983 (month unknown) - August 1987 (Heath et al., 2006). 
 
4.1.2.3. vCJD cases. 
Thirty-three definite UK autopsy cases of vCJD with consent for research were used 
as age-matched controls for the paraffin-embedded tissue studies on the hGH-iCJD 
cases. These comprised 11f and 22m patients. The age at death ranged from 20-41y 
(mean 29.9y, ± sd 6.2y) (Figure 4.1). 
 
4.1.2.4. sCJD cases  
Fifteen definite UK autopsy cases of sCJD with consent for research were used as age-
matched controls for the paraffin-embedded tissue studies on the hGH-iCJD cases. 
These cases included 6f and 9m patients. The age at death ranged from 20-46 y (mean 
41.3y, ± 6.5y) (Figure 4.1). Data from 1,080 unselected cases of UK sCJD of known 
PRNP codon 129 genotype with deaths between 1990-2015 were used for PRNP 
genetic comparison with the UK hGH-iCJD cases. A smaller group of UK sCJD cases 
 95 
(n=108) that were referred to NCJDRSU during the period 1991-2011 were used for 
biochemical comparison with the hGH-iCJD group.  These cases were selected on the 
basis of sufficient frozen tissue available for research (minimal set: temporal cortex, 
occipital cortex, parietal cortex and thalamus) for PrPres type classification according 
to the revised method of Parchi et al. (Parchi et al., 2009) (see Appendix 3 for full 
details).    
 
Figure 4.1. 
Age distributions of hGH-iCJD and control cases (vertical bars represent the mean 












The control cases were chosen to be as close as possible in range to the hGH-iCJD 
cases. Cases of sCJD under the age of 50y are rare; the sCJD control cases are clustered 
in the 40-50y age range with higher mean age values. In contrast, cases of vCJD over 
the age of 40y are rare; the upper age limit for the vCJD cases is 41y. 
 
Abbreviations: hDM: human dura mater; hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-
Jakob disease; sCJD: sporadic Creutzfeldt-Jakob disease; vCJD: variant Creutzfeldt-Jakob disease. 
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4.2. Neuropathological examination 
4.2.1. Laboratory details 
All cases were examined in the Laboratory in the NCJDRSU, which has a containment 
suite of laboratories that have both Category 2* and Category 3 (derogation) facilities 
for the safe handling and storage of fixed and unfixed tissues from patients with human 
prion diseases. The Laboratory’s premises, procedures and policies comply fully with 
the relevant guidance from the Advisory Committee on Dangerous Pathogens TSE 
Subgroup (https://www.gov.uk/government/ uploads/system/uploads /attachment _ 
data /file/ 209769 /Annex_K_-_Guidelines _for_pathologist_and_ pathology _ 
laboratories.pdf). The Laboratory is subject to regular inspection by the Health and 
Safety Executive and participates in the UK National External Quality  Assessment 
Scheme for Cellular Pathology Technique – Neuropathology. 
 
4.2.2. Tissue fixation and sampling 
The 33 hGH-iCJD and 12 hGH control brains (27 whole brains, 6 half brains and 12 
cases with multiple CNS tissue samples, according to the consent/authorisation status) 
and hDM-iCJD, vCJD and sCJD cases were all fixed in 15% unbuffered formalin for 
a minimum period of 3 weeks prior to weighing, external examination, dissection and 
sampling for histology. Extensive histological sampling included the brain regions 
recommended in the National Institute on Aging-Alzheimer’s Association guidelines 
for the assessment of Alzheimer’s disease (Hyman et al., 2012) whenever possible 





Table 4.1. Brain regions sampled and assessed for ABC scoring  
(modified from Hyman et al., 2012) 
 
Each brain region receives a haematoxylin and eosin stain, plus additional stains/IHC as indicated.  
 AD LBD 
 A B C 
Region 
 
4G8 and 6F/3D 













DMV    
1o: IHC or H&E 3 
 
Pons including LC    1o: IHC or H&E 3 
Midbrain 
including SN 
3o: if 2o is +   1o: IHC or H&E 3 
Cerebellar cortex 
and dentate n. 
3o: if 2o is +2    
Thalamus and 
subthalamic n. 1 
    
Basal ganglia at 
level of AC with 
basal nucleus of 
Meynert 1 
2o: if 1o is + Consider   
Hippocampus and 
EC 1 
2o: if 1o is +2 Yes Consider 2o: IHC in at least 
one if 1o is + 
Cingulate, 
anterior 
   










2o: IHC in at least 
one if 1o is + 
Superior & middle 




(BA 17 & 18) 1 
Consider2 Yes Consider  
 
1 Consider taking bilateral sections if both cerebral hemispheres are available 
2 Screen leptomeningeal and parenchymal vessels for cerebral amyloid angiopathy (CAA) 
3 Screen for LBs with immunohistochemistry or H&E in brainstem and immunohistochemistry in amygdala. If 
positive, then expand immunohistochemistry for LBs in brainstem, limbic, and neocortical regions. 
4 Stains for Aβ/amyloid plaques should be considered in other regions not needed for classification, such as in the 
precuneus or cingulate gyrus, as neuroimaging studies indicate that these sites are among the earliest to demonstrate 
retention of amyloid-binding molecules, a marker of fibrillar Aβ accumulation. 
 
Abbreviations: AC: anterior commissure; AD: Alzheimer’s disease; BA: Brodmann area; DMV: dorsal motor 
nucleus of the vagus; EC: entorhinal cortex; H&E: haematoxylin and eosin stain; IHC: immunohistochemistry; 
LBs: Lewy bodies; LBD: Lewy body disease; LC: locus ceruleus; n: nucleus; NP: neuritic plaques; NFT: 
neurofibrillary tangles;  SN: substantia nigra; +: positive. 
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Formalin fixed, non-CNS tissue samples were available in 19/33 hGH-iCJD and 2/12 
hGH control cases. These were fixed in 15% unbuffered formalin for no more than 7 
days prior to sampling. All CNS and non-CNS tissue blocks were incubated in 96% 
formic acid for 1h as a prion risk reduction step (Brown et al., 1990) prior to processing 
into paraffin wax for microtomy (Appendix 4).  Full details of the non-CNS tissues 
sampled for microscopy are provided in Appendix 5. 
 
4.2.3. Histological stains 
All CNS and non-CNS blocks were cut at 5m and stained with haematoxylin and 
eosin (H&E). Selected CNS blocks were cut at 8m and stained with Luxol Fast 
Blue/Cresyl Violet (LFB/CV) for myelin (Dawson et al., 2003). Sections were cut at   
8m for the Bielschowsky silver stain for neuritic plaques on the CNS blocks indicated 
in Table 4.1. Full details of the protocols for microtomy and histological stains are 
provided in Appendix 6. 
 
4.2.4. Immunohistochemistry 
Sections from all CNS blocks were labelled with two monoclonal anti-PrP antibodies 
recognising different epitopes of the prion protein: 12F10 (amino acids 142-160, 
Bioquote Ltd, UK) and KG9 (amino acids 140-180, TSE Resource Centre, Roslin 
Institute, UK). CNS blocks were selected for immunohistochemistry for A6F/3D 
and 4G8 antibodies), A Aphospho-tau and -synuclein according to 
the National Institute on Aging-Alzheimer’s Association guidelines (Hyman et al., 
2012); additional blocks from other regions including the spinal cord were examined 
when available. CNS blocks from hGH-iCJD and hGH control cases were also labelled 
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with antibodies to apolipoprotein E (pan-apoE), apoE-4, glial fibrillary acidic protein 
(GFAP), TDP-43, ubiquitin and CD68. Selected non-CNS tissues were labelled with 
the antibodies to PrP and A.  
 
All  immunohistochemistry for a single antigen was performed in batches using the 
sensitive NovolinkTM Polymer Detection System (Leica Biosystems, UK). Details of 
all antibodies used, including antigen specificity, pretreatment protocols, dilutions, 
incubation times and positive control tissues are summarised in Table 4.2. Negative 
controls for immunohistochemistry were carried out by omitting the primary antibody 
in the reaction.  Full details of the antibodies used are provided in Appendix 7 and the 
full protocol for immunohistochemistry is provided in Appendix 8. 
 
4.2.5. Microscopy and photography 
Tissue sections were analysed independently by two experienced assessors (Dr Diane 
L Ritchie and Professor James W Ironside) using a Leica DMR light microscope. 
Image capture was carried out with a Leica DFC 500 camera in combination with the 
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Abbreviations: AD: Alzheimer’s disease; CJD: Creutzfeldt-Jakob disease; FA: formic acid; LBD: Lewy body disease; min: 
minutes; mmol: millimolar; MND: motor neurone disease; MW: microwave; PK: Proteinase K; s: sporadic; vCJD : variant.  
* All antibodies diluted in antibody diluent unless stated in the protocol (Leica Biosystems, UK: Product RE7133-CE)  
† All primary antibodies are incubated at room temperature 
 101 
4.2.5.1. Assessment of CNS tissues for prion-related pathology on H&E sections 
H&E sections from all CNS regions sampled in the hGH-iCJD cases were examined 
for the characteristic neuropathological features of human prion diseases: spongiform 
change, neuronal loss, gliosis and amyloid plaque formation (Head et al., 2015). The 
distribution, severity and nature of the spongiform change (microvacuolar, confluent, 
mixed, status spongiosis) neuronal loss, gliosis and amyloid plaque formation (kuru-
type, multicentric, florid, microplaque) were assessed and scored in a semiquantitative 
manner (Parchi et al., 2009) using 4 scores ( 0-absent, 1-mild, 2-moderate, 3-severe), 
along with assessment of the results of PrP immunohistochemistry (see below) to allow 
subclassification by histotyping (Parchi et al., 2009, 2012) to determine whether the 
range of neuropathological phenotypes identified in this group of patients 
corresponded to those occurring in the recognised sCJD subtypes (Figure 1.5), or not. 
 
4.2.5.2. Assessment of PrP immunoreactivity in the CNS 
All CNS sections from the hGH-iCJD cases were stained with the 12F10 and KG9 
anti-PrP antibodies and examined to determine the distribution, severity and nature of 
the abnormal PrP accumulation (granular/synaptic, perineuronal/pericellular, plaque-
like, plaques, amorphous deposits, perivascular, vascular) (Head et al., 2015). The 
findings were assessed in conjunction with those from the examination of the H&E 




4.2.5.3. Assessment of A, tau and -synuclein pathology 
Sections from the CNS of cases of hGH-iCJD, hGH controls, hDM-iCJD, vCJD 
controls and sCJD controls were stained by immunohistochemistry for A (6F/3D and 
4G8 antibodies), phospho-tau (AT8 antibody) and -synuclein (5G4 antibody) 
according to the National Institute on Aging-Alzheimer Association guidelines for the 
neuropathological assessment of Alzheimer’s disease (Hyman et al., 2012) (Table 
4.1). An “ABC” score for the level of Alzheimer’s disease neuropathology was 
calculated according to Hyman et al. (Hyman et al., 2012). This score is derived from 
the classification of the A phase on sections stained using A immunohistochemistry 
(Thal et al., 2002), the Braak and Braak stage for neurofibrillary tangles using 
immunohistochemistry for PHF-tau (Braak et al., 1991, 2006) and the neuritic plaque 
score on Bielschowsky silver-stained sections by the method of the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) (Mirra et al., 1991). The 
combination of the results of these assessments in the ABC scoring method is 
summarised in Table 4.3. 
 
“A” score: (Thal phase for A deposits): in brief, in Thal phase 1, Aβ deposits (diffuse 
and non-diffuse plaques, but not including CAA) are found only in the neocortex, 
while in phase 2 there are additional Aβ deposits in allocortical brain regions. In Thal 
phase 3 there are further A deposits in the diencephalon, basal forebrain and striatum. 
The midbrain and medulla become involved in Thal phase 4, while in phase 5 there 
are additional Aβ deposits in the cerebellum and pons (Thal et al., 2002).  
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“B” score: Braak & Braak stage for neurofibrillary tangles, modified for use with tau 
immunohistochemistry (Braak et al., 2006). The distribution of neurofibrillary tangles 
is briefly summarised as follows for the 3 groups scored in Table 4.3:  in the 
transentorhinal region and the entorhinal region (transentorhinal stages I/II); 
additionally in the hippocampus and the occipito-temporal gyrus up to the medial 
temporal gyrus (limbic stages III/IV); additionally in the remaining neocortex,  finally 
including the parastriate and striate cortex in the occipital lobe (neocortical stages 
V/VI) (Braak and Braak, 1991; Braak et al., 2006).  
 
“C” score: the CERAD score for neuritic plaques is performed on Bielschowsky silver 
stained sections of the grey matter of the neocortex (superior and middle temporal gyri, 
middle frontal gyrus and the inferior parietal lobule) and examined at x100 
magnification to obtain a semiquantitative assessment of the single highest number of 
neuritic plaques per microscopic field as follows: none; sparse (between 1-5); 
moderate (between 6-19); frequent (20 or more) (Mirra et al., 1991).  
 
4.2.5.4. Assessment of cerebral amyloid angiopathy 
Sections of the frontal cortex, parietal cortex, temporal cortex, occipital cortex and 
cerebellum from all cases of hGH-iCJD, hGH controls, hDM-iCJD, vCJD and sCJD 
were stained using the 6F/3D and 4G8 anti-A antibodies (Table 4.2) to detect cerebral 
amyloid angiopathy (CAA) in vessels in the leptomeninges, the brain  
parenchyma and brain capillaries. CAA was scored according to the criteria of Love 
et al. (Love et al., 2014) (Table 4.4) and the total score for each case was recorded.  
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All cases with CAA were also stained with the anti-A1-40 antibody (11A50-B10) 
and the anti-A 1-42 antibody (12F4) (Table 4.2), and the distribution of 
immunoreactivity for each antibody in the CAA blood vessels was recorded. 
 
Table 4.3. ABC score for Alzheimer’s disease pathology (from Hyman et al., 2012) 
A Thal phase for 
Aβ plaques 
 







0 0 0 None 0 None 
1 1 or 2 1 I or II 1 Sparse 
2 3 2 III or IV 2 Moderate 
3 4 or 5 3 V or VI 3 Frequent 
The ABC score is derived by adding the numerical value for A, B and C for the corresponding Thal A 
phase (Thal et al., 2002), the Braak and Braak stage for neurofibrillary tangles (Braak and Braak, 1991; 
Braak et al., 2006) and the CERAD neuritic plaque score (Mirra et al., 1991). 
Abbreviations: A: amyloid beta; CERAD: Consortium to Establish a Registry for Alzheimer’s disease; NFT: neurofibrillary 
tangle. 
 
Table 4.4. Scoring protocol for cerebral amyloid angiopathy (CAA) and CAA-











Absent Absent Absent 






















Abbreviation: A: amyloid beta 
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4.2.5.5. Assessment of the co-localisation of PrP, phospho-tau, CD68, GFAP and 
Apathology 
Sections of the CNS from selected cases of hGH-iCJD, sCJD and vCJD that showed 
immunoreactive Adeposits in the parenchyma and/or blood vessels were double 
immunostained for A and either PrP or phospho-tau, CD68 or GFAP in order to 
determine whether co-localisation existed between these 4 proteins and the Aβ protein. 
Sections were double stained with the anti-PrP antibody, 12F10; the anti-phospho-tau 
antibody, AT8; the anti-CD68 antibody, PGM1; the anti-glial fibrillary acidic protein, 
GFAP and the anti-A antibody, 6F3D (Table 4.2). Full details of the antibodies used 
are provided in Appendix 7 and the full details of the double immunohistochemistry 
protocol are provided in Appendix 8. 
 
4.2.5.6. Immunohistochemistry for apoE and apoE-4 
Sections of the CNS from cases of hGH-iCJD and hGH controls that contained 
immunoreactive A in the parenchyma or in blood vessels and in which no frozen 
tissue was available for APOE genotype analysis were stained with antibodies to apoE 
and apoE-4 (Table 4.2). Immunoreactivity was compared to cases of AD of known 
APOE 3/3 genotype as a positive control for apoE expression. AD cases of known 
3/4 and 4/4 genotypes were used as positive controls for apoE-4 expression. Cases 
that showed selective labelling of AD pathology with both anti-apoE-4 antibodies were 
judged to be cases with an apoE4 phenotype and categorised as apoE4+(IHC); other 




4.2.6. Paraffin embedded tissue (PET) Blot 
Paraffin-embedded tissue (PET) blotting was performed on formalin fixed non-CNS 
tissues from hGH-iCJD cases in which no frozen tissues were available for WB 
analysis (Ritchie et al., 2004).  PET blots were performed using two monoclonal anti-
PrP antibodies recognising different epitopes of the prion protein; 3F4 (amino acids 
109-112, Cambridge Bioscience, UK) and 12F10 (amino acids 142-160, Bioquote Ltd, 
UK) (Appendix 6). Stained PET blot sections were analysed with a Leica M295 
stereoscopic microscope and image capture carried out with a Leica DFC 320 camera 
in combination with the Leica LAS image acquisition software (Leica Microsystems, 
UK). The full protocol for the PET blot technique and microscopy is provided in 
Appendix 9. 
 
4.3. Genetic analysis 
4.3.1. DNA extraction from tissues 
DNA was extracted from frozen tissues for PRNP codon 129 genotype analysis from 
cases in which no blood samples had been taken in life. DNA extraction from formic 
acid treated paraffin-embedded tissues was attempted in cases for which no frozen 
tissues or blood samples were available.  
 
DNA extraction was attempted from either unfixed grey matter-enriched frozen brain 
tissue samples (20-30mg) of the cerebellar cortex or frontal cortex, or up to 25mg of 
formic acid treated paraffin-embedded tissue from the cerebellar cortex cut as 10m 
unmounted sections using a Qiagen DNeasy Blood and Tissue kit (Qiagen, Hilden, 
Germany) using the method in the accompanying handbook (www.qiagen.com). DNA 
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extraction from paraffin-embedded tissues was also attempted using the method 
described by Nicoll et al. (Nicoll et al., 1997). Full protocols for DNA extraction from 
fixed and frozen tissues are provided in Appendix 10.  
 
4.3.2. PRNP codon 129 analysis  
PRNP codon 129 genotype analysis was performed by PCR of the PRNP gene, 
followed by restriction enzyme digestion at 37°C with NspI (New England Biolabs, 
UK). This enzyme cleaves the amplicon at PRNP codon 155 and at codon 129 only 
when the latter sequence codes for valine (-GTG-). This allows for discrimination of 
the three PRNP codon 129 genotypes: Homozygous methionine (MM), heterozygous 
(MV) and homozygous valine (VV) by agarose gel electrophoresis and staining as 
previously described (Bishop et al., 2009), but using a SYBR® Safe DNA Gel Stain 
(Invitrogen, Cat# S33102), (Figure 4.2). The full protocol used for PRNP codon 129 












Figure 4.2. PRNP codon 129 genotype interpretation 
  










PRNP codon 129 genotyping by PCR amplification and restriction enzyme digestion.  
The 600 bp band on the 100 bp molecular ladder is indicated by an arrow. Controls  
for MM, MV and VV genotypes are included on the gel. Case 1 is from a patient with 
a PRNP codon 129 VV genotype and Case 2 is from a patient with a PRNP codon 129 
MV genotype. 
 
Abbreviations: bp: base pair; M: methionine: PCR: polymerase chain reaction; PRNP: prion protein 
gene; V: valine. 
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4.3.3. Exome sequencing and analysis  
Exome sequencing and analysis, and APOE genotype analysis by polymerase chain 
reaction (PCR) were performed in the Universities of Newcastle and Cambridge by Dr 
Michael Keogh, Dr Wei Wei and Professor Patrick Chinnery, University of 
Cambridge, as part of the project “Maximising the value of MRC Brain Banks - High 
throughput genotype and imaging studies to enrich data available to the research 
community” (Medical Research Council grant MC_PC_13044; Professor JW 
Ironside). This summary of the methods used and the results from these investigations 
were kindly provided by Dr Keogh, Dr Wei and Professor Chinnery. 
 
Genomic DNA was fragmented, exome enriched and sequenced (Nextera Rapid 
Exome Capture 62Mb or TruSeq rapid 37Mb kit on a HiSeq 2000 with 100bp paired-
end reads). Bioinformatic analysis was performed using an in-house pipeline including 
alignment (human reference genome hg19, UCSC) using Burrows-Wheeler Aligner 
(BWA) (Langmead et al., 2009). Variant calling was performed using FreeBayes 
(Garrison, 2012). Subsequent analysis was restricted to on-target homozygous, 
heterozygous, and compound heterozygous variants with a minimum read depth of 10, 
and base quality score of 20. Further analysis selected variants in 5’ untranslated region 
(UTR), 3’ UTR or exonic regions within genes of interest that may influence the 
aggregation of A in the CNS (APP, C9ORF72, CHMP2B, CSFIR, FUS, GRN, 
ITM2B, MAPT, NOTCH3, PSEN1, PSEN2, SERPINI1, SQSTM1, TARDBP, TREM2, 
TYROBP, VCP) and with a minor allele frequency <5% in the 1000 Genome Project 
Database (1000 Genomes Project Consortium et al., 2012) of European/American 
cases from the NHLBI ESP exomes database (NHLBI GO Exome Sequencing Project, 
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2013) and the ExAC server ( Exome Aggregation Consortium, 2015), using Qiagen 
Ingenuity Variant Analysis software (Qiagen, Hilden, Germany).   
 
4.3.4. APOE genotyping 
APOE genotyping was performed by competitive allele-specific PCR, using KASPTM 
genotyping assays (LGC Genomics, Hoddesdon, UK) for both rs7412 and rs429358. 
Subsequent genotype data was converted into APOE allele status (Weisgraber et al., 
1982). Full methods for the KASPTM genotyping platform are available from LGC 
Genomics (http://www.lgcgenomics.com/genotyping/kasp-genotyping-reagents/). 
 
4.3.5. C9orf72 PCR 
Screening for the C9ORF72 hexanucleotide repeat expansion was performed as 
described by Renton et al. (Renton et al., 2011) in the laboratory of Professor Stuart 
Pickering-Brown, University of Manchester. Positive results were confirmed by 
Southern blot (Beck et al., 2013) allowing an estimate of the repeat size. 
 
4.4. Western blot analysis of PrPres in frozen CNS tissues 
4.4.1. Western blot method  
Samples of frozen grey matter from the cerebral cortex (frontal, parietal, temporal and 
occipital cortex), cerebellar cortex, thalamus (dorsomedial region) and spinal cord 
were examined where available. The PrPres types present in brain samples from the 
sCJD, hDM-iCJD and hGH-iCJD cases were determined using the refined Western 
blot (WB) protocol of Parchi et al. (Parchi et al., 1999). Briefly, 100mg samples of 
frozen CNS samples were subjected to stringent sample preparation (including strong 
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buffering to pH 6.9 at 37oC) and digestion with proteinase K (Roche, Lewes, UK) 
using 10U/ml corresponding to ~200µg/ml (depending on the batch) at 37oC for 1h 
prior to WB analysis.  Immunodetection of PrP was carried out using monoclonal 
antibody 3F4 (Millipore, UK) at a final concentration of 75ng/ml or the monoclonal 
antibody 12B2 (Central Veterinary Institute of Wageningen UR, Lelystad, The 
Netherlands) at a final concentration of 200ng/ml for 1h. The full WB protocol is 
provided in Appendix 11. 
 
4.4.2. PrPres analysis and classification 
The WB protocol allows a distinction to be made between PrPres types based on the 
migration of the unglycosylated (bottom) band of the typical triplet glycoform pattern 
(Figure 1.2).  Three different unglycosylated PrPres fragment mobilities are recognised 
within the 21-19kDa range: type 1 in which the unglycosylated PrPres has a molecular 
mass of ~21kDa; type 2 in which the unglycosylated PrPres fragment has a molecular 
mass of ~19kDa, and an additional type with a mobility of ~20kDa migrating between 
type 1 and 2 and therefore referred to as type i (for intermediate) (Figure 1.2).  PrPres 
types 1, i and 2 are not mutually exclusive. Certain individual samples and cases may 
contain more than one PrPres type; this diversity is recognised by classifying such 
samples and cases as 1+2, 1+i, or i+2.  
 
4.4.3. Western blotting with sodium phosphotungstic acid (NaPTA) preciptation  
WB analysis of non-CNS tissues was performed using the sodium phosphotungstic 
acid (NaPTA) precipitation method, which gives enhanced sensitivity for the detection 
of low levels of PrPres in non-CNS tissues as previously described (Wadsworth et al., 
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2001; Glatzel et al., 2003; Peden et al., 2006, 2010). Frozen, non-CNS tissue samples 
were available in 11/33 hGH-iCJD cases. Appendix 5 gives full details of the non-
CNS tissues sampled for NaPTA analysis. 10% w/v extracts were made of 65-100mg 
samples of tissue by homogenising in an appropriate volume of ice-cold 2% 
sarkosyl/phosphate-buffered saline (PBS), pH 7.4, using the FastPrep instrument 
(Qbiogene, Cambridge, UK). The samples were then cleared by centrifugation at 
5,200g for 5min at 4oC. Cleared spleen tissue homogenate (5%) from a non-CJD 
patient was used as a non-CJD negative control. In addition, iCJD or sCJD brain tissue 
homogenate (10%, 10l, corresponding to 100g brain) was diluted and mixed into 
1ml of 5% cleared non-CJD spleen tissue homogenate for use as positive control.  
 
Samples (0.5ml) of the cleared lysates were diluted with a further 0.5ml of 2% 
sarkosyl/PBS and incubated for 10min at 37oC. Benzonase (Sigma, Poole, UK) and 
MgCl2 were added at final concentrations of 50U/ml and 1mmol/l, respectively, and 
incubation at 37°C was continued for a further 30min. Eighty-one μl of a stock solution 
of 4% w/v NaPTA and 170mmol/l MgCl2, pH 7.4, were added (final concentration of 
NaPTA, 0.3% w/v), and precipitation was allowed to occur for 30min at 37°C. The 
samples were centrifuged at 20,800g for 30min at 37°C. The resultant supernatant was 
discarded and the pellets were resuspended in 20μl of 0.1% w/v sarkosyl in PBS, pH 
7.4, and digested with 50μg/ml proteinase K for 30min. Digestion was terminated by 
the addition of 1mmol/l PefaBloc SC (Roche, Lewes, UK). Immunoblotting for 
proteinase resistant PrPSc following NaPTA precipitation was performed as in 4.4.1 
above using the monoclonal antibody 3F4 (Millipore, UK) at a final concentration of 
 113 
75ng/ml for 1h (see Appendix 11 for the full WB protocol). A full protocol for WB 
with NaPTA precipitation is provided in Appendix 12. 
 
4.5. In vitro conversion assays  
4.5.1. Real-time quaking-induced conversion (RT-QuIC) 
The methods described by Peden et al. (Peden et al., 2012, 2014) for the RT-QuIC PrP 
conversion assay were used with minor modifications. Full length hamster 
recombinant PrP (recPrP, aa 23–231; GenBank accession no. K02234) was used as a 
substrate for seeded conversion. Brain samples to seed the reactions were homogenised 
in phosphate buffered saline (PBS) containing 1mmol EDTA, 150mmol NaCl, 0.5 % 
Triton X-100 and CompleteTM Mini EDTA-free Protease Inhibitor Cocktail (Roche). 
The tissue was disrupted using one cycle of lysis (45sec, 6ms-1) in a Fastprep-24 
homogeniser (MP Biomedicals, USA). An appropriate volume of homogenisation 
buffer was used to give a final tissue concentration of 10 % (w/v). Cellular debris was 
cleared from the homogenates by centrifugation at 5,200g at 4°C. Further serial ten-
fold dilutions of the cleared tissue homogenate were made using PBS.   
 
The 100l RT-QuIC reactions were set up in quadruplicate in the wells of a clear-
bottomed black 96-well microplate (Fisher Scientific, UK). Stock solutions containing 
the reaction components were filtered through a 0.22m Millex PES filter prior to 
making a master mix. recPrP was the final addition to the master mix, which was mixed 
and then dispensed into the wells in 98l volumes. At least four replicate analyses 
were performed on each patient sample. The RT-QuIC reactions (final volume = 
100l, recPrP final concentration = 0.1mg/ml) were initiated by the addition of 2 l of 
a 103-fold dilution of the 10% (w/v) brain homogenate. The plates were sealed with 
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film, incubated at 42o C and shaken intermittently (87 sec shaking at 900rpm in a 
double orbital configuration followed by a 33sec rest) using a FLUOstar OMEGA 
microplate reader (BMG Labtech, UK). Fluorescence readings were taken at 480nm 
every 15min from the bottom of the wells after excitation with 20 flashes per well at 
450nm.  
 
In order to quantify prion seeding efficiency we used a method based on the one 
described by Shi et al. (Shi et al., 2013), where the lag time to conversion is used as 
an inverse measure of seeding potential. The lag time to the start of PrPC conversion 
was taken to be the time (in hours (h)) from the start of the assay to when the RT-QuIC 
fluorescence reading was three times the average reading at 0.5h (the baseline). A 
mean lag period for four replicate analyses was thus obtained for each sample (Figure 









The lag time to the start of PrPC conversion is taken to be the time (h) from the start of 
the assay to when the RT-QuIC fluorescence reading (Y axis) was three times the 
average reading at 0.5h (at least 4 replicate analyses are performed on each sample). 
Time (h) on the X axis starts at 0.5 h. 
 
Abbreviations: h: hours; PrPC: cellular prion protein; RT-QuIC: real-time quaking-induced conversion; 
ThT: Thioflavin T. 
 
4.5.2. Protein misfolding cyclic amplification (PMCA) 
PMCA experiments were carried out as described previously (Barria et al., 2014). 
Briefly, brain homogenates from humanised transgenic mice of  PRNP codon 129 
methionine homozygous (129MM), valine homozygous (129VV) and heterozygous 
(129MV) genotypes (Bishop et al., 2006) were prepared using a manual homogeniser 
and conversion buffer (phosphate-buffered saline 1X, 150mmol NaCl, 1% Triton X-
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PMCA “substrate”). The homogenised tissue was cleared by centrifugation at 2,000 
rpm for 40sec in a refrigerated centrifuge (4°C), and the supernatant was aliquoted and 
stored at −80oC.  The sCJD and iCJD brain homogenates (the PMCA “seeds”) were 
prepared following the method used for substrate preparation.  
 
Aliquots of 10% brain homogenate substrates were mixed with 10% CJD brain 
homogenates seed in PCR tubes (Figure 4.4). Low molecular weight heparin was 
included at 100μg/ml for all PMCA reactions. Prior to the amplification procedure, 
19μl of the PMCA reaction mixture were taken (from the final volume of 120μl) for 
each reaction (referred to as the “frozen” sample) for comparison with the sonicated 
samples (referred to as the “sonicated” sample). Amplification employed cycles of 
sonication and incubation in a programmable sonicator (Qsonica, model Q-700) at 
37°C. A total of 96 PMCA cycles were performed comprising 20sec of sonication (at 
an amplitude of 38%, wattage: 278-299) followed by 29min 40 sec of incubation for 
each cycle. Frozen and sonicated samples were digested with proteinase K (in a final 
concentration of 50µg/ml at 37oC for 1h) and analysed by WB using the monoclonal 
antibody 3F4 as described previously (Barria et al., 2014). Amplification efficiency 
was expressed as the increase in PrPres signal in the sonicated sample compared to the 
frozen sample, as judged by densitometry of WB images acquired and analysed using 
the ChemiDocTM XRS+ System with Image Lab Software (Bio-Rad, Hemel 
Hempstead, UK). The full protocol used for PMCA is provided in Appendix 14. 
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4.6. Statistical analyses 
Advice on appropriate methods for statistical analyses was kindly provided by Dr 
Anna Molesworth, NCJDRSU, University of Edinburgh and Catriona Graham, Lead 
Statistician, Edinburgh Clinical Research Facility, University of Edinburgh. 
 
Excel (Microsoft, Reading, UK) and Prism 7.00 (GraphPad Software, Inc, La Jolla, 
USA, on license) were used for data storage and processing for statistical analysis of 
the data. The threshold used for statistical significance was p< 0.05. All graphs were 







5.1. Clinical features 
5.1.1. hGH-iCJD cases 
The clinical features (sex, age at death, age at iCJD onset, duration of illness, duration 
of hGH treatment, the mid-point of treatment to death, incubation period and PRNP 
codon 129 genotype) of the 35 hGH-iCJD cases are summarised in Table 5.1. The 
duration of hGH treatment varied from 2-11.2y (mean 6.6y, ± sd 2.6y) and the duration 
of illness ranged from 2-32 months (mo) (mean 11.3mo, ± sd 6.6mo ). All patients had 
received hGH produced by the modified Wilhelmi method for periods ranging from 
0.5-8.2y.  
 
The disease incubation period varied from 7.8-32.3y (mean 17.6y, ± sd 5.9y) and the 
period from the mid-point of treatment to death ranged from 8.2-32.9y (mean 18.6y, ± 
sd 6y). The commonest cause of hGH deficiency was idiopathic hGH deficiency (26 
cases), followed by craniopharyngiomas (5 cases). Single cases of panhypopituitarism, 
histiocytosis X, Russell-Silver syndrome and pilocytic astrocytoma were also 
included.  No cases had a history of head injury as a cause of hGH deficiency. Further 
details are provided in Appendix 1. 
 
The distribution of PRNP codon 129 genotypes in relation to the year of death is shown 
in Figure 5.1.A for the 30/35 cases for which data are available. The PRNP codon 129 
genotype in one case (hGH-iCJD31) was obtained from DNA extracted from a formic-
acid treated paraffin block; this method was unsuccessful in the five other cases. Figure 
5.1B shows the PRNP codon 129 genotype in relation to the year of death in the 21 
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cases with frozen tissue available for research; these cases appear to be representative 
of the total cases in Figure 5.1A. The UK hGH-iCJD group is dominated by patients 
of the MV and VV PRNP codon 129 genotypes; the 4 hGH-iCJD cases in individuals 
with the MM PRNP codon 129 genotype tended to occur in the latter part of the hGH-
iCJD epidemic. 
 
Statistically significant associations between the PRNP codon 129 polymorphism and 
the disease incubation period and the duration of illness in the hGH-iCJD patients are 
illustrated in Figure 5.2. Codon 129 MV patients have a significantly longer duration 
of illness (mean 16.3mo, ± sd 6mo) than the MM (mean 6mo, ± sd 1.4mo) and VV 
(mean 6.18mo, ± sd 1.8mo) patients. In contrast, the codon 129 MM patients have the 
longest incubation periods (mean 28.1y, ± sd 6.1y) in comparison to the MV patients 














Clinical and genetic features of hGH-iCJD cases  
         



























hGH-iCJD1* m 34 33 (1989) 8 4 17.5 16.9 MV 
hGH-iCJD2 m 31 30 (1991) 6 10 16.9 16.5 VV 
hGH-iCJD3 m 27 26 (1992) 17 6 14.9 13.2 MV 
hGH-iCJD4 m 30 29 (1992) 9 4 14.2 12.8 VV 
hGH-iCJD5 m 25 25 (1993) 5 6 11.9 11.4 VV 
hGH-iCJD6 f 33 32 (1994) 6 4 18.5 18.1 VV 
hGH-iCJD7 f 31 30 (1995) 12 4 17.1 16.2 MV 
hGH-iCJD8 m 29 28 (1996) 6 8 17.5 16.8 VV 
hGH-iCJD9 m 33 32 (1985) 14 10 20.0 18.8 MV 
hGH-iCJD10 m 36 36 (1996) 8 4 19.8 19.2 VV 
hGH-iCJD11 m 37 35 (1996) 18 4 19.1 17.8 MV 
hGH-iCJD12 m 27 27 (1998) 5 7 16.8 16.4 VV 
hGH-iCJD13 m 34 32 (1997) 16 5 18.2 17.2 MV 
hGH-iCJD14 m 29 28 (1997) 15 9 18.2 17.2 MV 
hGH-iCJD15 m 37 37 (1999) 9 6 20.4 19.1 MV 
hGH-iCJD16 m 30 28 (2000) 16 3 21.5 20 MV 
hGH-iCJD17* f 41 38 (2001) 22 10 25.2 23.7 MV 
hGH-iCJD18 f 34 32 (2003) 23 8 24.1 22.6 MV 
hGH-iCJD19 f 29 27 (2004) 32 7 24.5 22 MV 
hGH-iCJD20 m 46 46 (2011) 5 3 29.9 29.4 MM 
hGH-iCJD21 m 42 42 (2012) 8 8 31.6 31.7 MM 
hGH-iCJD22 m 20 19 (1997) 7 11 8.2 7.8 VV 
hGH-iCJD23 f 20 20 (1990) 2 11 15.1 10.5 VV 
hGH-iCJD24 m 32 31 (1992) 13 6 14.4 13.7 MV 
hGH-iCJD25 m 30 29 (1991) 16 3 13.7 12.5 N/A 
hGH-iCJD26 m 27 26 (1994) 7 8 13.7 13.2 VV 
hGH-iCJD27 m 24 23 (1994) 7 6 13.1 12.8 VV 
hGH-iCJD28 f 22 22 (1984) 11 5 10.4 9.5 MV 
hGH-iCJD29 m 20 20 (1989) 5 9 9.3 9.0 N/A 
hGH-iCJD30 m 23 23 (1996) 8 5 14.2 13.6 N/A 
hGH-iCJD31 m 28 28 (1997) 5 2 19.7 19.1 †MM 
hGH-iCJD32 m 36 35 (1999) 9 10 22.2 21.4 N/A 
hGH-iCJD33 m 31 29 (2000) 20 7 19.8 18.1 N/A 
hGH-iCJD34 m 38 37 (2003) 19 10 26.9 25.4 MV 
hGH-iCJD35 f 45 45 (2006) 6 9 32.9 32.3 MM 
 
 
*Insufficient paraffin-embedded tissue available for full pathological investigation 
† PRNP codon 129 genotype was obtained from DNA extracted from a formic-acid treated paraffin 
block 
 
Abbreviations: f: female; hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; 
m: male; M: methionine; PRNP: prion protein gene; V: valine.   
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Figure 5.1.  









The graphs indicate that both groups of cases cover all PRNP codon 129 genotype 
within a wide time period across the hGH-iCJD epidemic and can therefore be 
considered as representative of the larger hGH-iCJD cohort. 
Abbreviations: CNS: central nervous system; hGH: human growth hormone; iCJD: iatrogenic 





















































































































































































































































Relationship of PRNP codon 129 polymorphisms to hGH-iCJD incubation period and 




Diagram (A) shows differences in the incubation periods for hGH-iCJD in relation to 
PRNP codon 129 genotype, with the MM genotype having significantly longer 
incubation periods than the MV and VV genotypes.  Diagram (B) shows differences 
in the hGH-iCJD disease duration in relation to PRNP codon 129 genotype, with the 
MM and VV genotypes having significantly shorter disease durations than the MV 
genotype. Statistical analyses were performed using one-way ANOVA followed by 
Tukey’s multiple comparison test.  
 
Abbreviations: hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; M: 
methionine; PRNP: prion protein gene; V: valine. 
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5.1.2. hGH control cases 
The clinical features (sex, age at death, duration of hGH treatment, period from mid-
point of treatment to death and PRNP codon 129 genotype) of the 12 cases are 
summarised in Table 5.2. The PRNP codon 129 genotype in two cases was obtained 
from frozen tissue and in three cases from formic-acid treated paraffin blocks; the 
remaining seven cases have no codon 129 genotype data available (Table 5.2). The 
duration of treatment varied from 1-12.3y, (mean 5.1y, ± sd 3.7y) and the period from 
the mid-point of treatment to death ranged from 2.7-35.1y (mean 16.2y, ± sd 9.8y). 
8/12 of the patients had received hGH produced by the modified Wilhelmi method for 
periods ranging from 0.5-6.6y. The commonest underlying disorder was 
craniopharyngioma (five cases), with two cases of idiopathic panhypopituitarism and 
single cases of idiopathic hGH deficiency, mitochondrial cytopathy, Prader-Willi 
syndrome, ependymoma and pilocytic astrocytoma. No cases had a history of head 
injury as a cause of hGH deficiency. Further details are provided in Appendix 2. 
 
Table 5.2.  
Clinical and genetic features of hGH control patients 





Midpoint of hGH 




hGH control1 m 18 1.0 2.7 N/A 
hGH control2 f 18 2.3 5.0 N/A 
hGH control3 m 13 1.0 6.4 *MV 
hGH control4 m 28 3.5 8.9 *MV 
hGH control5 f 24 10.3 13.4 N/A 
hGH control6 f 31 7.3 19.6 N/A 
hGH control7 m 30 6.3 17.5 N/A 
hGH control8 m 33 5.3 16.4 *MV 
hGH control9 m 42 7.5 21.6 N/A 
hGH control10 m 37 3.3 16.7 MV 
hGH control11 m 45 12.3 30.3 MM 
hGH control12 m 35 1.0 35.1 N/A 
* PRNP codon 129 genotype was obtained from a formic-acid treated paraffin block  
Abbreviations: f: female; hGH: human growth hormone; m: male; M: methionine; N/A: data not 
available; PRNP: prion protein gene; V: valine. 
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5.1.3. hDM-iCJD cases 
The clinical features (sex, age at death, year of dural graft, disease duration, incubation 
period and PRNP codon 129 genotype) of the five cases referred to NCJDRSU and 
available for research are summarised in Table 5.3. All cases underwent dura mater 
grafting with Lyodura between 1983-1987. The incubation periods ranged from 3.8- 
14.8y (mean 8.2y, ± sd 3.7y) and the duration of illness ranged from 4-33mo (mean 
11.5mo, ± sd 12 mo). Three cases had PRNP codon 129 genotype analysis performed 
on blood samples taken in life. Extraction of DNA from formic-acid treated paraffin 
blocks for PRNP codon 129 analysis was unsuccessful in the remaining two cases 
(Table 5.3). 
 
Table 5.3.  
Clinical and genetic features of hDM-iCJD patients 
 
Study ID Sex Age at 
death 
(years) 
















hDM-iCJD2 f 27 April 1986 8.6 33 MM 
hDM-iCJD3 m 34 August 1987 14.8 5 MM 
hDM-iCJD4 m 31 October 1985 3.8 4 N/A 
hDM-iCJD5 m 47 July 1985 7.2 11 N/A 
 
Abbreviations: f: female; hDM: human dura mater; m: male; M: methionine; N/A: data not available; 
PRNP: prion protein gene; V: valine. 
 
5.1.4. vCJD cases 
The clinical features (sex, age at death, duration of illness and PRNP codon 129 
genotype) of the 33 age-matched vCJD patients are summarised in Table 5.4. No cases 
of secondary vCJD transmission were included. The duration of illness ranged from 7-
39mo (mean 14.4mo, ± sd 6.7mo). All cases were PRNP codon 129 MM genotypes 
(analysis performed on blood samples taken in life). 
 125 
Table 5.4.  
Clinical and genetic features of vCJD age-matched patients 
Study ID Sex Age at death 
(years) 
Duration of illness 
(months) 
PRNP codon 129 
genotype 
vCJD1 f 29 11 MM 
vCJD2 m 25 14 MM 
vCJD3 f 24 25 MM 
vCJD4 f 25 13 MM 
vCJD5 m 25 14 MM 
vCJD6 m 27 10 MM 
vCJD7 m 21 39 MM 
vCJD8 f 20 16 MM 
vCJD9 m 26 10 MM 
vCJD10 m 28 8 MM 
vCJD11 m 25 14 MM 
vCJD12 m 31 9 MM 
vCJD13 f 33 30 MM 
vCJD14 m 36 15 MM 
vCJD15 m 39 11 MM 
vCJD16 m 35 12 MM 
vCJD17 m 39 14 MM 
vCJD18 m 38 12 MM 
vCJD19 f 30 10 MM 
vCJD20 m 34 19 MM 
vCJD21 m 34 17 MM 
vCJD22 m 30 9 MM 
vCJD23 f 32 8 MM 
vCJD24 f 41 18 MM 
vCJD25 m 41 7 MM 
vCJD26 m 20 7 MM 
vCJD27 m 20 11 MM 
vCJD28 f 22 18 MM 
vCJD29 m 26 12 MM 
vCJD30 f 30 18 MM 
vCJD31 m 33 11 MM 
vCJD32 m 33 18 MM 
vCJD33 f 35 14 MM 
 




5.1.5. sCJD cases  
The clinical features (sex, age at death, duration of illness and PRNP codon 129 
genotype) of the 15 age-matched sCJD patients are summarised in Table 5.5. The 
duration of illness varied from 2-54mo (mean 16.8mo, ± sd 15mo). All cases had 
PRNP codon 129 genotype analysis performed on blood samples taken in life. Nine 
cases were PRNP codon 129 MM genotypes, two  were codon 129 MV and four were 
codon 129 VV genotypes. 
 
Table 5.5.  
Clinical and genetic features of sCJD age-matched patients 
 
Study ID Sex Age at death 
(years) 
Duration of illness 
(months) 
PRNP codon 129 
genotype 
sCJD1 f 44 5 MM 
sCJD2 m 38 N/A VV 
sCJD3 m 42 10 VV 
sCJD4 m 42 33 VV 
sCJD5 f 20 54 MV 
sCJD6 f 46 17 MM 
sCJD7 m 39 23 MM 
sCJD8 m 43 10 MM 
sCJD9 f 41 21 MM 
sCJD10 m 45 35 MM 
sCJD11 m 46 7 VV 
sCJD12 m 38 8 MV 
sCJD13 m 45 6 MM 
sCJD14 f 46 2 MM 
sCJD15 f 45 4 MM 
 
Abbreviations: f: female; m: male; M: methionine; N/A: data not available; PRNP: prion protein gene; 










5.2.1. hGH-iCJD  
The neuropathological features were reviewed in all 35 hGH-iCJD patients. Records 
of the macroscopic brain examination of the brain were available in 34/35 cases. 
Whole brain weights were recorded in 26/35 cases and ranged from 825-1625g, the 
case with the lowest brain weight (hGH-iCJD19) corresponded to panencephalopathic 
CJD (Jansen et al., 2009) with severe grey matter atrophy and white matter 
degeneration. A plot of brain weights in relation to the duration of illness is provided 
in Figure 5.3, with comparable data for the hDM-iCJD cases and sCJD and vCJD 
controls. 
 
No significant abnormalities in the cerebral hemispheres were recorded in 16/34 cases. 
Cerebral atrophy was present to a mild degree in 16/34 cases, with more severe atrophy 
recorded in 2/34 cases (hGH-iCJD19: aged 29y, brain weight 825g; and hGH-iCJD25: 
aged 30y, brain weight 1050g). Cerebellar atrophy, particularly involving the vermis, 
was present in 26/34 cases (Figure 5.4).  Focal abnormalities included gliosis at the 
base of the brain relating to the site of neurosurgical excision of a craniopharyngioma 
(5 cases); the cerebellum in one case (hGH-iCJD3) showed a gliotic defect in the right 
hemisphere representing the site of resection of a pilocytic astrocytoma. Subsequent 
microscopic examination confirmed the macroscopic findings described above. No 
residual astrocytoma was identified in hGH-iCJD3, but the right cerebellar hemisphere 
showed gliosis and white matter degeneration, with vascular changes in keeping with 




Figure 5.3.  
Brain weights in hGH-iCJD and control cases in relation to the duration of illness
 
 
The unfixed brain weights recorded at autopsy are plotted against the disease duration 
for the available cases of hGH-iCJD, hDM-iCJD, sCJD controls and vCJD controls. 
No significant differences were found between these disease groups, but all show a 
trend towards a lower brain weight with increasing disease duration (adjusted R2 test 
= 0.25). 
 
Abbreviations: Abbreviations: CJD: Creutzfeldt-Jakob disease; hDM: human dura mater; hGH: 
human growth hormone; i: iatrogenic; s: sporadic; v: variant. 
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Figure 5.4.  




Macroscopic pathology in a case of hGH-iCJD (hGH-iCJD34), PRNP codon 129 MV, 
age 38y at death with a 19mo duration of illness. The cerebral hemispheres show 
evidence of mild atrophy of the cortex with sulcal widening. The subcortical grey 
matter structures are not atrophic, but the cerebellar vermis shows cortical atrophy, 
particularly in the superior vermis (arrow). 
 
Abbreviations: hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; M: 
methionine; PRNP: human prion protein gene; V: valine.  
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A widespread spongiform encephalopathy was present in all 35 cases, accompanied 
by variable neuronal loss and gliosis, with amyloid plaques in the cerebellum identified 
in 16/35 cases. The distribution, severity and nature of the spongiform change, gliosis, 
amyloid plaque formation and the accumulation of disease-associated prion protein on 
immunohistochemistry were recorded in all cases. The case with the lowest brain 
weight (hGH-iCJD19) exhibited status spongiosis in the cerebral cortex, with marked 
neuronal loss, severe gliosis and collapse of the cortical cytoarchitecture. This patient 
was MV at PRNP codon 129 and had the longest disease duration of the hGH-iCJD 
cases, at 32mo. A summary of the neuropathological features of each hGH-iCJD case 
along with the PRNP codon 129 genotype (where available) and PrPres type (where 
available) is recorded in Table 5.6. In general, the distribution and nature of the 
pathological features in the CNS in the hGH-iCJD cases showed close similarities to 
those in sCJD cases with the corresponding PRNP codon 129 genotype, allowing a 
histotype to be assigned to each case (Table 5.6). 
 
Three major histotypes were identified in relation to the established classification of 
subtypes of sCJD (Table 1.3 and Figure 1.5) (Parchi et al., 2012): 
 
1. MV2K subtype (14 cases), with widespread spongiform change 
(predominantly microvacuolar) in the cerebral cortex, hippocampus, basal 
ganglia, thalamus and cerebellar cortex. Occasional areas of confluent 
spongiform change are also present in the cerebral cortex in four cases, which 
can be subclassified as MV2K+2C (Table 5.6). Kuru-type amyloid plaques are 
present in the cerebellar granular layer in all cases, but occasionally also in the 
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molecular layer and in the cerebral cortex. Perineuronal, plaque and plaque-
like PrP deposits, particularly in the cerebellar granular and molecular layers 
(Figure 5.5 a-d), but also in the cerebellar white matter, basal ganglia, thalamus, 
hippocampus and in the cerebral cortex. One additional case for which no 
PRNP codon 129 genotype could be determined (hGH-iCJD33) had 
neuropathological features corresponding to the MV2K histotype. 
 
2. VV2 subtype (11 cases), with small and medium sized vacuoles, often in a 
linear distribution in layer 5 of the cerebral cortex. Spongiform change is most 
severe in the basal ganglia and is also marked in the CA1 region of the 
hippocampus and the subiculum. Severe neuronal loss and gliosis is apparent 
in the cerebellar cortex, often resulting in cerebellar cortical atrophy. PrP 
immunohistochemistry shows synaptic and perineuronal deposits in the 
cerebral cortex in layer 5, with decoration of apical ascending dendrites (Figure 
5.5 e-h). Plaque-like deposits occur in layer 3 of the cerebral cortex and in the 
hippocampus, basal ganglia, thalamus and cerebellar cortex, but no true 
amyloid plaques are present. Intense PrP labelling occurs in the cerebellar 
granular layer and around the neurones of the dentate nucleus. Three additional 
cases (hGH-iCJD29, 30 and 32) for which no PRNP codon 129 genotype could 
be determined had neuropathological features corresponding to the VV2 
histotype. 
 
3. MM/MV1 subtype (two codon 129 MM cases), with a widespread spongiform 
encephalopathy of microvacuolar type, most severe in the frontal and occipital 
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cortex. The hippocampus is relatively spared and there is variable spongiform 
change in the basal ganglia and medial thalamic nuclei. Patchy spongiform 
change occurs in the molecular layer of the cerebellar cortex, bbut no amyloid 
plaques are present. PrP deposition occurs in a widespread granular/synaptic 
pattern throughout affected grey matter regions (Figure 5.5 i-l). One additional 
case (hGH-iCJD25) for which no PRNP codon 129 genotype could be 



































PRNP codon 129 genotype, PrPres type and neuropathology in 35 hGH-iCJD cases 






Prominent neuropathological features Histotype 
*hGH-iCJD1 MV i+2 
Microvacuolation with some large confluent vacuoles; 
neuronal loss and gliosis most severe in the cerebellum 
with kuru plaques prominent in the cerebellar cortex. 
MV2K+2C 
hGH-iCJD2 VV 2 
Microvacuolation most prominent in deeper cortical 
layers; PrP staining shows synaptic and perineuronal 
deposits with plaque-like accumulations in the cerebral 
and cerebellar cortex. 
VV2 
hGH-iCJD3 MV i+2 
Microvacuolation with synaptic and perineuronal PrP 
staining in all cortical layers. Kuru plaques and plaque-
like accumulations prominent in the cerebral and 
cerebellar cortex. 
MV2K 
hGH-iCJD4 VV 2 
Microvacuolation with some focal confluent vacuoles; 
PrP staining shows synaptic and perineuronal deposits 
with plaque-like accumulations in the cerebral and 
cerebellar cortex. 
VV2 
hGH-iCJD5 VV 2 
Prominent microvacuolation with perineuronal PrP 
staining in addition to plaque-like accumulations in the 
cerebral cortex. 
VV2 
hGH-iCJD6 VV 2 
Prominent microvacuolation with perineuronal PrP 
staining in addition to plaque-like accumulations in the 
cerebral cortex. 
VV2 
hGH-iCJD7 MV i+2 
Microvacuolation with some large confluent vacuoles; 
PrP staining shows synaptic and perineuronal PrP 
staining with kuru plaques and plaque-like deposits 
prominent in the cerebral and cerebellar cortex. 
MV2K+2C 
hGH-iCJD8 VV 2 
Microvacuolation most prominent in deeper cortical 
layers with  perineuronal PrP staining and numerous 
plaque-like deposits in the cerebral cortex. 
VV2 
hGH-iCJD9 MV i+2 
Microvacuolation with synaptic and perineuronal PrP 
staining in all cortical layers. Kuru plaques and plaque-
like accumulations prominent in the cerebral and 
cerebellar cortex. 
MV2K 
hGH-iCJD10 VV 2 
Prominent microvacuolation in deeper cortical layers 
with synaptic and perineuronal PrP staining in addition 
to plaque-like accumulations. 
VV2 
hGH-iCJD11 MV i+2 
Prominent microvacuolation with some confluent 
vacuolation in deeper cortical layers. Perineuronal PrP 
staining in addition to plaque-like accumulations. Kuru 








hGH-iCJD12 VV 2 
Microvacuolation with PrP staining showing synaptic 
and perineuronal deposits with plaque-like 
accumulations in the cerebral and cerebellar cortex. 
VV2 
hGH-iCJD13 MV i+2 
Microvacuolation with synaptic and perineuronal PrP 
staining. Kuru plaques and plaque-like accumulations 
prominent in the cerebral and cerebellar cortex. 
MV2K 
hGH-iCJD14 MV i+2 
Prominent microvacuolation in deeper cortical layers 
with perineuronal and synaptic PrP staining in addition 
to plaque-like accumulations. Kuru plaques present in 
the cerebellar cortex. 
MV2K 
hGH-iCJD15 MV i+2 
Prominent microvacuolation in deeper cortical layers 
with perineuronal PrP staining in addition to plaque-
like accumulations. Kuru plaques present in the 
cerebral and cerebellar cortex. 
MV2K 
hGH-iCJD16 MV i+2 
Prominent microvacuolation in deeper cortical layers 
with perineuronal PrP staining in addition to plaque-
like accumulations. Kuru plaques present in the 
cerebral and cerebellar cortex. 
MV2K 
hGH-iCJD17 MV i+2 
Microvacuolation with PrP staining shows synaptic and 
perineuronal deposits in addition to plaque-like 
accumulations. Kuru plaques present in the cerebellar 
cortex. 
MV2K 
hGH-iCJD18 MV i+2 
Microvacuolation with synaptic and perineuronal PrP 
staining. Kuru plaques and plaque-like accumulations 
prominent in the cerebral and cerebellar cortex. 
MV2K 
hGH-iCJD19 MV i+2 
Status spongiosis with collapse of cerebral architecture. 
Synaptic PrP staining with plaque-like accumulations. 
Kuru plaques present in the cerebellar cortex. 
MV2K 
hGH-iCJD20 MM i 
Microvacuolation with some large confluent vacuoles; 
PrP staining shows synaptic and perineuronal deposits 
in addition to plaque-like accumulations. Kuru plaques 




hGH-iCJD21 MM 1 
Microvacuolation with synaptic PrP staining in 
cerebral and cerebellar cortex. MM1 
hGH-iCJD22 VV N/A 
Microvacuolation most prominent in  deeper cortical 
layers; PrP staining shows perineuronal deposits with 




hGH-iCJD23 VV N/A 
Microvacuolation with PrP staining showing synaptic 
and perineuronal deposits with plaque-like 
accumulations in the cerebral and cerebellar cortex.  
Resembles
VV2 
hGH-iCJD24 MV N/A 
Microvacuolation with PrP staining showing synaptic 
and perineuronal PrP staining with kuru plaques and 
plaque-like accumulations prominent in the cerebral 




hGH-iCJD25 N/A N/A 
Status spongiosis with collapse of cerebral architecture. 
Severe neuronal loss and gliosis; PrP staining shows 
coarse synaptic accumulations.  
Resembles 
MM/MV1 
hGH-iCJD26 VV N/A 
Prominent microvacuolation in deeper cortical layers 
with synaptic and perineuronal PrP staining in addition 
to plaque-like accumulations. 
Resembles
VV2 
hGH-iCJD27 VV N/A 
Microvacuolation with PrP staining showing synaptic 
and perineuronal deposits with a few plaque-like 
accumulations in the cerebellar cortex cortex. 
Resembles
VV2 
hGH-iCJD28 MV N/A 
Microvacuolation with little confluent vacuolation. PrP 
staining shows synaptic and perineuronal deposits with 
a few plaque-like accumulations in the cerebral cortex. 
Resembles 
MV2C 
hGH-iCJD29 N/A N/A 
Microvacuolation with PrP staining showing weak 
perineuronal deposits.  
Resembles 
VV2 
hGH-iCJD30 N/A N/A 
Microvacuolation with PrP staining showing synaptic 
and perineuronal deposits with plaque-like 




hGH-iCJD31 *MM N/A 
Prominent microvacuolation in deeper cortical layers 
with synaptic and perineuronal PrP staining in addition 
to plaque-like accumulations. 
Atypical: 
some VV2- 
like features   
hGH-iCJD32 N/A N/A 
Prominent microvacuolation in deeper cortical layers 
with synaptic and perineuronal PrP staining in addition 
to plaque-like accumulations. 
Resembles 
VV2 
hGH-iCJD33 N/A N/A 
Mild microvacuolation with synaptic and perineuronal 
PrP staining with kuru plaques and plaque-like deposits 
prominent in the cerebral and cerebellar cortex. 
Resembles
MV2K 
hGH-iCJD34 MV N/A 
Microvacuolation with some confluent vacuoles.  
Synaptic and perineuronal PrP labelling. Kuru plaques 
and plaque-like accumulations in the cerebral and 
cerebellar cortex. 
MV2K+2C 
hGH-iCJD35 MM N/A 
Severe microvacuolation with synaptic PrP staining in 
cerebral and cerebellar cortex. MM1 
*hDM-iCJD1 MM 1 
Microvacuolation most marked in the cerebral cortex 
with relatively little cerebellar pathology. 
Resembles 
MM1 
hDM-iCJD2 MM 1 
Status spongiosis with collapse of cerebral architecture. 
Synaptic PrP staining in cerebral and cerebellar cortex. MM1 
hDM-iCJD3 MM 1 
Microvacuolation with synaptic PrP staining in 
cerebral and cerebellar cortex. MM1 
hDM-iCJD4 N/A N/A 
Prominent microvacuolation in deeper cortical layers 
with synaptic and perineuronal PrP staining in addition 
to plaque-like accumulations. 
Resembles 
VV2 
hDM-iCJD5 N/A N/A 
Status spongiosis with collapse of cerebral architecture. 




N/A- PrPres type information not available as no frozen CNS material for analysis 
* Fixed tissue not available for PrP immunohistochemical analysis      
Abbreviations: C: cortical; CNS: central nervous system; hDM: human dura mater; hGH: human growth 
hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; K: kuru plaques; M: methionine; PRNP: prion 
protein gene; V: valine. 
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PRNP codon 129 MV hGH-iCJD cases show spongiform vacuoles of varying size, 
with occasional cortical kuru plaques (arrow). Coarse granular and perineuronal PrP 
staining in the cerebral cortex, with more intense staining of the kuru plaques (a,b). 
Kuru plaques are a more prominent feature in the cerebellar cortex (arrow), along with 
coarse granular PrP staining in the molecular layer (c,d).  PRNP codon 129 VV hGH-
iCJD cases show microvacuolation with a combination of synaptic, perineuronal and 
plaque-like accumulations of PrP in the cerebral and cerebellar cortex (e-h). PRNP 
codon 129 MM hGH-iCJD cases show widespread microvacuolation with a 
predominantly synaptic accumulation of PrP in the cerebral and cerebellar cortex (i-l). 
(Sections a, c, e, g, i and k are stained with haematoxylin and eosin and sections b, d, 
f, h, j, and l are stained by immunohistochemistry for PrP using the KG9 antibody). 
Scale bar=250m. 
 
Abbreviations: CJD: Creutzfeldt-Jakob disease; hGH: human growth hormone; i: iatrogenic; K; kuru 
plaque; M: methionine;  PRNP: prion protein gene; PrP: prion protein; UK: United Kingdom; V: valine. 
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5.2.1.1. Atypical neuropathological phenotypes in hGH-iCJD 
Two hGH-iCJD PRNP codon 129 MM cases (hGH-iCJD20 and hGH-iCJD31), 
exhibited neuropathological phenotypes that did not correspond to those described by 
Parchi et al. (Parchi et al., 1999) in sCJD cases with PRNP codon 129 MM. Case hGH-
iCJD20 contained a mixture of both microvacuolar and confluent spongiform change 
in the cerebral cortex, particularly in layers 5-6, hippocampus and basal ganglia, with 
lesser involvement of the thalamus and cerebellum (Figure 5.6 a,c). PrP IHC showed 
a combination of synaptic, perineuronal and perivacuolar PrP deposits in a widespread 
distribution, with plaque-like deposits and kuru plaques in the cerebral and cerebellar 
cortex (Figure 5.6 b,d). These features most closely resemble the sCJD MV2K +C 
histotype (Parchi et al., 2012). 
 
Case hGH-iCJD31 showed some similar features to hGH-iCJD20, with predominantly 
microvacuolar spongiform change in the cerebral cortex, particularly in layers 5-6, 
hippocampus and basal ganglia. The thalamus and cerebellum showed less spongiform 
change, but no kuru-type plaques were identified in the cerebellum (Figure 5.6 e,g). 
PrP immunohistochemistry showed a combination of synaptic, perineuronal and 
plaque-like PrP deposits in a widespread distribution, including the cerebral and 
cerebellar cortex, basal ganglia, hippocampus and thalamus. An occasional plaque-
like deposit was present in the parietal cortex, with intense labelling on PrP 
immunohistochemistry. (Figure 5.6 f,h). This phenotype was distinct from both the 
MM/MV1-like phenotype and the MV2-like phenotype in hGH-iCJD, and from MM1 
and MV2 cases of sCJD. However, there are some similarities to the VV2 phenotype 
in both sCJD and hGH-iCJD. 
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Legend to Figure 5.6. 
Both cases have atypical neuropathological features in comparison with the codon 129 
MM hGH-iCJD cases in Figure 5.5 i-l. Case hGH-iCJD20 has a mixture of 
microvacuolar and confluent vacuolation and occasional large PrP positive kuru 
plaques in the cerebral cortex (a,b). Kuru plaques (arrow) are also present in the 
cerebellum, with dense PrP labelling and coarse PrP positivity in the granular layer 
(c,d), resembling the MV2K+C histotype. Case hGH-iCJD31 has microvacuolation in 
the lower layers of the cerebral cortex and in the cerebellar cortex (e,g), with a 
combination of synaptic, perineuronal and plaque-like accumulations of PrP in the 
cerebral and cerebellar cortex (f,h). No kuru-type amyloid plaques were present in any 
brain region. These features show some similarities to the VV2 histotype in sCJD. 
(Sections a, c, e, and g, are stained with haematoxylin and eosin and sections b, d, f, 
and h are stained by immunohistochemistry for PrP using the KG9 antibody). 
Scale bar=250m. 
 
Abbreviations:  CJD: Creutzfeldt-Jakob disease; hGH: human growth hormone; i: iatrogenic; K; kuru 
plaque; M: methionine;  PRNP: prion protein gene; PrP: prion protein; UK: United Kingdom; s: 
sporadic; V: valine. 
 
5.2.2 hGH control cases 
Most (10/12) of the hGH-control cases were not examined initially in NCJDRSU. 
Records of the macroscopic pathology are available for 9/12 cases, although most of 
these are incomplete. The brain weights varied from 1042-1640g; the lowest weight 
occurred in a 24 year-old patient with a recurrent craniopharyngioma (case hGH-
control5). Craniopharyngiomas had also been resected in four other patients, two of 
whom (hGH-control2 and hGH-control5) had recurrent craniopharyngiomas at the 
time of death.  No residual ependymoma was present in the gliotic cerebellum in a 
patient (hGH-control10) who had undergone neurosurgical resection with post-
operative radiotherapy. However, a recurrent pilocytic astrocytoma was identified in 
the 3rd ventricle in patient hGH-control1, who had undergone neurosurgical resection. 
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The microscopic neuropathology ranged from no significant abnormalities (two cases 
with idiopathic panhypopituitarism, and single cases of idiopathic growth hormone 
deficiency, mitochondrial cytopathy and the Prader-Willi syndrome) to focal 
abnormalities with tissue disruption and gliosis in cases with resected neoplasms. The 
presence of recurrent craniopharyngiomas in hGH-controls 2 and 5, and a recurrent 
pilocytic astrocytoma in hGH-control1 was confirmed. No recurrent ependymoma was 
identified in hGH-control10, but the cerebellum showed white matter degeneration 
with macrophage infiltration and vascular changes in keeping with previous 
radiotherapy. A small focus of neuronal loss with gliosis was also present in the right 
inferior temporal cortex. No evidence of a spongiform encephalopathy or prion protein 
immunoreactivity was found in any of the hGH control cases. 
 
5.2.3 hDM-iCJD cases 
Records of the macroscopic pathology are available for 3/5 cases. The brain weights 
varied from 958-1675g, with the lowest weight recorded in hDM-iCJD2, who had the 
longest duration of illness (33mo). This case showed severe cerebral and cerebellar 
atrophy, corresponding to panencephalopathic CJD (Figure 5.6 a-d). The three hDM-
iCJD cases with frozen tissue available and PRNP genotype data all showed 
microscopic features in keeping with the MM1 histotype (Figure 5.7 e,h). Of the two 
cases with no frozen tissue available, hDM-iCJD5 also showed the features of the 
MM/MV1 histotype, while hDM-iCJD4 resembled the VV2 histotype.  Kuru-type 











































PRNP codon 129 MM hDM-iCJD2 shows severe cerebral and cerebellar neuronal loss 
and gliosis in keeping with panencephalopathic CJD, with a predominantly synaptic 
accumulation of PrP in the cerebral and cerebellar cortex (a- d). The other codon 129 
MM hDM-iCJD cases have less severe neuronal loss and gliosis and show 
microvacuolar spongiform change with granular/synaptic PrP accumulation, 
resembling the sCJD MM1 histotype (e-h). (Sections a, c, e, and g, are stained with 
haematoxylin and eosin and sections b, d, f, and h are stained by 
immunohistochemistry for PrP using the KG9 antibody). Scale bar=250µm. 
 
Abbreviations:  CJD: Creutzfeldt-Jakob disease; hDM: human dura mater; i: iatrogenic;  M: methionine;  
PRNP: prion protein gene; PrP: prion protein; UK: United Kingdom. 
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5.3. Co-pathology  
5.3.1. A pathology in hGH-iCJD 
Awas detected as cerebral amyloid angiopathy (CAA) and/or CNS parenchymal 
deposits by IHC in 18/33 hGH-iCJD cases with sufficient paraffin-embedded tissue 
for analysis. 6/18 Apositive cases had CAA alone, 4/18 had parenchymal deposits 
without CAA and 8/18 had both CAA and parenchymal deposits (Figure 5.8). All cases 
with parenchymal deposits contained diffuse (immature) plaques. Variable numbers 
of cored plaques, some with a surrounding corona of diffuse A, were detected by A 
IHC. Neuritic plaques were identified with the Bielschowsky silver stain in five cases 
(Figure 5.9 a-d). Patchy diffuse subpial A deposits were also present in five cases 
(Figure 5.9 g,h), but other forms of diffuse A (such as lake-like or fleecy deposits) 
were absent. No A deposits were identified in the entorhinal cortex, hippocampus, 
basal ganglia, thalamus, brain stem, cerebellum, spinal cord or white matter. Two cases 
had diffuse A plaques in the anterior cingulate gyrus in addition to the neocortex, but 
the full Thal phase 2 distribution of A deposits was absent e.g. in the entorhinal cortex 
and hippocampus. These were therefore recorded as Thal phase 1* in the ABC scores 
(see Table 5.7), as recently reported in hDM-iCJD cases (Kovacs et al., 2016a). 
 
Focal A deposits (diffuse and cored plaques, neuritic plaques and subpial deposits) 
occurred in the cerebral cortex in an unpredictable and varied distribution, either singly 
or in clusters, in one or more cortical regions. No evidence of a selective laminar 
distribution of plaques was found and no areas of pancortical involvement were 
identified. The plaque frequency varied from occasional diffuse grey mater plaques to 
more numerous diffuse and neuritic plaques (up to CERAD score 2). The neurites 
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around the cored plaques were relatively sparse on IHC with the AT8 antibody (Figure 
5.10a). However, ubiquitin IHC showed more widespread neurites (Figure 5.10b). 
Reactive astrocytes surrounded the cored/neuritic plaques with extensive processes 
and microglial cells were present in both the plaque cores and the periphery (Figure 
5.10 c,d). No neurofibrillary tangles were identified in the cortical regions with neuritic 
plaques or in any other brain regions with the Bielschowsky silver stain and tau IHC.  
 
CAA varied from occasional focal A deposits in meningeal vessel walls to more 
extensive circumferential deposition in meningeal and intraparenchymal vessels, with 
variable perivascular A accumulation (Figure 5.11 a-d). None of the cases showed 
vasculopathy related to CAA. Case hGH-iCJD18 displayed sparse capillary CAA in 
addition to parenchymal and meningeal CAA. CAA was present most often in the 
occipital meningeal vessels and occipital cortex, but occasional cases had isolated 
CAA in the parietal or frontal cortex. A single case also had CAA in the cerebellar 
meningeal vessels, with no cerebellar parenchymal involvement (Figure 5.11c). CAA 
was absent in the hippocampus, basal ganglia, thalamus or brain stem in all cases.   
 
Immunohistochemistry for A 1-40 showed preferential labelling of CAA and plaque 
cores, while the A1-42 antibody showed more labelling of diffuse Adeposits in the 
subpial region, diffuse plaques and the diffuse corona around some cored plaques 
(Figure 5.11 e,f). Capillary CAA lesions labelled with the antibody to A 1-42, with 
less intense labelling with the A 1-40 antibody. Perivascular diffuse A deposits were 
present in the cases with most widespread intraparenchymal CAA (Figure 5.11d), with 
some dyshoric vessels identified.  
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Figure 5.8. 
Frequency of Aβ accumulation in hGH-iCJD and control cases 
 
 
There is a significant difference in the percentage of cases with CNS A deposition 
in the two groups treated with hGH (51%) compared to the three groups not treated 
with hGH (6%); p<0.001 (Fisher’s exact test). Comparison of the hGH-iCJD, hGH 
control and non hGH-treated groups confirms the association between CNS A 
accumulation and hGH treatment; p<0.001 (Chi-squared test). 
 
Abbreviations: A: amyloid beta; CAA: cerebral amyloid angiopathy; CNS: central nervous system; 
CJD: Creutzfeldt-Jakob disease; hGH: human growth hormone; i: iatrogenic; s: sporadic; v: variant
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Figure 5.9. CNS Aβ deposition in hGH-iCJD cases 
 
 
Aβ IHC (6F/3D antibody) (a-d, g,h) and Bielschowsky silver stain (e,f) showing the 
range of Aβ plaques in hGH-iCJD cases. Diffuse plaques (a,b) were a feature of all 
hGH-iCJD cases in which CNS A deposition was observed. Cored plaques were 
less frequently observed following A immunohistochemistry (c,d). Neuritic plaques 
were demonstrated with the Bielschowsky silver stain in 5 cases (e,f). Patchy diffuse 
subpial Aβ deposits (g,h) were also identified in  5 cases by IHC. Scale bar=250µm.  
  
Abbreviations: A: amyloid beta; CJD: Creutzfeldt-Jakob disease; hGH: human growth hormone; i: 
iatrogenic; IHC: immunohistochemistry. 
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Figure 5.10 Aβ plaque reactions in hGH-iCJD cases 
 
 
The AT8 anti-tau antibody labels sparse neurites around a cored A plaque (a). The 
ubiquitin antibody labels extensive neurites around a cored A plaque (b). Reactive 
astrocytes around a cored A plaque revealed on double IHC for A (6F/3D 
antibody-red) and GFAP (GFAP antibody-brown) (c). Double IHC for A (6 F/3D 
antibody-red) and CD 68 (PGM1 antibody-brown) shows microglial cells around and 
within a cored A plaque (d). Scale bar=250µm.   
 
Abbreviations: A: amyloid beta; CJD: Creutzfeldt-Jakob disease; GFAP: glial fibrillary acidic protein; 
hGH;  human growth hormone; i: iatrogenic; IHC: immunohistochemistry. 
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Figure 5.11. CAA in hGH-iCJD cases 
 
 
Patchy deposition of A in the wall of a meningeal vessel (a). More extensive A 
deposition in occipital vessels of varying size in the meninges and adjacent cortex (b). 
Patchy A deposition in the wall of meningeal vessels overlying the cerebellar cortex 
(c). Circumferential deposition in a cortical arteriole with extensive perivascular A 
forming a cored plaque-like structure (d). (f). IHC with A 1-40 (e) and 1-42 (f) 
antibodies on adjacent sections. The 1-40 antibody shows intense labelling of vessels 
and plaque cores, while the 1-42 antibody shows intense labelling of a large diffuse 
A deposit. Scale bar=250µm. The 6F/3D anti-A antibody was used in a-d. 
 
Abbreviations: A: amyloid beta; CAA: cerebral amyloid angiopathy; CJD: Creutzfeldt-Jakob 
disease; hGH; human growth hormone; i: iatrogenic; IHC: immunohistochemistry. 
 149 
5.3.2 A pathology in control cases 
5.3.2.1 hGH controls 
Similar patterns of CNS A accumulation were identified in 5/12 hGH control cases, 
with 3/5 cases containing parenchymal A deposits only, and a single case with 
meningeal and intraparenchymal CAA, but no parenchymal deposits or capillary CAA 
(Figure 5.12 a,b). The remaining case had extensive meningeal and intraparenchymal 
CAA with capillary CAA and widespread diffuse and neuritic cerebral cortical plaques 
with scanty neurites (up to CERAD score 2), and patchy subpial A deposits (Figure 
5.12 c-d). Dyshoric CAA vessels were also present and occasional A-laden vessels 
exhibited splitting of the vessel wall (Figure 5.12 e-g). The distribution of these lesions 
was very similar to those in the hGH-iCJD cases, with no plaques or CAA identified 
in the entorhinal region, hippocampus, basal ganglia, thalamus, brain stem, cerebellum 
or spinal cord in any of the cases examined. Two cases were scored as Thal phase 1* 
(see section 5.3.1 above).  
 
Immunohistochemistry for A1-40 and A-42 gave similar results to the hGH-iCJD 
cases (Figure 5.12h). No neurofibrillary tangles were identified on the Bielschowsky 
silver stain or tau IHC in relation to the A pathology. However, numerous tau-
positive neurites were identified around cored A plaques and around A deposits 
surrounding intraparenchymal blood vessels (Figure 5.13 a,b). Reactive astrocytes 
and microglial cells were also identified around and within the cored A plaques 
(Figure 5.13 c,d).  
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5.3.2.2. hDM-iCJD cases 
No Alabelling was identified in either the CNS parenchyma or blood vessels (Figure 
5.7). This may reflect the periods of survival following dura mater graft surgery; all 
died within 20y of surgery, while all the hDM-iCJD cases with CNS Aaccumulation 
reported by Frontzek et al. (Frontzek et al., 2015) had survived surgery for over 20 y. 
 
5.3.2.3. vCJD control cases 
Two vCJD cases (vCJD22 and vCJD32) showed occasional diffuse A plaques in the 
occipital and parietal cortex (Figure 5.13 f,g). The A deposits appeared to co-localise 
with the PrP amyloid in some florid plaques, but double IHC with antibodies to A 
and PrP showed some separation of the diffuse deposits  (Figure 5.13g). No cored or 
neuritic A plaques were identified and no meningeal or parenchymal CAA was 
present. No A deposits were present in any subcortical grey matter regions.  
 
5.3.2.4. sCJD control cases 
A single sCJD control case (sCJD14) showed focal A deposits in the walls of 
occasional small to medium sized meningeal blood vessels over the occipital and 
temporal lobes and in the superficial occipital cortex (Figure 5.13h), with very few 
vessels exhibiting circumferential deposition. No A deposits were found in the 
cerebral cortex or any subcortical grey matter regions.  
 
The results of the ABC and CAA scores for the hGH control, vCJD and sCJD cases 
are summarised in Table 5.7. 
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Diffuse A deposits and plaques in the frontal cortex (a). CAA with patchy 
meningeal deposits and circumferential deposition in a superficial cortical vessel (b). 
Extensive CAA in meninges and cortex with diffuse and perivascular A deposits 
(c). Multiple cored plaques and smaller diffuse Adeposits. Severe capillary CAA 
with marked thickening of vessel walls (e). A dyshoric cortical vessel and an 
adjacent cored plaque (f). Vasculopathy with splitting of an intracortical arteriole 
wall (g). Meningeal and intracortical CAA with diffuse subpial deposits, perivascular 
deposits and diffuse and cored A plaques. Scale bar=250µm. The 6F/3D antibody 
was used for A IHC in a-d and f-h. 
   
Abbreviations: A: amyloid beta; CAA: cerebral amyloid angiopathy; CJD: Creutzfeldt-Jakob 
disease; hGH; human growth hormone; i: iatrogenic; IHC: immunohistochemistry. 
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Tau positivity (brown) in neurites around A (red) in (a) a cored plaque (b) a 
dyshoric vessel with CAA (b) in hGH control11. Astrocytes (brown) surround a 
cored A plaque (red) (c) and microglial cells (brown) are present within a cored A 
plaque (red) in a hGH control10 (d). apoE-4 positivity in diffuse A deposits in hGH 
control6 (e). Diffuse A deposits in the parietal cortex in vCJD22 (f). The diffuse 
cortical Adeposits in vCJD 37 (red) do not all colocalise with the abundant PrP 
deposits (brown) (g). Patchy localised meningeal CAA in the occipital region in 
sCJD14 (h). Scale bar=250µm.  
Antibodies used for IHC: 6F/3D (A): a-d, f-h; AT8 (tau): a,b; GFAP: c; CD 68: d; 5A9 (apoE-4): e; 
KG9 (PrP): g. 
 
Abbreviations: A: amyloid beta; CAA: cerebral amyloid angiopathy; CJD: Creutzfeldt-Jakob 
disease; hGH; human growth hormone; i: iatrogenic; IHC: immunohistochemistry. 
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Table 5.7. 
ABC scores for Alzheimer pathology and CAA scores for hGH-iCJD, hGH control, 
sCJD and vCJD cases 
Study ID ABC score 
(Hyman et al., 
2012) 
Hybrid protocol (from Love et al., 2014) 
 








hGH-iCJD 4 1 0 0 0 0 0 0 
hGH-iCJD 5 0 0 0 0 1 0 0 
hGH-iCJD 6 0 0 0 1 2 0 0 
hGH-iCJD 8 0 0 0 2 2 0 0 
hGH-iCJD 9 0 0 0 1 2 0 0 
hGH-iCJD 10 1 0 1 2 2 0 0 
hGH-iCJD 12 1 0 0 0 0 0 0 
hGH-iCJD 15 1 0 0 2 2 0 0 
hGH-iCJD 16 1 0 2 1 2 0 0 
hGH-iCJD 18 1*  0 2 2 2 1 0 
hGH-iCJD 19 1 0 0 2 2 0 0 
hGH-iCJD 26 0 0 0 0 1 0 0 
hGH-iCJD 29 0 0 0 2 2 0 0 
hGH-iCJD 31 1 0 1 1 2 0 0 
hGH-iCJD 32 1 0 1 2 3 0 0 
hGH-iCJD 33 1 0 0 2 2 0 0 
hGH-iCJD 34 1 0 0 0 0 0 0 
hGH-iCJD 35 1*  0 0 0 0 0 0 
hGH-control6 1 * 0 0 0 0 0 0 
hGH-control7 1 0 0 0 0 0 0 
hGH-control9 0 0 0 2 2 0 0 
hGH-control10 1 0 0 0 0 0 0 
hGH-control11 1* 0 2 3 3 1 1 
sCJD14 0 0 0 1 2 0 0 
vCJD22 1 0 0 0 0 0 0 
vCJD32 0 0 0 0 0 0 0 
1*: Thal phase 1 with anterior cingulate gyrus involvement, but not the entorhinal cortex, insular cortex 
or hippocampus.  
         
Abbreviations: A: Thal phase score; B; Braak stage score; C: CERAD score; CAA: cerebral amyloid 
angiopathy; CJD; Creutzfeldt-Jakob disease; hGH: human growth hormone; i: iatrogenic; s: sporadic; 
v:variant. 
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5.3.3. Tau pathology 
Tau immunolabelling was present in all cases of hGH-iCJD, hDM-iCJD, sCJD and 
vCJD cases in the form of small neuritic dots in the neuropil in affected grey matter 
regions as previously described (Kovacs et al., 2016b). Additional labelling of fine 
neuritic processes was noted around PrP amyloid plaques, including kuru-type plaques 
in the hGH-iCJD cases and sCJD controls, and florid plaques in the vCJD controls 
(Figure 5.14 a,b). No neurofibrillary tangles, pretangles or other structures were 
labelled by the AT8 antibody or the Bielschowsky silver stain in the brain stem, 
entorhinal region, hippocampus or subcortical nuclei in the hGH-iCJD cases, hGH 
controls, hDM-iCJD, sCJD and vCJD cases. No glial tau pathology was identified.  
 
However, small numbers of AT8-positive pretangles and occasional neurofibrillary 
tangles were identified in the gliotic region in the inferior right temporal cortex in 
hGH-control10, who had undergone resection of an ependymoma (Figure 5.11c).  
This localised abnormality was not associated with A deposition and did not involve 
the entorhinal region or the hippocampus. No glial tau positivity was present, and no 
tau positivity was identified in the subcortical nuclei or brain stem. Case hGH-iCJD31 
(a patient with idiopathic hGH deficiency) had a small number of AT8-positive 
pretangles that were not labelled by the Bielschowsky silver stain in a localised area 
of the superior frontal cortex. No Adeposition or other adjacent pathology was 
evident. No glial tau positivity was present and no tau positivity was identified in the 




Figure 5.14. Non-A related tau pathology in hGH-iCJD and control cases 
 
Small neurites around a kuru-type plaque in hGH-iCJD (a). Numerous small rounded 
neurites and threads are present around a florid plaque in vCJD (b). Occasional 
neurofibrillary tangles and numerous neuropil threads are present in the focally gliotic 
temporal cortex in hGH control10 (c). Occasional pretangles and neuropil threads are 
present in a small region within the superior frontal cortex in hGH-iCJD31. No glial 
positivity was identified (e). All sections were stained with the AT8 anti-phosphotau 
antibody. Scale bar=250µm.   
 
Abbreviations: A: amyloid beta; CJD: Creutzfeldt-Jakob disease; GFAP: glial fibrillary acidic protein; 
hGH;  human growth hormone; i: iatrogenic; s: sporadic; v: variant. 
 
5.3.4. -synuclein and TDP-43 pathology 
No evidence of Lewy body disease was identified in any of the hGH-iCJD cases, hGH 
control cases, hDM-iCJD cases and sCJD and vCJD control cases. 
Immunohistochemistry for -synuclein showed no labelling of Lewy bodies or 
neurites in any of the cases examined. No TDP-43 labelling was found in any of the 
cases examined, regardless of whether CJD and/or A pathology was present or not. 
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5.3.5. Correlations with A pathology 
5.3.5.1. A pathology and age at death 
The frequency of Apositive cases in both the hGH-iCJD and hGH control groups are 
significantly higher than in the sCJD and vCJD age-matched groups (Figure 5.7). The 
age range at death for the 18/33 hGH-iCJD cases with CNS A deposition ranged from 
20-45y. The 15 A negative hGH-iCJD patients ranged from 20-46y at death. The 
differences in the age ranges in these two groups of hGH-iCJD patients is not 
statistically significant (Figure 5.15). The 5/12 hGH control cases with CNS A 
deposition ranged from 30-45y at death, while the seven A negative patients ranged 
from 13-35y at death. The difference between the age ranges in these two groups of 
hGH control patients is statistically significant (Figure 5.15). The single A positive 
sCJD case was 46 years old at death, while the 13 negative sCJD patients ranged from 
20-46y at death. The 2 A positive vCJD cases were aged 30y and 33y at death, while 
the 31 A negative vCJD cases ranged from 20-41y at death. 
 
5.3.5.2. Time, duration and type of treatment 
The timelines for the dates of first treatment and the dates of the midpoint of treatment 
for the hGH-iCJD and hGH control patients are shown in Figure 5.16. No significant 
differences in the dates of first treatment or the treatment midpoint were identified 
between the A positive and A negative hGH-iCJD cases, but there are non-
significant trends for the A positive hGH control cases to have been treated earlier 
and for longer than the Anegative control cases. No significant difference was found 
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in the time intervals from the end of treatment to death between the A positive and 
A negative hGH control cases (Figure 5.17). 
 
5.3.5.3 Duration of illness and incubation period for hGH-iCJD 
The iCJD disease incubation period and duration of the iCJD illness in the hGH-iCJD 
patients are displayed in relation to A positivity in Figure 5.18. No significant 
differences were found in these parameters between the two groups. 
 
Figure 5.15.  CNS Aβ accumulation and age at death in hGH-iCJD and hGH-control 
cases (horizontal bars represent mean with standard deviation values) 
 
Comparisons of the age at death for (A) hGH-iCJD and (B) hGH-control patients in 
relation to accumulation of Aβ. No significant difference in the age at death was found 
between the A positive and A negative hGH-iCJD cases. However, a significant 
difference was found between the A positive and A negative hGH control cases, 
with the A positive cases showing a higher age at death. Statistical analysis was 
performed an unpaired t-test.  
 
Abbreviations: Aβ; amyloid beta: hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob 
disease. 
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Figure 5.16. Timelines for dates of first treatment and midpoint of treatment in 
relation to CNS A positivity in hGH-iCJD and hGH control groups (vertical bars 
represent mean with standard deviation values) 
 
 
 (A) Year of first treatment and in the (B) mid-point of treatment for hGH-iCJD and 
hGH-control patients in relation to accumulation of Aβ. Differences were found in 
both the year of first hGH treatment and the mid-point of treatment in the hGH control 
cases with and without CNS A accumulation, but these did not reach levels of 
statistical significance. Statistical analysis was performed using an unpaired t-test. 
 
Abbreviations: Aβ; amyloid beta: hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob 
disease. 
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Figure 5.17. Duration of hGH treatment and period between the midpoint of hGH 
treatment and date of death (D.O.D) in hGH-iCJD cases and hGH controls 





(A) Duration of treatment and (B) time period from the mid-point of treatment until 
death for hGH-iCJD and hGH-control patients in relation to CNS Aβ accumulation. 
Differences were found in both the duration of treatment and mid-point of treatment 
until D.O.D in the hGH-iCJD cases with and without CNS A accumulation, but these 
did not reach levels of statistical significance. Statistical analysis was performed using 
an unpaired t-test.  
 
Abbreviations: Aβ; amyloid beta: D.O.D; date of death:  hGH: human growth hormone; iCJD: 
iatrogenic Creutzfeldt-Jakob disease. 
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Figure 5.18. Disease incubation period and duration of iCJD illness in hGH-iCJD 





 (A) Incubation periods and (B) durations of disease for hGH-iCJD in relation to CNS 
A accumulation. Differences were found in the incubation period and the disease 
duration between the A positive and A negative hGH-iCJD groups, but these did 
not reach statistical significance.  Statistical analysis was performed using an unpaired 
t-test 
 
Abbreviations: Aβ; amyloid beta: CNS: central nervous system; D.O.D; date of death:  hGH: human 
growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease. 
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5.3.5.4. Predisposing medical factors.  
No predisposing risk factors for Adeposition were identified in the clinical histories 
available in the hGH-iCJD, hGH-control, sCJD and vCJD cases. No A pathology was 
identified in 4/6 hGH-iCJD patients with brain tumours (5 craniopharyngiomas and 1 
astrocytoma), and 5/7 hGH control patients with brain tumours (5 
craniopharyngiomas, 1 astrocytoma and 1 ependymoma). In the four cases with brain 
tumours and A deposition in the CNS, there was no relationship between the sites of 
A deposition and the sites of neurosurgery. However, one hGH control case with a 
resected ependymoma had localised AT8-positive pretangles and occasional 
neurofibrillary tangles in a small focal gliotic area in the right inferior temporal cortex 
(see 5.3.3). 
 
5.3.2.5. Predisposing genetic factors 
APOE genotype analysis was available for 13/18 A-positive hGH-iCJD cases, 9/15 
A-negative hGH-iCJD cases, 2/-positive hGH controls, 2/2 A positive vCJD 
controls and the single A-positive sCJD control case (Table 5.7). No APOE 4 
homozygous cases were found in any of these groups. See section 5.6.4 below for 
further data on APOE genotype and apoE-4 phenotype analysis. The results of exome 
sequencing in hGH-iCJD, hGH controls, sCJD and vCJD cases with frozen tissue 
available found no major genetic risk factors for A deposition in the brain in any of 
the cases studied. See section 5.6.3 below for further data from the exome sequencing 
results. 
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5.4. hGH-iCJD and hGH control non-CNS tissues 
5.4.1. PrP immunohistochemistry and PET blot analysis  
Twenty-one different non-CNS tissues from 19 hGH-iCJD and two hGH controls were 
available for investigation in this study. There was considerable variability of both 
fixed and frozen tissue for each individual case. Analysis of formalin fixed tissues was 
carried out by PrP IHC and PET blot analysis, with frozen tissues analysed by Western 
blotting following NaPTA precipitation. Full details of the tissues analysed in each 
case are presented in Appendix 5. The results of the combined IHC, PET blot and 
NaPTA analysis of these tissues are summarised in Table 5.8. 
 
Accumulation of the disease associated prion protein was detected in sensory ganglia, 
with intense staining of ganglion cells in the trigeminal ganglia and dorsal root ganglia 
in all hGH-iCJD cases investigated (Figure 5.19a). In addition, PrP immunopositivity 
was found in the adrenal gland in three hGH-iCJD cases, generally in the chromaffin 
cells of the adrenal medulla (Figure 5.19b). PrP accumulation was also observed in 
lymphoreticular tissue, with labelling of the germinal centres of numerous lymphoid 
follicles in abdominal lymph nodes in a single hGH-iCJD case (hGH-iCJD15) (Figure 
5.19c).  
 
Most of the pituitary glands appeared histologically unremarkable. The glands from 
cases with panhypopituitarism tended to be smaller in size, but contained a normal 
population of cells in the adenohypophysis. No other abnormalities were noted. Over 
half of the pituitary glands from hGH-iCJD cases showed PrP immunoreactivity, with 
focal PrPres deposition in the neurohypophysis as previously described (Peden et al., 
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2007). PrP immunoreactivity was also observed in a single skeletal muscle sample 
(hGH-iCJD15), in a linear pattern with a distribution and morphology consistent with 
that of a small nerve (Figure 5.19d), as previously observed (Peden et al., 2006). No 
labelling of muscle spindles or motor end plates was observed. No PrP 
immunoreactivity was observed in the appendix, duodenum, large intestine, peripheral 
nerve, small intestine, spleen, sympathetic chain or tonsil in the hGH-iCJD patients or 
in the hGH control tissues by either IHC or PET blot analysis.  
 
5.4.2. A immunohistochemistry 
Immunohistochemistry for A using the 6F/3D antibody showed no labelling in any 
of the non-CNS tissues from the hGH-iCJD and hGH control cases, including the 
pituitary gland (Figure 5.19 e). However, the anti-A 4G8 antibody showed fine 
granular labelling with more intensely labelled dot-like structures within the cytoplasm 
of many endocrine cells in the anterior pituitary glands from both groups (Figure 5.19 
f). It has been reported recently that the 4G8 antibody recognises a sequence-
independent epitope associated with -synuclein and pancreatic islet amyloid 
polypeptide amyloid fibrils (Hatami et al., 2016). Peptide and protein hormones in 
secretory granules of pituitary endocrine cells are stored in an amyloid-like cross--
sheet rich conformation, which may represent a functional amyloid that contributes to 
normal endocrine cell physiology (Maji et al., 2009). It is conceivable that these 
conformations could contain the sequence-independent epitope recognised by 4G8, 
which would explain this unexpected observation. The 4G8 positivity in the anterior 
pituitary gland therefore cannot be considered as evidence of intracellular 
accumulation of A.   
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Figure 5.19. Results of immunohistochemistry and PET blot analysis on non-CNS 
tissues in hGH-iCJD cases
 
 
IHC with the KG9 anti-PrP antibody shows labelling of the ganglion cells in a dorsal 
root ganglion (a). PET blot analysis with the 12F10 anti-PrP antibody shows intense 
labelling (black) of a group of chromaffin cells within the adrenal medulla (b), in 
germinal centres within an abdominal lymph node (c) and in a small nerve within 
skeletal muscle (d). A IHC using the 6F/3D antibody shows no labelling in the 
anterior pituitary gland (e), but the 4G8 anti-A antibody shows some diffuse fine 
granular and discrete dot-like intracellular positivity in the endocrine cells (f).  
Abbreviations: A: amyloid beta; CJD: Creutzfeldt-Jakob disease; hGH; human growth hormone; i: 
iatrogenic; IHC: immunohistochemistry; PET: paraffin embedded tissue; PrP: prion protein. 
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5.4.3. Western blot analysis using NaPTA precipitation  
All the frozen non-CNS tissues listed in Appendix 5dys were investigated by Western 
blot analysis following NaPTA precipitation (NaPTA WB). Only four samples gave 
unequivocal positive reactions: dorsal root ganglion in a single case and the pituitary 
gland in three cases (Figure 5.20). Two of the pituitary glands were found to have a 
type 2 PrPres isoform (similar to that in the corresponding brain). The remaining case 
had a type 1 isoform, which was also present in the brain. Densitometric analysis 
indicated that the levels of PrPres in the pituitary gland and dorsal root ganglion were 
around 0.8% and 0.04% respectively in comparison with brain PrPres levels in a control 
hGH-iCJD case. Several other tissues gave indeterminate results on NaPTA WB, when 
two of the usual three PrPres bands were visible, including adrenal gland, bone marrow, 
kidney, heart, lung, lymph node, skeletal muscle and peripheral nerve. Skeletal muscle 
from one hGH-iCJD case had previously found to be positive on NaPTA WB, and also 
gave a positive signal for PrPres on PET blot analysis (see Figure 5.19d) (Peden et al., 
2006). Repeat NaPTA WB analysis of the indeterminate cases was attempted, but was 
restricted in some cases by tissue sample availability. None of the repeat NaPTA WB 
tests altered the classification of these samples.  
 









Table 5.8. Summary of PrP immunohistochemistry, PET blot and WB NaPTA results 
in non-CNS tissues in hGH-iCJD and control cases 
 
 hGH-iCJD (n=19) hGH-control (n=2) 
 IHC PET blot NaPTA IHC PET blot NaPTA 
AG 3/5 4/5 0/1 0/1 0/1 0/0 
AP 0/4 0/4 0/1 0/2 0/2 0/0 
BM 0/0 0/0 0/1 0/0 0/0 0/0 
DR 3/3 3/3 1/1 0/0 0/0 0/0 
DU 0/1 0/1 0/0 0/0 0/0 0/0 
HE 0/0 0/0 0/1 0/0 0/0 0/0 
KI 0/0 0/0 0/2 0/0 0/0 0/0 
LI 0/1 0/1 0/2 0/1 0/1 0/0 
LN 1/6 1/6 0/3 0/1 0/1 0/0 
MU 1/8 1/8 0/5 0/1 0/1 0/0 
PA 0/0 0/0 0/2 0/0 0/0 0/0 
PI 6/10 6/10 3/5 0/1 0/1 0/0 
PN 0/7 0/7 0/3 0/0 0/0 0/0 
SG 0/0 0/0 0/1 0/0 0/0 0/0 
SI 0/1 0/1 0/1 0/0 0/0 0/0 
SP 0/10 0/10 0/6 0/1 0/1 0/0 
SY 0/2 0/2 0/1 0/0 0/0 0/0 
TG 2/2 2/2 0/0 0/0 0/0 0/0 
TO 0/3 0/3 0/1 0/2 0/2 0/0 
TY 0/0 0/0 0/1 0/0 0/0 0/0 
 
Abbreviations: AG: adrenal gland; AP: appendix; BM: bone marrow; DR: dorsal root ganglion; DU: 
duodenum: HE: heart; hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; 
IHC: immunohistochemistry; KI: kidney; LI: large intestine; LN: lymph node; LU: Lung; LV: liver; 
MU: muscle; NaPTA: sodium phosphotungstic acid; PA: pancreas; PET: paraffin embedded tissue; 
PI: pituitary; PN: peripheral nerve; PrP: prion protein; SG: salivary gland; SI: small intestine; SP: 
spleen; SY: sympathetic chain; TG: trigeminal ganglion; TO: tonsil; TY: thyroid; WB: western blot  
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Western blot after NaPTA precipitation showing (left to right) iCJD brain, non-CJD 
spleen, non-CJD spleen spiked with iCJD brain, iCJD muscle, iCJD spleen, iCJD 
pituitary 1, iCJD pituitary 2, non-CJD spleen spiked with sCJD brain, sCJD brain. 
iCJD pituitary 1 gives a strong positive signal, with a weaker signal for iCJD pituitary 
2 (confirmed on a longer exposure). No signal is seen in the lanes for iCJD muscle and 
spleen.  
Abbreviations: CJD: Creutzfeldt-Jakob disease; i: iatrogenic; kDa: kilodaltons; MU: muscle; PI: 
pituitary; s: sporadic; SP: spleen 
 
5.5. CNS Biochemistry 
The results of the biochemical and genetic investigations and in vitro conversion 
assays described below are included in the recent publication by Ritchie et al. (Ritchie 
et al., 2016), a copy of which is provided in Appendix 15.  
 
5.5.1. Western blot analysis and classification of PrPres types in the CNS 
Western blot analysis of all available CNS samples from the 21 cases of hGH-iCJD 
for protease resistant prion protein (PrPres) was undertaken. Four PrPres types (types 
1, i, i+2 and 2) were identified in the hGH-iCJD cases, differing in mobility and in 
the number of unglycosylated bands found. Representative examples of the PrPres 
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types 1, i, i+2 and 2 are shown in Figure 5.21; sample Western blots for each 
individual case of hGH-iCJD and hDM-iCJD are shown in Figure 5.22.  
 
The majority of cases contained the 19kDa type 2 PrPres band (19/21 cases). However, 
in 12/19 cases the 20kDa type i PrPres band was also present. The relative abundance 
of the 19kDa type 2 PrPres band and the 20kDa type i PrPres band was variable, but the 
19kDa type 2 PrPres band usually predominated (Figure 5.22). Type i was found to 
predominate overall in only one hGH- iCJD case (hGH-iCJD20) and the 21kDa type 
1 PrPres was found in only one hGH-iCJD case (hGH-iCJD21). In contrast, all three 
cases of hDM-iCJD contained type 1 PrPres exclusively. Where assessed, regional 
PrPres variation within the brain was largely confined to the presence or absence of the 
PrPres types i band and the relative abundance of PrPres types i and 2 bands (Table 5.9). 
Comparison of the immunoreactivity of the 21kDa type 1, 20kDa type i, and 19kDa  
type 2 bands using the 3F4 antibody (epitope 106-112) with the 12B2 antibody 
(epitope 89-93) showed that the 21kDa type 1 PrPres and the 20kDa type i PrPres 
fragments both retain the 12B2 epitope, whereas type 2 PrPres fragments does not 
(Figure 5.21(b)).     
 
Analysis of the PrPres types in the CNS of 108 sCJD cases showed type 1, type 2, type 
i+2 and cases in which type 1 and type 2 were found in individual brains, either in the 
same or in different regions. The latter cases were designated type 1+2, irrespective of 
the relative abundance and location of the two types. The breakdown of these 108 
sCJD cases according to the combination of CNS PrPres type and PRNP codon 129 
genotype is shown in Appendix 13. 
 169 
Figure 5.21. PrPres types found in the hGH-iCJD cases 
 
 
(a) Four PrPres molecular types were detected by Western blot analysis of proteinase 
K treated brain extracts of hGH-iCJD patients: type 1, type i, type i+2 and type 2. 
Representative blots of each PrPres type are shown. Each sample (middle lane) is 
flanked by type 1 (T1) (left lane) and type 2 (T2) (right lane) reference standards from 
sCJD MM1 and VV2 subtype cases, respectively. Case number and codon 129 PRNP 
genotype are indicated above each blot whilst PrPres type is indicated below. The most 
informative exposure for the test and reference standard samples from a series of timed 
exposures is shown. Blots were probed using the monoclonal antibody 3F4.  
 
(b) Western blot analysis of proteinase K treated samples of PrPres types detected in 
hGH-iCJD patients using the monoclonal antibody 12B2, which detects type 1 PrPres.  
 
The approximate molecular mass is shown in kDa in (a) and (b). The immunoblots 
shown are representative of at least three technical repeats. 
 
Abbreviations: hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; kDa: 
kilodaltons; M: methionine; PRNP: prion protein gene; PrPres: protease-resistant prion proteins; sCJD 




Figure 5.22. PrPres typing of  21 hGH-iCJD cases and 3 hDM-iCJD cases 
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Legend to Figure 5.22. 
PrPres typing of (a) hGH-iCJD cases 1-21 and (b) hDM-iCJD cases 1-3. Each sample 
(middle lane) was run between a type 1 (left lane) and type 2 (right lane) reference 
standard from sCJD MM1 and VV2 subtype cases, respectively. Study identification 
number and brain region are indicated above each blot and PrPres type is indicated 
below. The immunoblots shown are representative of at least three technical repeats 
for each sample. Regional differences in PrPres types are illustrated for case hGH-iCJD 
15 and case hGH-iCJD 16. 
 
Abbreviations: CbC: cerebellar cortex; FC: frontal cortex; hDM: human dura mater; hGH: human 
growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; M: methionine; PC: parietal cortex; PrPres: 
protease-resistant prion proteins; SC: spinal cord; sCJD sporadic Creutzfeldt-Jakob disease; TC: 







PrPres types found in each available CNS region of the iCJD cases examined 
 
Study ID PrPres type 
FC TC PC OC CbC Th SC Consensus 
hGH-iCJD1 i+2 - - - - - - i+2 
hGH-iCJD2 - 2 - - - - 2 2 
hGH-iCJD3 - - - - i+2 - - i+2 
hGH-iCJD4 2 - - - 2 - - 2 
hGH-iCJD5 2 2 2 2 2 2 - 2 
hGH-iCJD6 - - - - 2 - - 2 
hGH-iCJD7 i+2 - - - i+2 - - i+2 
hGH-iCJD8 2 - - - 2 - - 2 
hGH-iCJD9 i+2 - - - - - - i+2 
hGH-iCJD10 2 - - - 2 - - 2 
hGH-iCJD11 i+2 - - - - - - i+2 
hGH-iCJD12 2 2 - - 2 - - 2 
hGH-iCJD13 i+2 - - - i+2 - - i+2 
hGH-iCJD14 i+2 - - - i+2 - - i+2 
hGH-iCJD15 i+2 2 2 i+2 i+2 i+2 - i+2 
hGH-iCJD16 2 - - - i+2 - - i+2 
hGH-iCJD17 i+2 - - - i+2 - - i+2 
hGH-iCJD18 i+2 - - - i+2 - - i+2 
hGH-iCJD19 i+2 i+2 - i+2 i+2 - - i+2 
hGH-iCJD20 i i i i i i - i 
hGH-iCJD21 - 1 - - - - - 1 
hDM-iCJD1 1 - - - - - - 1 
hDM-iCJD2 1 1 1 1 1 1 - 1 
hDM-iCJD3 1 - 1 - 1 - - 1 
 
Abbreviations: Cb: cerebellum; CC: cerebral cortex (unspecified); CNS: central nervous system; FC: 
frontal cortex;  hDM: human dura mater; hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-
Jakob disease; OC: occipital cortex; PC: parietal cortex; PrPres: protease-resistant prion protein; SC: 




5.6.1. PRNP codon 129 genotype 
Comparison of the PRNP codon 129 genotype distribution in the hGH-iCJD and sCJD 
cohorts shows striking differences. The MM PRNP codon 129 genotype is the most 
frequently occurring group within the UK sCJD group and occurs throughout the 
period of the hGH-iCJD epidemic (Figure 5.23A). In contrast, the PRNP codon 129 
MV and VV genotypes predominate in the hGH-iCJD cohort; the MM genotype is 
uncommon and occurs later in the epidemic (Figure 5.1).  
 
When considered as a whole, the distribution of codon 129 genotypes of the 21 
available hGH-iCJD cases and the 108 sCJD cases selected for biochemical analysis 
differ from each other and from the normal UK population, but appear to be broadly  
representative subsets of the larger hGH-iCJD and sCJD cohorts (Figure 5.23B).  
The PRNP genotype results of the hGH controls are incomplete even after attempts 
to extract DNA from formic acid pretreated paraffin blocks; the available results for 

















PRNP codon 129 genotype distribution in hGH-iCJD, sCJD and the UK population  
 
       
 
The PRNP codon 129 distribution by year of death for the 1,080 UK sCJD cases from 
1990 to 2015 is shown in (a). (b) compares the PRNP codon 129 distribution of the 
hGH-iCJD (n=21) and sCJD (n=108) cases with frozen tissue analysed with the larger 
cohorts of hGH-iCJD (n=37) and sCJD (n=1080) cases of which they are 
representative subsets. The UK normal population results are shown for reference.  
Abbreviations: hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; M: 
methionine; pop: population; PRNP: prion protein gene; sCJD: sporadic Creutzfeldt-Jakob disease; UK: 
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5.6.2. PRNP codon 129 genotype and PrPres type in iCJD and sCJD cases  
When the 21 cases of hGH-iCJD were grouped according to the combination of PRNP 
genotype and CNS PrPres type (Figure 5.24A) all PRNP codon 129 VV hGH-iCJD 
cases (7/7) were found to have type 2 PrPres exclusively.  All of the hGH-iCJD PRNP 
codon 129 MV genotype cases were found to have type i+2 PrPres (12/12). One of the 
PRNP codon 129 MM cases contained type 1 PrPres while the other contained type i 
PrPres. However, within the 108 sCJD cases those with type 1 PrPres and a PRNP codon 
129 MM genotype predominated (50/108); cases with type 1+2 PrPres were relatively 
common (26/108), but no examples of type i PrPres alone were found (Figure 5.24B). 
All three hDM-iCJD cases occurred in individuals of the PRNP codon 129 MM 
genotype and each had PrPres type 1 in the CNS, in keeping with their 
























Legend to Figure 5.24. 
Diagram A shows the classification of cases in the hGH-iCJD group (n=21) according to the 
combination of PrPres type (inner ring) and PRNP codon 129 genotype (outer ring). Diagram 
B shows the classification of cases in the sCJD group (n=108) according to the combination 
of PrPres type (inner ring) and PRNP codon 129 genotype (outer ring). 
 
Abbreviations: hGH: human growth hormone; iCJD: iatrogenic Creutzfeldt-Jakob disease; M: 
methionine; PRNP: prion protein gene; PrPres: protease-resistant prion protein; sCJD: sporadic 
Creutzfeldt-Jakob disease; V: valine. 
 
5.6.3. Exome sequencing 
Exome sequence analysis data for the hGH-iCJD cases, hGH-controls and sCJD 
cases with frozen tissue available found no coding, non-coding or 3- or 5-prime 
untranslated variants in genes that were likely to be associated with A accumulation  
in the CNS (APP, C9ORF2, CHMP2B, CSFIR, FUS, GRN, ATM2B, MAPT, NOTCH3, 
PSEN1 PSEN2, SERPINI1, SQTM1, TARDBP, TREM2, TYROBP, VCP).  
 
One of the hGH-iCJD cases (hGH-iCJD35) had a NOTCH3 variant (p.H1133Q) that 
appears to be non-pathogenic (Schmidt et al., 2011). One of the hDM-iCJD cases 
(hDM-iCJD2) had the TREM2 p.R62H variant that has been reported as a risk factor  
for AD (Jin et al., 2014), but showed no evidence of CNS A deposition. No other 
variants were detected in the hDM-iCJD cases. One of the vCJD cases (vCJD22) with 
diffuse A deposits in the brain had the PSEN1 p.E318G variant that increases the risk 
of AD in APOE4 carriers (Benitez et al., 2013) and a -48 C/T polymorphism in the 
PSEN1 promoter that is as genotype associated with an increased risk of AD and an 
increased A load in the brain (Lambert et al., 2001). Neither can be considered as 
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highly penetrant monogenic alleles causing disease. No other variants were detected 
in the vCJD cases. 
 
5.6.4 APOE genotype and apoE-4 phenotype analysis 
APOE genotype data was available for 22/33 hGH-iCJD cases and 2/12 hGH control 
cases (Table 5.10). No APOE 4/4 genotypes were identified and a mixture of APOE 
2/3, APOE 3/3 and APOE 3/4 genotypes was present in the hGH-iCJD cases. 
Immunohistochemistry for apoE-4 in 4 hGH-iCJD cases with CNS A accumulation 
found no positives (Table 5.10). In the 5 hGH control cases with CNS A 
accumulation there was a single case with the APOE 3/3 genotype and another with 
the APOE 3/4 genotype. Immunohistochemistry for apoE-4 in the 3 remaining hGH 
control cases with CNS A accumulation found a single positive case: hGH control6 
(Figure 5.13e) (Table 5.10). No information on the APOE genotype or apoE-4 
phenotype can be obtained on the remaining 6 hGH-iCJD cases and 7 hGH control 
cases with no CNS A accumulation, due to a lack of frozen tissue samples.  
 
The relationship of the APOE 4 genotype and the apoE-4+(IHC) phenotype to 
Adeposition in the CNS in all the hGH-iCJD and the hGH control cases with CNS 
A accumulation and the age at death is summarised in Figure 5.25. These data 
indicate that there are no significant differences in APOE genotypes between the A 
positive and A-negative hGH-iCJD cases; comparisons between the A –positive and 
A- negative hGH control cases are hampered by a lack of APOE genotype data for 
the A-negative cases.  
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The 2 vCJD cases with diffuse A parenchymal deposits included one case with the 
APOE 3/4 genotype (vCJD32) and one case with the APOE 2/3 genotype (vCJD22). 
Genomic analysis of the latter found the PSEN1 p.E318G variant and the -48 C/T 
polymorphism in the PSEN1 promoter (see section 5.6.3 above).  
 
Table 5.10.   
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0 0 0 0 
2/3 
 
1 1 0 0 
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0 0 0 0 
3/3 
 
8 6 1 0 
3/4 
 
4 2 1 0 
4/4 
 
0 0 0 0 
apoE-4+(IHC)+ 
+(IHC) (IHC)* 








18 9 5 0 
 
+apoE-4 phenotypes were determined on paraffin sections of the brains from 5 hGH-iCJD and 3 hGH-
control cases with CNS A accumulation using immunohistochemistry for the apoE-4 protein. 
 
*No data on the APOE genotype or apoE-4 phenotype on 6 hGH-iCJD cases and 7 hGH control cases 
with no CNS A accumulation, due to a lack of frozen tissue and an absence of A pathology.  
 
Abbreviations: A: amyloid beta; APOE: apolipoprotein E gene; apoE-4: apolipoprotein E4; CNS: 




Figure 5.25.  
Distribution of APOE 3/4 genotypes and apoE-4 positive phenotypes in relation to 
age at death and CNS A accumulation in hGH-iCJD and hGH control cases 




There is no evidence of a difference in the percentage of APOE4+ve hGH-iCJD cases 
in the A positive and A negative groups; p=1.00 (Fisher’s exact test). There is no 
evidence of a significant difference in the percentage of APOE4+ve cases between the 
A positive hGH-iCJD group and the A positive hGH control group; p=0.576 
(Fisher’s exact test). No apparent relationship between age and APOE4 status is 
detected. 
 
Abbreviations: A: amyloid beta; APOE4: APOE e3/4 genotype or apoE-4 phenotype on 






5.7  In vitro conversion assays 
5.7.1. RT-QuIC analysis 
The amyloid seeding activity of hGH-iCJD and sCJD cases was compared using the 
RT-QuIC assay. hGH-iCJD cases were selected on the basis of availability of cerebral 
cortex samples (n=20). sCJD cases (n=28) were selected on the basis of PrPres type and 
PRNP codon 129 genotype to match, as far as possible, those found in the hGH-iCJD 
cohort. RT-QuIC assays were seeded with CJD cerebral cortex homogenate diluted by 
a factor of 2 x 10-5 (each 100 l RT-QuIC reaction was seeded with the equivalent of 
2 x 10-7 g brain) and the seeding activity for each patient was assumed to be inversely 
proportional to the mean lag period (Figure 4.3).  The hGH-iCJD and sCJD seed 
amounts were determined empirically to be within the range for quantifying seeding 
activity by the lag time method. Figure 5.26 (a) shows that the hGH-iCJD group as a 
whole (and their subgroups) have a lower median seeding activity than the sCJD group 
(and their matched subgroups). The difference is significant for the hGH-iCJD group 
as a whole and for the VV and MV subgroups. The two PRNP codon 129 MM hGH-
iCJD cases had noticeably different lag times in this assay (hGH-iCJD20 at 43.5 hrs 
and hGH- iCJD21 at 27.5hrs) (Figure 5.26b). Three hDM-iCJD cases were also 
analysed by RT-QuIC and their median lag period (34.2hrs) was also greater than the 
sCJD MM1 subgroup, but this difference was not statistically significant (Figure 
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Legend for Figure 5.26. 
Diagram (a) shows the differences in the lag time between a group of 28 sCJD cases 
including MM1, VV2 and MV2 subtypes (red) and 20 hGH-iCJD cases with similar 
PRNP codon 129 genotypes and PrPres types (blue). The mean lag time for the iCJD 
cases as a group is significantly longer than that for the sCJD cases (Student’s t-test, 
p=0.0004), indicating that there is no evidence of enhanced propagation of hGH-iCJD  
PrPSc seeds as assessed by RT-QuIC PrP substrate conversion. 
Diagram (b) shows the differences in the RT-QuIC reactions for 3 sCJD MM1 cases 
(red), 3 hDM-iCJD MM1 cases (green), the single hGH-iCJD MM1 case (dark blue) 
and the single hGH-iCJD MMi case (light blue). The sCJD MM1 cases appear to have 
the shortest lag times in comparison with the iCJD cases as a group, as also 
demonstrated in diagram (A) above. However, there are differences between the hGH-
iCJD cases, with the MMi case showing a more prolonged lag time and slower RT-
QuIC reaction course than the MM1 case. 
 
The Shapiro-Wilk normality test was used to determine whether or not the RT-QuIC 
lag periods in the various iCJD and sCJD subgroups were normally distributed. In the 
statistical analysis of RT-QuIC data, a two-sided Mann-Whitney test was used to 
assess the statistical significance of differences between the median RT-QuIC lag 
periods of sCJD versus hGH-iCJD or hDM-iCJD cases.  The Kruskal-Wallis test was 
used for the combined analysis of sCJD (VV2, MV2, MM1) and hGH-iCJD (VV2, 
MV2) subgroups.  
 
Abbreviations: hDM: human dura mater; hGH: human growth hormone; i: intermediate; iCJD: 
iatrogenic Creutzfeldt-Jakob disease; M: methionine; PRNP: prion protein gene;  PrPres: protease-
resistant prion protein; PrPSc: disease-associated misfolded prion protein; RT-QuIC: real-time quaking-





5.7.2. Protein misfolding cyclic amplification (PMCA) 
The seeding characteristics of the two divergent hGH-iCJD PRNP codon 129 MM 
cases (hGH-iCJD20 and hGH-iCJD21) were further examined using PMCA. Samples 
of cerebral cortex were used to seed matched (PRNP codon 129 MM, designated 
HuMM) and mis-matched (PRNP codon 129 VV and codon 129 MV) humanised 
transgenic mouse brain substrates, (designated HuVV and HuMV respectively) and 
the results compared with those from seeds of sCJD MM1, MV2 and VV2  subtypes 
and hDM-iCJD MM1 seeds. PMCA reactions seeded with cerebral cortex samples 
from cases of sCJD of the MM1 subtype amplified poorly under the conditions used, 
whether in matched (MM) or mismatched (VV) humanised transgenic mouse brain  
substrate (Figure 5.27a). This was also true for the seeds from the three hDM-iCJD 
cases (hDM-iCJD1-3) (Figure 5.27a). The sCJD MV2 and hGH-iCJD MV2 seeds also 
gave similar results.  
 
Seeding of PMCA reactions with cerebral cortex samples from cases of sCJD of the 
VV2 subtype amplified more efficiently under these same conditions, with the 
amplification levels higher in the matched (VV) than in the mis-matched (MM) 
humanised transgenic mouse brain substrate (Figure 5.27a). The two hGH-iCJD PRNP 
codon 129 MM cases gave divergent results: hGH-iCJD20 amplified well and more 
efficiently in the HuVV substrate than the MM and MV substrates, whereas hGH-
iCJD21 failed to seed any of the three substrates efficiently (Figure 5.27b). This 
difference in amplification efficiency and substrate preference between hGH-iCJD20 




PMCA reactions in Tg human PRNP codon 129 MM, MV and VV mouse brain 
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Legend for Figure 5.27. 
In (a) hGH-iCJD, hDM-iCJD and sCJD brain homogenate (seeds) were diluted in 
humanised transgenic mouse brain homogenate (substrates) of PRNP codon 129 MM 
and VV genotypes. The PMCA amplification factor is shown as relative increase (fold) 
in PrPres signal after a single round of PMCA as determined by densitometry of the 
Western blot signal. PMCA reactions were normalised by seed PrPres amount.  
 
Similar low levels of amplification are seen with sCJD MM1 and hDM-iCJD MM1 
seeds in the Tg MM and VV substrates, and with sCJD MV2 and hGH-iCJD MV2 
seeds. In contrast, the sCJD VV2 and hGH-iCJD VV2 seeds show amplification in Tg 
MM and VV substrates, although the levels of amplification with the hGH-iCJD seeds 
are lower. Amplification results are shown for sCJD MM1, MV2 and VV2 seeds, 
hDM-iCJD MM1 seeds and hGH-iCJD MV2, VV2, MM1 (hGH-iCJD21) and MMi 
(hGH-iCJD20) seeds in Tg mouse brain MM (blue) and VV (red) substrates. 
 
Diverse results are seen with amplification of the two hGH-iCJDMM cases. Case 
hGH-iCJD21 (MM1) shows low levels of amplification in Tg mouse brain MM and 
VV substrates. However, case hGH-iCJD20 (MMi) shows higher levels of 
amplification in the Tg MM and VV substrates, similar to those seen with sCJD VV2 
and hGH-iCJD VV2 seeds (a). Humanised transgenic mouse brain homogenate 
(substrate) of the PRNP codon 129 MM (red) or VV (blue).  
 
These differences were maintained on PMCA of serial dilutions of the hGH-iCJD MM 
seeds in all three Tg mouse brain substrates: Tg MM, MV and VV (hGH-iCJD20: 
1/50, 1/100, 1/200, 1/400 and hGH-iCJD21: 1/4, 1/8, 1/16, 1/32). Results are shown 
as Western blots for all three Tg mouse substrates (b).  PMCA experiments seeded 
with hGH-iCJD, hDM-iCJD and sCJD samples were performed twice independently 
and repeated at least 4 times for the hGH-iCJD MM cases. 
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In (c), the PrPres types of MM hGH-iCJD cases 20 and 21 are assessed before and after 
PMCA. PMCA reactions employed matched (MM) and mis-matched (VV) PRNP Tg 
mouse brain substrates. Each sample was run between a type 1 (left lane) and type 2 
(right lane) reference standards from sCJD MM1 and VV2 subtype cases respectively 
(T1 and T2). Study identification numbers of the hGH-iCJD MM cases are indicated.  
 
In (d), PrPres analysis of sCJD VV2 PMCA products detected by Western blot. sCJD 
VV2 brain homogenate was diluted and amplified in matched (MM) and mismatched 
(VV) codon 129 substrate by a single round of PMCA. Samples corresponding to 
unamplified (Frozen) and amplified (PMCA) aliquots are shown with reference 
standards as described above. A total of 25 biological replicates of hGH-iCJD, hDM-
iCJD and sCJD were analysed. 
Abbreviations: hDM: human dura mater; hGH: human growth hormone; i: intermediate; iCJD: 
iatrogenic Creutzfeldt-Jakob disease; M: methionine; PMCA: protein misfolding cyclical amplification; 
PRNP: prion protein gene;  PrPres: protease-resistant prion protein; sCJD: sporadic Creutzfeldt-Jakob 
disease; Tg: transgenic; V: valine. 
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In the case of hGH-iCJD20, the choice of PRNP codon 129 substrate (HuMM or 
HuVV) also had an effect on the PrPres type of the PMCA product when analysed by 
Western blotting (Figure 5.27c). The cerebral cortex sample from hGH-iCJD20 was 
PrPres type i, but matching of the MMi seed with the HuMM substrate resulted in an 
up-shift in mobility of the reaction product, whereas mismatching the MMi seed with 
the HuVV substrate resulted in an apparent down-shift in mobility of the reaction 
product. hGH-iCJD21 amplified only poorly, and there was no evidence of any change 
in the type 1 PrPres when the PMCA products were analysed by Western blotting 
(Figure 5.27c). The possibility that PrPres type i results from replication of sCJD with 
type 2 PrPres in an individual with a PRNP codon 129 MM genotype was then 
modelled. When sCJD VV2 subtype brain homogenate was used to seed the HuMM 
substrate, an upward shift was seen, whereas amplification of the same seed in a PRNP 
codon 129 VV genotype resulted in conservation of the type 2 PrPres (Figure 5.27d). 
 
5.7.3. Comparison of the two hGH-iCJD PRNP codon 129 MM cases 
PRNP codon 129 MM is the rarest genotype within the UK hGH-iCJD cohort and 
tends to occur later during the epidemic. The two hGH-iCJD PRNP codon 129 MM 
cases with frozen tissue available to this study were divergent in their neuropathology, 
PrPres type and amplification potential in both the RT-QuIC and PMCA assays. In each 
of these respects hGH-iCJD21 resembled the sCJD MM1 subtype (and the limited 
number of hDM-iCJD MM1 cases analysed), whereas hGH-iCJD20 more closely 
resembled the sCJD MV2 or VV2 subtype, despite its PRNP codon 129 MM genotype. 
A summary of the key differences between cases hGH-iCJD20 and hGH-iCJD21 is 
provided in Table 5.11.  
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Table 5.11.  
Comparison of hGH-iCJD20 and hGH-iCJD21  
 hGH-iCJD20 hGH-iCJD21 







of GH deficiency 
Idiopathic hGH deficiency Craniopharyngioma 










APOE genotype 3/3 3/3 
 
PRNP codon 129 
genotype 
MM MM 
Neuropathology PrP positive kuru plaques 
present (similar to MV2K 
sCJD).  
Diffuse PrP positivity (resembling 








Long lag time Shorter lag time  
(closer to MM1 sCJD) 
PrPres type i (~20kDa) type 1 (~21kDa) 
 





VV > MM None 
PMCA product 
PrPres mobility 
Substrate MM   Upshift 
Substrate VV  Downshift 
type 1 
 
Abbreviations: A: amyloid beta; APOE: apolipoprotein E gene; CAA: cerebral amyloid angiopathy; 
hDM: human dura mater; hGH: human growth hormone; HWP-hGH: human growth hormone produced 
using the Hartree modification of the Wilhelmi protocol; i: intermediate; iCJD: iatrogenic Creutzfeldt-
Jakob disease; K: kuru plaque; kDa: kilodalton; M: methionine; PMCA: protein misfolding cyclical 
amplification; PRNP: prion protein gene;  PrPres: protease-resistant prion protein; RT-QuIC: real-time 






This thesis describes the findings of a detailed neuropathological and molecular 
genetic study of the largest series of iCJD cases occurring in recipients of hGH in the 
UK (or indeed in any other country). Without Coroners and Procurators Fiscal 
instructing an autopsy to be performed on these patients to determine the cause of 
death, or clinicians seeking consent for a hospital autopsy and, most importantly, the 
generosity of the relatives of the deceased in giving consent/authorisation for the 
subsequent retention of the brain and use of the retained tissue and accompanying 
clinical data in research, this study could not have taken place.  
 
6.2. hGH-iCJD epidemiology, genetics and prion strains 
6.2.1. hGH-iCJD epidemiology and genetics 
The results of this study indicate that hGH-iCJD epidemic in the UK occurred first in 
patients with the PRNP codon 129 VV and MV genotypes, and later emerged in the 
codon 129 MM genotype, in keeping with the recent findings of Rudge et al. (Rudge 
et al., 2015).  A report of eight recent UK hGH-iCJD cases not included in this study 
comprised six codon 129 MV and two codon 129 MM cases, but no codon 129 VV 
cases (Jaunmuktane et al., 2015). The PRNP codon 129 genotype has a major effect 
on the hGH-iCJD disease incubation period, with codon 129 MM cases having the 
longest incubation periods (up to 32y) (Table 5.1; Figure 5.2). This polymorphism also 
influences the duration of the illness, with codon 129 MV cases having the longest 
clinical duration (up to 32mo) (Table 5.1; Figure 5.2). This polymorphism also 
influenced the disease incubation period in kuru, with the longest incubation periods 
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(over 40 years) occurring in codon 129 MV patients (Collinge et al., 2006). However, 
the codon 129 MM kuru cases had the shortest incubation periods, in contrast to the 
UK hGH-iCJD cases. In another acquired human prion disease, vCJD, all but one of 
the definite cases occurring worldwide were codon 129 MM patients, but the most 
recent UK patient (who died in 2016) had the codon 129 MV genotype (Figure 1.6). 
The incubation periods in cases of vCJD are still uncertain; it is entirely possible that 
further cases of vCJD will emerge in the MV and the VV genotypes in the UK. 
 
The PRNP codon 129 polymorphism also has a major influence on the 
clinicopathological phenotype in sCJD and some forms of genetic CJD (Head et al., 
2015). In sCJD, six major subgroups are defined by the combination of this 
polymorphism and the brain PrPres type (Table 1.3). In contrast to UK hGH-iCJD, the 
codon 129 MM genotype occurs most frequently in sCJD, but within this genotype the 
duration of illness is greatly influenced by the brain PrPres isoform: MM1 cases have a 
median duration of illness of 3mo, while MM2 patients have a median duration of 
illness of 17mo (Table 1.3). The four codon 129 MM hGH-iCJD cases in this study 
have a median duration of illness of 5.5mo (range 5-8mo). Only two of these cases had 
frozen tissue available to determine the brain PrPres isoform; the MM1 case had a 
duration of illness of 8mo, while the MMi case had a duration of illness of 5mo (Table 
5.10). No hGH-iCJD MM2 cases were found in this study. 
 
6.2.2. Prion contamination of hGH preparations 
Iatrogenic CJD in hGH recipients is believed to result from contamination of hGH 
preparations for intramuscular injection with prions present in the pituitary glands 
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collected from hGH extraction. PrPres is detectable in the pituitary gland in sCJD and 
vCJD (Peden et al., 2007) and this study also identified PrPres in the pituitary gland in 
patients with hGH-iCJD (Figure 5.20). The most likely source of prions in hGH 
preparations is sCJD, which is the commonest form of human prion disease and occurs 
most frequently in elderly patients, who account for the majority of the hospital 
autopsies that were the main source of pituitary glands collected for hGH extraction. 
Another possible, but less likely, source of prion infectivity in pituitary glands 
collected in the UK is genetic CJD, which accounts for around 10% of all CJD cases, 
but tends to occur at a younger age than sCJD (Head et al., 2015). The first case of 
vCJD in the UK presented in 1995, so it is highly unlikely that any of the UK hGH 
preparations were infected with vCJD prions. Although the very large number of 
pituitary glands collected for hGH extraction in the UK up to 1985 may have included 
glands from more than a single case of CJD of either sporadic or genetic origin, this 
thesis proposes that infection with a single prion strain is the most likely explanation 
for the epidemiology and genetic features of hGH-iCJD in the UK. 
 
6.2.3. Prion strains in hGH-iCJD 
Prion transmission is substantially influenced by the strain of the infectious prion and 
the host prion protein genotype, which interact to determine disease susceptibility, 
incubation period and clinicopathological phenotype. The results of this study reflect 
these influences; both the incubation period and the duration of illness in the hGH-
iCJD cases are influenced by the PRNP codon 129 polymorphism, which also 
influences the neuropathological phenotype in conjunction with the PrPres isoform in 
the brain. According to the concept of molecular strain typing, brain PrPres isoforms 
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are surrogate markers for agent strain, since they reflect the differences in PrPSc 
conformation that  are responsible for individual strain properties (Parchi et al., 1999; 
Haik et al., 2011). The commonest form of sCJD is the MM1 subtype, in which the 
M1 strain of sCJD prions has been identified, while the second commonest sCJD prion 
strain, the V2 strain, is identified in both sCJD VV2 and sCJD MV2 (see section 
1.5.1.5). It is therefore conceivable that the predominance of hGH-iCJD patients in the 
PRNP codon 129 VV and MV genotypes in the UK might result from infection with 
the V2 sCJD strain, while the predominance of hGH-iCJD patients in the PRNP codon 
129 MM genotype in France (see section 2.1.5) might result from infection with a 
different strain of sCJD prions (Brandel et al., 2003), specifically the M1 strain. 
Experimental transmission studies of hGH-iCJD cases of differing PRNP codon 129 
genotype from both France and the UK are required to address these possibilities; such 
experiments are currently underway (Andreoletti et al., 2016). 
 
6.3. hGH-iCJD neuropathology and biochemistry 
6.3.1. Neuropathology 
The neuropathological phenotype in sCJD is determined largely by the PRNP codon 
129 genotype of the patient and the PrPres isoform in the brain (Figure 1.5). Since sCJD 
is the most likely source of the prion infectivity responsible for hGH-iCJD, the 
question arises as to whether the neuropathological phenotype in hGH-iCJD is subject 
to similar influences. The results in the 21 hGH-iCJD cases with frozen brain tissue 
available for biochemical analysis show that many of the hGH-iCJD cases showed a 
similar neuropathological phenotype to the recognised sCJD subtypes. This was 
particularly true for the seven PRNP codon 129 VV hGH-iCJD cases, which had both 
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a neuropathological phenotype very similar to the sCJD VV2 subtype and an identical 
PrPres brain isoform (type 2) on Western blot examination. The neuropathological 
features of the sCJD MV2 subtype are variable and can be subclassified according to 
the presence of kuru-type plaques in the cerebellum (MV2K) or the presence of 
confluent vacuolation in the cerebral cortex with perivacuolar PrP accumulation on 
IHC, but no kuru–type plaques (MV2C). Some cases of sCJD MV2 contain both kuru-
type plaques in the cerebellum and confluent vacuolation in the cerebral cortex, when 
the term MV2K+C is used (Parchi et al., 1999). In addition to this neuropathological 
heterogeneity, there is also biochemical heterogeneity in this subgroup. The MV2K 
sCJD subtype is characterised by PrPres type i+2 (a doublet of approximately 20 kDa 
(intermediate) and 19 kDa (type 2)) in the brain, whereas the MV2C subtype is 
characterised by a type 2 brain PrPres only (Parchi et al., 2009; Kobayashi et al., 2013). 
The 12 codon 129 MV hGH-iCJD cases all showed a neuropathological phenotype 
similar to the sCJD MV2K subtype, with characteristic kuru-type plaques present in 
the cerebellum and occasionally in the cerebrum. All these cases contained a mixture 
of type 2 and intermediate (20 kDa) brain PrPres isoforms, but only 3/12 showed 
confluent vacuolation in the cerebral cortex.  
 
6.3.1.1. Atypical neuropathological phenotypes 
The two PRNP codon 129 MM cases with frozen tissue available for brain PrPres 
analysis in this study showed divergent neuropathological phenotypes, with case hGH-
iCJD21 exhibiting the typical features of sCJD MM1, accompanied by brain PrPres 
type 1 on Western blot examination. In contrast, case hGH-iCJD20 showed an atypical 
phenotype with kuru-type plaques in the cerebellum and cerebral cortex, and confluent 
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vacuolation in the cerebral cortex, resembling sCJD MV2K+C. Western blot 
examination found an intermediate (20 kDa) brain PrPres isoform alone in all six brain 
regions examined, with no type 1 or type 2 PrPres identified. The two additional hGH-
iCJD cases with PRNP codon 129 MM (but no frozen tissue available for WB analysis) 
also showed a divergent neuropathological phenotype; case hGH-iCJD35 showed 
neuropathological features similar to the sCJD MM1 subtype, while   
hGH-iCJD31 showed atypical features, with some similarities to the sCJD VV2 
histotype, perhaps reflecting incomplete adaptation of the infecting V2 prion strain in 
this codon 129 patient. 
 
6.3.1.2. The significance of kuru-type plaques in iCJD 
In a recent report, three PRNP codon 129 MM genotype hGH-iCJD cases from the 
USA all had a type 1 brain PrPres isoform (Cali et al., 2015). However, one of the cases 
(case 1) had kuru-type plaques in the brain and other neuropathological similarities to 
the MMi case in this study, while the others resembled the sCJD MM1 phenotype. The 
apparent discrepancy between the brain PrPres isoforms between the USA and UK 
codon 129 MM cases with kuru-type plaques is likely to reflect methodological 
differences in the Western blotting technique used in these studies, since the technique 
used in the USA study is not optimised for the detection of intermediate-sized PrPres 
isoforms.  
 
Kuru-type amyloid plaques have reported in other cases of PRNP codon 129 MM 
genotype hGH-iCJD in France (Billette de Villemeur et al., 1994; Delisle et al., 1993) 
and in the UK (Markus et al., 1992); however, not all of the French codon 129 MM 
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hGH-iCJD cases contain kuru plaques (Billette de Villemeur et al., 1994). No data on 
brain PrPres isoforms is available in these studies. The authors of these reports and the 
recent USA report (Cali et al., 2015) noted that the disease duration in the French and 
USA codon 129 MM cases with kuru plaques (10-36mo) was longer than in the two 
USA codon 129 MM cases without plaques (2mo). However, this is not the case for 
an additional codon 129 MM hGH-iCJD case resembling sCJD MM1 from the 
Netherlands (Croes et al., 2002), who died 11mo after the onset of the first symptoms 
of the disease. In this study, the codon 129 MM cases resembling sCJD MM1 and 
without kuru-type plaques had durations of illness of 6mo and 8mo, while the two 
codon MM cases with atypical neuropathology containing kuru-type plaques each had 
a duration of illness of 5mo, indicating that the relationship between atypical 
neuropathology with kuru plaques and the duration of the clinical illness is not 
predictable.  
 
Similar neuropathological diversity has also been described in the 142 cases of  hDM-
iCJD in Japan. The majority (68%) resemble the sCJD MM1 subtype in terms of the 
clinical features, neuropathology and brain PrPres isoform. The remaining 32% contain 
kuru-type amyloid plaques in the brain and are referred to as plaque-type dura mater-
associated iCJD (Kobayashi et al., 2014); these cases also contain an intermediate 
(20kDa) brain PrPres band on Western blot examination. The experimental 
transmission properties and in vitro conversion properties in both the non-plaque and 
plaque hDM-iCJD cases in Japan have been extensively investigated (see below). The 
three UK cases of hDM-iCJD with data on brain PrPres isoforms in this study all 
belonged to the codon 129 MM group and all had PrPres type 1 in the brain (Table 5.6). 
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The neuropathology in all three cases resembled that of the sCJD MM1 subtype, with 
no kuru-type plaques present.  
 
Kuru-type amyloid plaques have also been reported on several occasions in atypical 
cases of sCJD in PRNP codon 129 MM patients, sometimes in the white matter alone 
(Schoene et al., 1981; Ishida et al., 2003; Kobayashi et al., 2008; Gelpi et al., 2013; 
Berghoff et al., 2015). On the basis of the identification of the plaque hDM-iCJD cases 
in Japan, it has been suggested that the presence of kuru-type places in an apparent 
sporadic CJD case in a PRNP codon 129 MM patient should raise the possibility of an 
iatrogenic origin, particularly if the intermediate 20kDa brain PrPres isoform is also 
detected (Kobayashi et al., 2016); this suggestion has been explored further by 
experimental transmission studies and in vitro conversion studies.  
 
6.3.1.3. Neuropathological comparisons in hGH-iCJD and sCJD 
Despite this suggestion, it is clear from this study that most cases of hGH-iCJD in the 
UK have a neuropathological and biochemical phenotype that is indistinguishable 
from sCJD when it occurs in VV2, MVi+2 and MM1 patients (Table 5.6), which as a 
group account for 20/21 the hGH-iCJD cases in which both PRNP codon 129 genotype 
and PrPres isoform data are available. Of the remaining 14 cases, only one case (hGH-
iCJD 31) had an atypical neuropathological phenotype, while the others could all be 
assigned a histotype that corresponded to one of the recognised sCJD histotypes. 
Particular care must be taken in interpreting the neuropathological findings in the five 
cases in which neither PRNP codon 129 genotype nor PrPres isoform data are available 
(hGH-iCJD25, 29, 30, 32 and 33) (Table 5.6). Case 25 resembled the sCJD MM/MV1 
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histotype, while cases 29, 30 and 32 resembled the sCJD VV2 histotype. Case 33 
resembled the sCJD MM/MV2K histotype; however, the possibility that this case 
could have a MM genotype and an intermediate PrPres brain isoform (as in case 20, 
Table 5.6) cannot be excluded. Even if this were so, over 90% (32/35) of the UK hGH-
iCJD cases would have neuropathological and biochemical features that are 
indistinguishable from one of the sCJD histotypes; a detailed clinical history of 
iatrogenic exposure to CJD prions is therefore essential for diagnosis.  
 
Rudge et al. (Rudge et al., 2015) have reported that the UK hGH-iCJD patients tend 
to have a clinical history that begins with gait ataxia and lower limb dysaesthesiae 
rather than the rapidly progressive dementia that is typical, but by no means universal, 
in sCJD. Patients in the sCJD VV2 subtype and, to a lesser extent, the MV2 subtype 
can have a clinical presentation with gait ataxia (see section 1.5.1.3). The clinical 
features noted by Rudge et al. may therefore simply reflect the large predominance of 
VV2 and MVi+2 cases in the UK hGH-iCJD cohort, rather than specific features 
indicative of hGH-iCJD. 
 
6.3.2. Biochemistry and experimental transmission  
6.3.2.1. The concept of the traceback phenomenon 
A molecular traceback phenomenon was proposed Kitamoto and co-workers to 
explain the phenotypic diversity of MV2 sCJD cases, and the transmission properties 
and origin of hDM-iCJD in Japan (Kobayashi et al., 2007, 2010, 2013). These 
experiments are represented diagrammatically in Figure 6.1. Transmission of the V2 
prion strain from sCJD VV2 into transgenic mice expressing human PRNP codon 129 
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MM was only achieved after a lengthy incubation period. Examination of these mouse 
brains found amyloid plaques (not present in human sCJD VV2) and an intermediate 
PrPres type, termed type i. Subsequent passage into transgenic mice expressing either 
human PRNP codon 129 MM or codon 129 VV found that the codon 129 VV mice 
were highly susceptible to infection in comparison with the codon 129 MM mice. The 
prions generated in the initial transmission of sCJD VV2 into codon 129 MM 
transgenic mice (which were necessarily composed of PrPSc with methionine at codon 
129) exhibited a traceback phenomenon on subsequent passage, since they transmitted 
preferentially to transgenic mice with the codon 129 VV genotype from which they 
originated. We have modelled the traceback phenomenon in hGH-iCJD prions using 
PMCA reactions with PRNP codon 129 MM and VV substrates in place of the 
corresponding transgenic mice used by Kobayashi et al.  
 
6.3.2.2. The traceback phenomenon in hGH-iCJD: in vitro modelling 
The molecular mechanism of the traceback phenomenon is not fully understood, but 
the data of Kitamoto and co-workers indicates that PrPres type i is a key component  
of this phenomenon and may indicate a transitional phase of prion adaptation in a 
host of differing codon 129 genotype (Kobayashi et al., 2007, 2013). PrPres type i is 
also associated with the presence of kuru-type PrP amyloid plaques in the brains of 
both transgenic mice and humans, perhaps reflecting a high propensity for -sheet 





Figure 6.1. The molecular traceback phenomenon in experimental prion transmission 
studies (modified from Kobayashi et al., 2014) 
 
   
 
Inoculation of the sCJD V2 strain into humanised transgenic mice with different 
PRNP codon 129 genotypes found rapid transmission (green) into the VV mice, 
generating VV2 prions, but inefficient transmission (red) across the genotypic barrier 
to the MM mice, generating MMi prions. Subsequent transmissions of these MMi 
prions found rapid transmission across the genotypic barrier (green) to the VV mice, 
generating VV2 prions, but inefficient transmission (red) with no genotypic barrier to 
the MM mice. The preference of MMi prions to replicate in VV mice and produce 
VV2 prions demonstrates a molecular traceback to the original sCJD V2 prion strain. 
 
Abbreviations: i: intermediate type PrPres; M: methionine; PRNP: human prion protein gene; PrPres: 
protease-resistant prion protein; sCJD: sporadic Creutzfeldt-Jakob disease; V: valine. 
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This group has also proposed that kuru plaques in PRNP codon 129 MM apparent 
sCJD cases can be used as an indication of an iatrogenic aetiology with a traceback 
potential (Kobayashi et al., 2015, 2016). The neuropathological and biochemical 
characterisation of case hGH-iCJD20 in this study supports this proposal and extends 
the traceback phenomenon to include UK hGH-iCJD in addition to hDM-iCJD in 
Japan. The association of a PRNP codon 129 MM genotype with kuru plaques in three 
national independent hGH-iCJD cohorts (France, USA and UK) adds further weight 
to this phenomenon. The data reported in this study from PMCA experiments (Figure 
5.19) confirm that the traceback phenomenon in hGH-iCJD can be modelled in cell-
free systems in addition to animal transmission studies, as predicted for hDM-iCJD by 
Kobayashi et al. (Kobayashi et al., 2016) and subsequently demonstrated by Takeuchi 
et al. (Takeuchi et al., 2016) using PMCA. 
 
6.3.2.3. In vitro modelling: implications for human to human transmission 
The results of the in vitro conversion studies using RT-QuIC and PMCA did not 
support the hypothesis that human to human transmission of CJD results in acquired 
replicative efficiency (Xiao et al., 2014), but instead indicated the opposite. The RT-
QuIC assay showed consistently reduced seeding activity in hGH-iCJD and hDM-
iCJD in comparison to matched sCJD subtypes, indicating that secondary transmission 
of sCJD in human does not result in an enhanced propensity for PrPC conversion. 
Similar findings were noted in the PMCA studies, where the amplification factors 
achieved by the hGH-iCJD seeds were never higher than the corresponding matched 
sCJD seeds in identical substrates.  
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While these results may appear reassuring in terms of any public health concerns over 
the secondary transmission of prion infectivity from hGH-iCJD patients, the current 
steps to identify hGH recipients who are about to undergo surgery or donate blood 
should remain in place (see section 1.5.7.1). The (admittedly preliminary) novel 
finding in this study of abnormal prion protein accumulation in lymph nodes in hGH-
iCJD (Table 5.9) indicates a potential for prion infectivity in non-CNS tissues in hGH-
iCJD.  
 
The UK experience with hGH-iCJD and other acquired human prion diseases indicates 
that the consequences of exposure can be manifested over a considerable period of 
time, not only as a result of primary exposure to the infectious prions, but also to 
secondary transmission as a consequence of prion infectivity in non-CNS tissues, as 
has occurred in the cases of secondary vCJD associated with blood transfusion. These 
prolonged consequences also reflect the lengthy incubation periods in acquired human 
prion diseases, which in turn are influenced by the PRNP codon 129 genotypes in the 
exposed population. The occurrence of a new case of vCJD in the PRNP codon 129 
MV genotype in 2016, some three years after the last PRNP codon 129 MM patient 
(Figure 1.6) and twenty years after vCJD was first identified (Will et al., 1996) 
exemplifies this point.  
 
6.3.3. Origin of the UK hGH-iCJD epidemic 
The data presented in this thesis support the hypothesis that the hGH-iCJD epidemic 
in the UK results from infection with the V2 sCJD strain. The PRNP genotypes of the 
hGH treated patient cohort, if similar to the UK blood donor population would be 44% 
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MM, 45% MV and 11% VV (Bishop et al., 2009). Exposure of the PRNP codon 129 
VV hGH-iCJD recipients to the V2 sCJD strain cases could explain the early 
emergence of iCJD in this subgroup in the absence of a genotypic barrier and relatively 
short incubation periods. The subsequent appearance of more cases in PRNP codon 
129 MV recipients may reflect both a larger genotypic barrier to transmission and the 
larger numbers of PRNP codon 129 MV individuals in the hGH treated patient group. 
Finally, the appearance of a limited number of PRNP codon 129 MM hGH-iCJD cases 
later in the epidemic could be interpreted as evidence of a substantial PRNP codon 129 
genotypic barrier to transmission of V2 sCJD strain, resulting in prolonged incubation 
periods.  
 
Although the possibility of a mixture of other contaminating prion strains (e.g. the M1 
strain) during the period hGH was administered in the UK cannot be excluded, the 
relatively late appearance of the codon 129 MM hGH-iCJD cases argues against this 
possibility. Since the V2 sCJD strain appears to be responsible for both VV2 and MV2 
sCJD, distinguishing between these sources as the cause of the UK hGH-iCJD 
epidemic is difficult. This difficulty is reinforced by the recent finding that the 
proportion of PrPres derived from the two PRNP M and V alleles can vary dramatically 
in sCJD, so heterozygous sCJD cases might in effect contain only PrPres derived from 
the 129 V or the 129 M alleles (Moore et al., 2016). The proposed sources, mechanisms 





Proposed model for the UK hGH-iCJD epidemic and the study outcomes 
 
 
(a) A summary of the molecular and genetic findings in the 21 hGH-iCJD cases with 
frozen tissue available, showing correlations between PRNP codon 129 genotype, 
PrPres type and pathology, the genetics of the exposed patient group and the proposed 
causative V2 sCJD strain (from either a sCJD VV2 or a sCJD MV2 case).  
 
(b) Graphic representation of the numbers of hGH-iCJD subtypes (PRNP codon 129 
genotype and PrPres type) in the 21 hGH-iCJD cases with frozen tissue available 
plotted according to increasing estimated incubation period. 
 
Abbreviations: CJD: Creutzfeldt-Jakob disease; hGH: human growth hormone; i: iatrogenic; M: 




6.3.4. Route and pathogenesis of hGH-iCJD infection 
The route of hGH administration was by intramuscular injection, raising the question 
of how the infectious prions in the inoculum reach the CNS during a prolonged 
incubation period. Data from experimental prion transmissions by a variety of non-
CNS) routes (including intramuscular and subcutaneous routes) have found 
variations in the peripheral pathogenesis that may reflect agent strain (Kimberlin & 
Walker, 1988; Mabbott & MacPherson, 2008). Some prion strains (including vCJD)  
replicate in lymphoid tissues (e.g. spleen, tonsil) before invading the CNS (Peden et 
al., 2004). CNS spread may occur via the blood-borne route, or by slow retrograde 
spread along autonomic nerve to the spinal cord and/or brainstem, then spreading to 
the brain itself (Mabbott & MacPherson, 2008). These complex mechanisms partly 
explain the lengthy incubation period in prion diseases (Kimberlin & Walker, 1988).  
 
The results of this study on this limited amount of non-CNS tissues available give 
some support for involvement of the peripheral nervous system (nerves, dorsal root 
ganglia and trigeminal ganglia) and, in a single case, involvement of lymphoid 
tissues, with evidence of PrPres accumulation in the germinal centres within lymph 
nodes. It may be that hGH-iCJD has some similarities to vCJD in terms of its 
peripheral pathogenesis, but the levels of PrPres detected in lymphoid and peripheral 
nervous system structures appear lower and more restricted in distribution than in 
vCJD. Nevertheless, these novel findings merit further study in a relevant 
experimental model, which may provide support for the development of biomarkers 
of asymptomatic hGH-iCJD infection.  
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6.4. Co-pathology in hGH-iCJD  
6.4.1. Pathogenesis of CNS A accumulation in hGH recipients 
When attempting to understand the pathogenesis of the CNS A accumulation 
observed in the hGH-iCJD and hGH control cases in this study, the following points 
should be considered: 
1. Source of the A: this is presumed to originate from A in the pituitary glands 
collected for hGH extraction (Irwin et al., 2013; Jaunmuktane et al., 2015), 
many of which are likely to have been derived from elderly patients undergoing 
autopsy, including patients with AD pathology and symptomatic AD (no 
restrictions were made on the collection of glands from patients with dementia 
or most other neurological disorders until 1980). The processing of the glands 
for hGH extraction using the modified Wilhelmi protocol may have had some 
effect on the A aggregates in the pituitary gland, but it appears to have neither 
removed nor denatured the A sufficiently for it to lose its capacity to act as a 
propagon (Eisele & Duyckaerts, 2016). 
2.  The investigations of the limited numbers of non-CNS tissues in this study 
yielded no information on the involvement of these systems in the spread of 
A to the CNS. Possible routes include retrograde spread via the peripheral 
nervous system or vascular spread, as for prions.  
3.  The pathogenesis of CAA in AD is considered to result from failure of 
perivascular drainage of soluble A from the brain (Keable et al., 2016). The 
similarities of the CAA in this study to that occurring in AD are considerable 
and include a predominant involvement of the occipital region, affecting 
arterioles, venules and capillaries. This implies a similar pathogenesis and 
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suggests that soluble A accumulates in the brain before CAA becomes 
established in hGH recipients. CAA in hGH recipients therefore cannot be 
taken to provide evidence of a vascular route of spread to the CNS.  
4. Analysis of co-pathology in the brains of the cohorts studied is complicated by 
the other existing pathologies: widespread CJD-related pathology (in hGH-
iCJD, sCJD and vCJD cases) and other pathologies relating to the medical 
history and cause of death in the hGH controls, including recurrent brain 
tumours, neurosurgery and radiotherapy. Nevertheless, it has been possible to 
assess fully the co-pathology in these cases by performing a detailed analysis 
by two independent observers using internationally accepted standardised 
assessment criteria and recording the results in relation to the other existing 
pathologies, as in the cases of hDM-iCJD described by Kovacs et al. (Kovacs 
et al., 2016a): 
 
6.4.2. CNS A accumulation in hGH-iCJD cases and hGH controls 
CNS A accumulation in the cerebral cortex and/or meningeal and intraparenchymal 
blood vessels (including capillaries) was identified in 18/33 hGH-iCJD patients and 
5/12 hGH controls. In both groups of patients, the cortical pathology varied from 
occasional diffuse A plaques in one or more cortical regions to more widespread 
involvement with diffuse subpial and perivascular Adeposits and diffuse and neuritic 
A plaques. No parenchymal A deposition was identified in the entorhinal cortex, 
hippocampus, basal ganglia, thalamus, brain stem, cerebellum or spinal cord in any of 
these cases.  The vascular A pathology varied in both groups from patchy focal 
deposition with only occasional circumferential deposits in the meningeal vessels 
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(generally arterioles) to extensive deposition in meningeal and intraparenchymal 
vessels, including arterioles, veins and capillaries, with dyshoric vessels. One hGH 
control case also showed early vasculopathy, with splitting of occasional vessel walls. 
Overall, there were no major differences in the nature or range of severity of the 
pathology between the hGH-iCJD and hGH control groups (Table 5.7). 
 
No significant differences were found between the A positive and A negative cases 
in hGH-iCJD and hGH control groups in terms of the time period or duration of their 
hGH treatment, although there was a trend for the hGH controls with A pathology to 
have been treated with hGH in an earlier time period (p=0.054) and for longer 
(p=0.077) than the A negative cases. The most severe A pathology tended to occur 
in the patients who had survived for longest after the end of their hGH treatment, 
perhaps reflecting a lengthier period for Apropagation and seeding in the CNS prior 
to death.  
 
6.4.3. CNS A and tau accumulation in hGH recipients compared to AD 
A number of differences between the A and tau accumulation in the CNS of hGH 
recipients and the neuropathology of AD are apparent: 
1. The Adeposits in the hGH recipients resembled some of the deposits found 
in AD (Duyckaerts et al., 2009), with diffuse A deposits, focal deposits 
(diffuse plaques and neuritic plaques) and CAA present.  Stellate deposits were 
not identified.  
2. Diffuse A deposits were found in the subpial region in a minority of cases. 
However, the “lake-like” diffuse deposits in the presubiculum and the “fleecy” 
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diffuse deposits in the entorhinal cortex found in AD (Duckaerts et al., 2009) 
were entirely absent. 
3. Focal A deposits included diffuse plaques and cored/neuritic plaques, as in 
AD. The neuritic plaques had short neurites that labelled with antibodies to 
ubiquitin and tau. Cored plaque formation around vessels with CAA was 
relatively common; these plaques and the adjacent perivascular A deposits 
were also surrounded by tau-positive neurites. Reactive astrocytes also 
surrounded the cored plaques and microglial cells were identified in the core 
region and the periphery of these plaques. 
4. The anatomical distribution of the focal and cored/neuritic plaques was more 
restricted than in AD; most cases had patchy collections of plaques in an 
unpredictable distribution in the neocortex, corresponding to Thal phase 1. In 
the few cases where the cingulate cortex was also involved there was never 
accompanying involvement of the entorhinal cortex or hippocampus, as 
included in Thal phase 2, so a provisional designation of Thal phase 1* was 
made. No evidence of laminar involvement of the cerebral cortex with A 
deposits was identified. 
5. CAA pathology was similar to that occurring in AD, but cored plaques 
occurred commonly adjacent to the larger intraparenchymal vessels with CAA 
and perivascular A. 
6. The accompanying tau pathology was restricted to short neurites around 
cored/neuritic plaques and perivascular deposits with cored plaques. Very 
occasional neuropil threads were identified in the cortical grey matter, but 
neurofibrillary tangles, neurites and neuropil threads were absent in the 
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entorhinal cortex and hippocampus, making it impossible to assign a Braak 
stage for neurofibrillary pathology. 
 
The other main differences from AD are the age of the individuals involved and the 
absence of a clinical history of slowly progressive cognitive impairment. Most hGH 
recipients with CNS A accumulation were under the age of 40y, most of whom did 
not have the APOE 3/4 genotype or were negative for apoE-4 on IHC (see below). 
 
6.4.4. Genetic factors influencing CNS Aaccumulation 
None of the hGH-iCJD cases or hGH controls with frozen tissue available for full 
exome sequencing had any evidence of a genetic abnormality on a wide range of genes 
affecting A accumulation in the CNS (including APP, PS1 and PS2). The use of 
apoE-4 IHC to identify individuals with an apoE-4 phenotype is not novel (Saki et al., 
2014) and was performed by using two different apoE-4 antibodies, controlled and 
validated with a pan-apoE antibody and the use of appropriate AD controls of known 
APOE genotypes. The results of the APOE genotype analysis and apoE-4 IHC did not 
find any significant association between APOE 4 or apoE4+IHC and A 
accumulation in the brain; most of the cases with CAA in this study had the APOE 
3/3 genotype and the two cases with capillary CAA in this study both had the APOE 
3/3 genotype. The hGH-iCJD case with the greatest amount of A positivity (hGH-
iCJD18) had the APOE 3/3 genotype (combined ABC and CAA score: 8), as did the 
hGH control case (hGH-control11) with the greatest amount of Aaccumulation in 
the CNS (combined ABC and CAA score: 11). The PRNP genotype also had no 
significant association with A accumulation in the CNS in hGH-iCJD cases. 
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The single sCJD case with CAA had the APOE 3/4 genotype, while the two vCJD 
cases with diffuse A parenchymal deposits comprised one case with the APOE 3/4 
genotype and one case with the APOE 2/3 genotype. The latter (vCJD 27) was 
identified on exome sequencing to have the PSEN1 p.E318G variant that increases the 
risk of AD in APOE 4 carriers (but possibly not relevant in the APOE 2/3 genotype) 
(Benitez et al., 2013), and the -48 C/T polymorphism in the PSEN1 promoter that is 
associated with an increased risk of AD and an increased A load in the brain (Lambert 
et al., 2001), which might be of relevance to the finding of sparse diffuse A brain 
parenchymal deposits at 30y of age. 
 
6.4.5. Age and APOE genotype/apoE-4 phenotype   
In a recent study of the brains of 154 individuals between the ages of 30-50y 
(Pletnikova et al., 2015), A deposition was not identified in any individuals under the 
age of 40y, but was present in the brains of 13 individuals aged between 40-49y in the 
form of diffuse plaques throughout the cerebral cortex. Of these, 5/13 cases had subtle 
tau positivity in the entorhinal cortex and/or hippocampus. None of the cases with A 
positivity had clinical evidence of dementia or mild cognitive impairment. All 
individuals with A positivity carried 1 or 2 APOE 4 alleles; however, of the 28 
individuals aged 40-50y with the APOE 3/4 genotype, 10 (36%) had A deposition 
in the brain, but 18 (64%) did not, indicating that the A deposition in the brain before 
the age of 50y occurs in only around 1/3 of non-demented individuals with the APOE 
3/4 genotype. In the earlier study by Braak and Braak (Braak & Braak, 1997), 
Adeposits were found in the brains of only 9/280 individuals under the age of 45y 
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(five at amyloid stage stage A and four at amyloid stage B, with no cases at amyloid 
stage C). CAA was not assessed in this publication. These results in this study (Figure 
5.20) indicate no apparent influence of the APOE 3/4 genotype or the apoE-4 
phenotype on the presence of either parenchymal or vascular Aaccumulation in the 
groups of hGH-iCJD and hGH control patients, which include a patient as young as 
20y of age with CAA and an apoE-4-ve(IHC) phenotype.  
 
6.4.6. Other factors influencing CNS A accumulation in hGH recipients 
6.4.6.1. hGH preparations used for inoculation 
The lack of a relationship between the duration of hGH treatment and the development 
of A pathology suggests that the amount of A contaminating the hGH inocula was 
variable and unpredictable. The same can be said for the lack of a relationship between 
the development of iCJD and the duration of hGH treatment; prion contamination of 
the hGH inocula must also have been variable and unpredictable. It has been observed 
that hGH recipients who developed iCJD were all treated for at least six months with 
hGH produced using the modified Wilhelmi protocol, which was used to treat hGH 
deficiency in the UK between 1967-1980 (Swerdlow et al., 2003). This study has 
found that all the hGH recipients with CNS A accumulation had also been treated 
(for varying periods of time) with this preparation. While not all patients treated with 
this preparation developed either hGH-iCJD or CNS A accumulation, the four 
patients who were never treated with this hGH preparation did not develop either iCJD 
or CNS Aaccumulation. 
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Subsequent studies of the hGH produced by the modified Wilhelmi protocol were 
reported in 1982 (Stein et al., 1982). Using polyacrylamide gel electrophoresis and 
amino acid analysis of the high molecular weight fraction of this preparation, the 
investigators found that it contained “aggregated hGH as well as other material not 
separated from hGH by the purification procedure” Could this “other material” have 
included PrPSc and A? None of these preparations are available to investigate this 
possibility either by protein analysis or by experimental transmission into relevant 
animal models, so it is not possible to investigate this intriguing question further. 
 
6.4.6.2. Other potential factors 
In relation to the doubts raised by Feeney et al. (Feeney et al., 2016) concerning 
potential predisposing factors for A deposition in the 8 hGH-iCJD patients described 
by Jaunmuktane et al. (Jaunmuktane et al., 2015), there was no history or 
neuropathological evidence of traumatic brain injury as the cause of the hGH 
deficiency in the first two groups. Further to the additional questions raised by Feeney 
et al. (2016) concerning more generalised disorders that can be associated with A 
deposition in the CNS, no history or neuropathological evidence of epilepsy, fragile X 
syndrome, Down’s syndrome or Parkinson’s disease was evident for any of the 
patients included in this study. The morphology and distribution of A lesions and 
relative lack of tau pathology argue against an underlying traumatic aetiology for the 
Apathology reported in this study, as does the lack of any morphological evidence 
of previous trauma e.g. axonal bulbs, microglial accumulation, or white matter 
degeneration. In the two cases with incidental focal isolated tau pathology (pretangles 
and occasional tangles) unrelated to areas of A deposition, the localised abnormalities 
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did not match the recent proposed diagnostic criteria for chronic traumatic 
encephalopathy (McKee et al., 2016) and did not resemble the early stages of 
tauopathies such as corticobasal degeneration (Uchihara, 2014). In hGH-control10, the 
accompanying neuronal loss and gliosis indicates longstanding focal brain tissue 
damage that may relate to previous neurosurgery. The pretangles in hGH-iCJD 31 are 
more difficult to explain, but might represent a local reaction to a previous focal insult 
no longer apparent in the post mortem brain. Pretangles in the brains of very young 
individuals were identified in a large study by Braak et al. (Braak et al., 2011) in 
subcortical sites, but not in the cerebral cortex. However, subcortical pretangles or 
tangles were not found in this or any other case examined.  
 
6.5 Comparison of the co-pathology with findings in other iCJD studies 
CNS A accumulation in patients with different forms of iCJD has been reported in 
4/8 recent cases of UK hGH-iCJD (Jaunmuktane et al., 2015) and 5/7 cases of hDM-
iCJD in Europe (Frontzek et al., 2015; Kovacs et al., 2016a), while a recent study of 
16 Japanese hDM-iCJD cases reported a significant association with subpial A 
deposition and meningeal amyloid angiopathy (Hamaguchi et el., 2016). The report on 
the eight UK hGH-iCJD cases claimed in the title that the findings provided “Evidence 
for human transmission of amyloid- pathology”, provoking a reaction in the media 
and scientific journals that included “Seeds of neuroendocrine doubt” (Feeney et al., 
2016). Most of this reaction resulted from use of the term “transmission” in the title. 
which implies a prion-like process, but did not include any apparent clinical 
manifestations of the A pathology. The reaction to the articles on hDM-iCJD has 
been more measured, perhaps due to the absence of the term “transmission” in their 
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titles, but perhaps also because it was considered that A spread from a human dura 
mater graft to the underlying cerebral cortex did not constitute an unimaginable 
possibility due to its anatomical proximity. Table 6.1 summarises the key findings in 
these reports and compares their findings with those from this study. All four previous 
papers provide evidence of CNS A accumulation in cases of hGH-iCJD and hDM-
iCJD, but the level of detail varies both in the descriptive pathology of the CNS and 
the results of associated genetic investigations.  
 
This study adds considerably to these reports in terms of the number of cases studied, 
the inclusion of hGH control cases without iCJD, and in the young age of the patients 
included. The detailed neuropathological description provided is comparable with that 
in Kovacs et al. (Kovacs et al., 2016a), particularly in relation to the nature and 
localisation of the Adeposition and its relationship to AD. This study has found more 
evidence of tau deposition in relation to Adeposits, but this still falls short of 
resembling a full AD neuropathological phenotype, particularly in the conspicuous 
absence of neurofibrillary tangles.  CNS Aaccumulation in hGH recipients is not 
indicative of AD, but rather represents a partial phenotype that is restricted in both the 
nature and anatomical distribution of and tau lesions. This study also found no 
evidence of the subcortical forms of tau accumulation that appear to represent part of 
the preclinical phase of the pathological processes underlying AD (Braak et al., 2011).  
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Table 6.1 Comparison of results with other studies on CNS A accumulation in iCJD 

















CJD CJD CJD CJD CJD Not 
CJD 
Cause of iCJD hGH hDM hDM hDM hGH None 
Number of cases 8 7 2* 16 33 12 
Other autopsy 
tissues examined 










No hGH control 
cases – see 
Table 5.8 
 
Genetic analysis APOE +  AD 
genes 
No APOE + 
AD 
genes 






























28-63 28,33 35-81 27-45 30-45 





28,33 28,33 35, 39 27-38 30-37 
Number with A 
CAA 
3 +1 focal 5 2* 11 14 2 
Age of cases 
with A CAA 
5th decade-
51y 
28-63 28,33 35-81 20-37 42-45 
Age of cases <40 
y with A CAA 
None 28,33 28-33 35-39 20-37 None 
AD - related tau 
pathology 











Abbreviations: A: amyloid beta: AD; Alzheimer’s disease; APOE: apolipoprotein E gene; CAA: 
cerebral amyloid angiopathy; CJD: Creutzfeldt-Jakob disease; hDM: human dura mater; hGH: human 
growth hormone: i: iatrogenic; s: sporadic; v: variant: y:years; *: cases also included in the study by 
Frontzek et al., 2015 
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6.6. Conclusions of this study 
 
6.6.1. How the results address the Aims of the thesis 
1. Determine the pathological phenotype of hGH-iCJD in the UK. 
The pathological phenotype of hGH-iCJD in the UK is diverse. All cases exhibit a 
spongiform encephalopathy with predominantly microvacuolar spongiform change in 
a variety of distributions (see 2 below). Amyloid plaque formation is a prominent part 
of the pathology in some cases of hGH-iCJD, with kuru-type plaques present in the 
cerebellar cortex and occasionally also in some other brain regions including the 
cerebral cortex, and basal ganglia. In approximately 50% of hGH-iCJD cases there is 
co-existing A pathology (CAA, diffuse and cored plaques, or both CAA and plaques) 
that cannot readily be explained by the APOE genotype and other genetic factors (see 
5. below). No evidence of significant accompanying -synuclein or TDP-43 pathology 
was identified.  
 
2. Explore whether the pathological phenotype is influenced by the PRNP codon 
129 genotype and CNS PrPres isoform in the same way as in sCJD (Parchi et 
al., 1999). 
The pathological phenotype in UK hGH-iCJD is strongly influenced by the PRNP 
codon 129 genotype and the brain PrPres isoform. In the codon 129 VV2 and MV2 
subtypes of hGH-iCJD, the neuropathology, PrP immunohistochemistry and brain 
PrPres isoform are similar to those in the corresponding VV2 and MV2 sCJD subtypes. 
However, the MM subgroup shows a divergent phenotype, with the MM1 cases 
resembling the sCJD MM1 subtype in terms of neuropathology, PrP 
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immunohistochemistry and brain PrPres isoform. However, the MMi subtype of hGH-
iCJD shows neuropathological, immunohistochemical and brain PrPres isoform 
features more similar to the MV2 sCJD subgroup. This combination of features has 
not been described in UK cases of either hDM-iCJD or sCJD with PRNP codon 129 
MM, but they have been described in cases of hDM-iCJD in Japan in PRNP codon 
129 MM genotype patients.  Kobayashi et al. (Kobayshi et al., 2016) have suggested 
that the combination of a PRNP codon 129 genotype and the presence of kuru plaques 
in the cerebellum and cerebral cortex in a patient with apparently sporadic CJD should 
lead to a suspicion of an iatrogenic source of infection. 
 
3. Investigate the peripheral pathogenesis of hGH-iCJD following intramuscular 
inoculation. 
The PET blot studies and WB studies using NaPTA precipitation in this thesis show 
that PrPres can be detected in the peripheral nervous system (peripheral nerves, adrenal 
medulla, dorsal root ganglia and trigeminal ganglia), the lymphoreticular system 
(lymph nodes) and the pituitary gland in hGH-iCJD. This evidence is incomplete and 
patchy in terms of the number of positive tissues from a limited selection of non-CNS 
tissues in a total of 19 patients. However, it does give an indication that both the 
peripheral nervous system and lymphoreticular system are possible routes through 
which the infectious agent may spread to the CNS after intramuscular inoculation. 
These routes are also involved the spread of infection in vCJD in humans and in 
experimental scrapie in rodents. In contrast, no evidence of A accumulation was 
found in any of the non-CNS tissues in this study. 
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4. Characterise the causal agent strain in hGH-iCJD and establish whether it 
relates to any of the known sCJD strains (Haik et al., 2011). 
From the combination of data concerning the neuropathological phenotype of UK  
hGH-iCJD, the brain PrPres isoforms and the chronological sequence of PRNP codon 
129 genotype involvement, it seems most likely that the causative agent is the V2 
strain of sCJD (Bishop et al., 2010; Haik et al., 2011). This possibility is reinforced 
by the result of the PMCA experiments on the hGH-iCJD codon 129 MM cases, in 
which evidence demonstrating a traceback phenomenon to a VV2 origin for the MMi 
hGH-iCJD case was obtained (Kobayshi et al., 2009, 2010). In a separate study, 
experimental transmission of UK iCJD hGH-iCJD cases and sCJD cases to 
transgenic mice over-expressing human PRNP codon 129 genotypes is being 
undertaken as part of an ongoing collaboration to determine the disease transmission 
characteristics and establish whether further evidence of a traceback phenomenon 
can be obtained in vivo (Andreoletti et al., 2016) 
 
5. Seek evidence in hGH-iCJD and other non-iCJD hGH recipients for 
transmission/seeding of other neurotoxic proteins found in the pituitary gland 
- A, tau, synuclein (Irwin et al., 2013; Jaunmuktane et al., 2015). 
The results of this study indicate that CNS  deposition occurs in around 50% of all 
UK hGH recipients, regardless of whether they died from hGH-iCJD or not, as a likely 
consequence of A seeding from contaminated hGH extracts. These findings also 
indicate a trend towards an association between the length of survival from the end 
date of the period of hGH treatment and the presence of A seeding and accumulation 
in the CNS, but this was not statistically significant. No clear association with the 
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APOE genotype or any other genetic predisposing factors was identified. The A 
pathology in the CNS occur as parenchymal deposits (diffuse subpial deposits, diffuse 
plaques and cored/neuritic plaques) and as CAA, or both CAA and parenchymal 
deposits. Plaques occur in the cerebral cortex in a patchy distribution that does not 
appear to resemble the pattern that is characteristic of Alzheimer’s disease, but is more 
similar to the patterns of A pathology described in hDM-iCJD graft patients (Kovacs 
et al., 2016a). Accompanying tau accumulation occurs in neuritic processes and sparse 
neuropil threads, but no neurofibrillary tangles were identified. No -synuclein or 
TDP-43 pathology was observed, but evidence of an astrocytic and microglial reaction 
to the A deposits was present. The CAA involved both meningeal and 
intraparenchymal vessels, including capillaries; occasional cases had dyshoric 
intraparenchymal vessels and one had evidence of vasculopathy.  
 
The full neuropathological phenotype of AD was not present in these cases; in 
particular, there was an absence of neurofibrillary tangles. These findings are in 
keeping with the clinical data, particularly for the hGH controls, where no evidence of 
progressive cognitive decline was recorded. This incomplete phenotype cannot be 
regarded as a model for AD, but confirms the capacity of A to act as a propagon in 
humans (Eisele & Duyckaerts, 2016) and to produce a range of CNS A pathology, 
with tau pathology and glial reactions apparently occurring as secondary phenomena 
(Kovacs, 2016).  
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6.6.2. Advantages and limitations of this study 
This study has a number of advantages beyond its size. The cases have occurred across 
the entire timescale of the hGH-iCJD epidemic in the UK (Figure 2.1) and are therefore 
more likely to be representative of the epidemic as a whole, unlike the small series of 
recent UK hGH-iCJD cases reported by Jaunmuktane et al. (Jaunmuktane et al., 2015). 
The wider temporal distribution of cases in this study also contains cases of all three 
possible PRNP codon 129 genotypes (unlike the study by Jaunmuktane et al.), 
allowing the molecular biology of prion transmission from UK hGH to be studied 
across all PRNP codon 129 polymorphic barriers across a wide period of time in a 
well-characterised patient cohort. 
 
 Another advantage is the availability of a clinical database in the Institute of Child 
Health, London that contains many details of the individual patients, including their 
date of birth and gender, the underlying disease causing their growth hormone 
deficiency, dates of hGH treatment (including use of the Hartree-modified Wilhelmi 
preparation of hGH), the date of onset of hGH-iCJD and their date of death. These data 
allow the incubation period for the hGH-iCJD infection to be estimated (Table 5.1). 
This wealth of clinical data on is supplemented by additional data from the NCJDRSU, 
in particular the results of analysis of the codon 129 polymorphism in the prion protein 
gene. Brain tissue from the cases in this study was referred to the NCJDRSU for 
diagnosis as part of the National CJD Surveillance Project. The brain tissue from each 
case was examined and sampled in a standardised way and a diagnosis made using 
consistent clinical and neuropathological criteria (Table 1.9). The requirement for 
unfixed frozen brain tissue samples for Western blot analysis for PrPres to confirm a 
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diagnosis of iCJD allowed frozen tissue samples to be retained for research (when 
appropriate consent was provided) in the MRC Edinburgh Brain Bank (EBB). The 
frozen tissue available for this study was essential for the genetic, biochemical and 
molecular biological components of this study. Some hGH-iCJD cases had multiple 
frozen tissue samples from different brain areas available to investigate regional 
variation in brain PrPres isoforms (Table 5.9), which has not been described in any 
previous study of hGH-iCJD. 
 
This study also benefits from the availability of similar data and brain tissue samples 
from the EBB for use as controls for the hGH-iCJD cases. In particular, brain tissue 
samples were available from a group of patients who were also treated over a similar 
time period with UK hGH, but who did not develop hGH-iCJD and died instead from 
complications of the underlying conditions causing their GH deficiency, the most 
common of which were intracranial neoplasms. These cases provide an ideal control 
group for the hGH-iCJD cases when investigating the co-pathology (AD, CAA, LB 
and TDP-43 pathology) in the brain, since the influence of co-existing iCJD pathology 
can be assessed. Cases of sCJD and vCJD were also available for use as age-matched 
controls of other forms of human prion disease of different pathogenesis (respectively 
idiopathic and acquired from a bovine source), who had never been treated with hGH. 
 
This study does have its limitations; it is necessarily an observational study that was 
conducted in retrospect using pre-existing tissue samples and data that were not 
collected for this specific purpose. The most significant disadvantage is the lack of 
frozen brain tissue samples in some cases, which precludes any biochemical, genetic 
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or molecular biological studies. This disadvantage is partly overcome by the ability to 
perform PRNP codon 129 analysis successfully in a small number of cases from DNA 
extracted from the formic acid-pretreated paraffin-embedded brain tissue blocks, and 
the use of antibodies to apoE-4 to determine the apoE-4 phenotype in hGH-iCJD and 
hGH control cases with co-existing AD pathology. Fortunately, cases without frozen 
brain tissue were in the minority, and the full range of the investigative techniques 
employed in this study were used on the majority (21) of the hGH-iCJD cases.   
 
6.7. Tests of the stated hypotheses of this thesis:  
1. Disease phenotype: The clinicopathological phenotype of hGH-iCJD in the UK is 
determined by the PRNP codon 129 polymorphism of the patient and the PrPres 
isoform in the brain. 
 
This hypothesis is supported by the evidence of a statistically significant association 
between PRNP codon 129 polymorphisms and both the disease incubation period and 
duration of clinical illness, and by the observation of a strong influence of the PRNP 
codon 129 genotype and the brain PrPres isoform on the pathological phenotype in UK 
hGH-iCJD.  
 
2. Increased propagation efficiency: The secondary transmission of sporadic CJD 
prions has led to the acquisition of greater propagation efficiency in hGH-iCJD 
prions (Xiao et al., 2014). 
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This hypothesis is not supported by the results of the in vitro conversion assays in this 
thesis. The RT-QuiC assays did not show the shortened lag time for hGH-iCJD cases 
or hDM-iCJD cases that would indicate increased propagation efficiency; the lag times 
for the hGH-iCJD cases were found to be significantly slower than for the sCJD cases. 
Similarly, the PMCA assays did not show evidence of an increased amplification of 
iCJD seeds in comparison to sCJD seeds of all possible PRNP codon 129 genotypes 
in identical PMCA substrates. 
 
3. Traceback phenomenon: The origin of the prions in hGH-iCJD can be inferred 
by ready reversion to their original state when given an appropriate host genotype 
(Kobayashi et al., 2009, 2010). 
 
This hypothesis is supported by the results of the PMCA assays, which show evidence 
to support a traceback phenomenon for the hGH-iCJD MMi case. The PMCA seed 
prepared from this case amplified more efficiently in a VV substrate than a MM 
substrate, consistent with an origin from a V2 strain of sCJD. In contrast, the hGH-
iCJD MM1 case and the sCJD MM1 cases did not amplify efficiently in either 
substrate.  
 
 4. Origin: The origin of hGH-iCJD in the UK can be inferred by the molecular and 
genetic changes occurring in the disease over time. 
 
This hypothesis is supported by the data in this thesis, which indicate from the results 
referred to in (3) above that an origin of UK hGH-iCJD from a V2 strain of sCJD 
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appears likely. This is reinforced by the temporal distribution of PRNP codon 129 
genotypes in the UK hGH-iCJD cohort; recipients with the matching PRNP codon 
129VV genotype are affected first, followed by the MV genotype and eventually the 
MM genotype. The latter are phenotypically heterogeneous in terms of their 
neuropathology, possibly indicating incomplete adaption of the V2 strain in the MMi 
hGH-iCJD cases. 
 
5. Co-pathology: Aseeding occurs in hGH recipients in the UK both with and 
without iCJD, resulting in the pathological accumulation of A in the CNS. 
 
This hypothesis is supported by the data from this study, with around 50% of UK hGH 
recipients showing evidence of A accumulation in the CNS as cerebral amyloid 
angiopathy, parenchymal deposits including diffuse and cored plaques, or both CAA 
and parenchymal deposits. No clear association with APOE genotype or other genetic 
predisposing factors was identified. For the first time, CNS A accumulation in hGH 
recipients who died from causes other than iCJD has been demonstrated, indicating 
that A seeding in the CNS is not dependent on co-existing prion infection. The A 
pathology in the hGH-iCJD cases and hGH controls is very similar in each group, and 
has undoubted similarities to the pathology of AD. However, there are also major 
pathological differences from AD in terms of the restricted distribution of the A 
deposits in the brain, a relative paucity in the number of tau-positive neurites around 
neuritic plaques, and the absence of neurofibrillary tangles.  
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6.8. Wider implications of the results in this thesis 
The findings of this study indicate that A can behave as a propagon in humans, able 
to spread to the CNS following intramuscular injection and subsequently seed in the 
parenchyma of the brain and in cerebral blood vessels, but not resulting in AD or any 
other apparent clinical manifestations. CNS A accumulation occurred in around 50% 
of hGH-iCJD and hGH control cases, and is therefore not dependent on co-existing 
PrPSc accumulation or other CJD pathology. This behaviour of A as a propagon in 
humans has possible broader implications when other opportunities for the potential 
exposure to Amay occur, for example in the re-use of A-contaminated 
neurosurgical instruments previously used on the brains of elderly patients, or via 
blood transfusions from elderly donors who may have increased levels of plasma 
ABlennow et al., . Recent epidemiological studies have found no evidence of 
either previous surgery or blood transfusion as risk factors for AD (Vanderweyde et 
al., 2010; Edgren et al., 2016), but the possibility that such scenarios could occur as 
rare events after prolonged incubation periods requires further consideration.  
 
These findings also indicate that a significant number of the remaining survivors in the 
cohort of UK hGH recipients are at increased risk of CNS A accumulation and, 
although they may not progress to symptomatic AD, they may subsequently develop 
vascular complications. The severe CAA found in the older hGH control patients in 
this study suggests that surviving hGH recipients may be at future risk of the 
complications of CAA, including spontaneous lobar cerebral haemorrhage, 
perivascular inflammation and cognitive impairment (Gahr et al., 2013).  
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Although human growth hormone therapy in the UK was abandoned over thirty years 
ago, cases of hGH-iCJD still occur- the most recent patient died earlier this year. These 
findings indicate that unrecognised or poorly assessed risks associated with medical 
interventions can have very long-term ramifications when it comes to patient safety. 
The study also underscores the importance of continued CJD surveillance and deep 
phenotyping of cases of this rare but fatal and transmissible condition in order to 
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Appendix 1. Details of hGH-iCJD cases from Dr Peter Adlard, Institute of Child 
Health 
 



















Cause of GH 
deficiency 
hGH-iCJD 1 m 1970-1974 2.5 16.9 8 34 CP 
hGH-iCJD 2 m 1970-1980 4 16.5 6 31 IGHD 
hGH-iCJD 3 m 1975-1981 3.8 13.2 17 27 astrocytoma  
hGH-iCJD 4 m 1977-1981 3.5 12.8 9 30 IGHD 
hGH-iCJD 5 m 1979-1985 1.8 11.4 5 25 IGHD 
hGH-iCJD 6 f 1974-1978 3 18.1 6 33 IGHD 
hGH-iCJD 7 f 1977-1981 3.3 16.2 12 31 IGHD 
hGH-iCJD 8 m 1975-1983 1 16.8 6 29 IGHD 
hGH-iCJD 9 m 1972-1982 5.8 18.8 14 33 IGHD 
hGH-iCJD 10 m 1975-1979 4.3 19.2 8 36 IGHD 
hGH-iCJD 11 m 1976-1980 4 17.8 18 37 IGHD 
hGH-iCJD 12 m 1978-1985 0.8 16.4 5 27 IGHD 
hGH-iCJD 13 m 1978-1983 3.2 17.2 16 34 IGHD 
hGH-iCJD 14 m 1976-1985 4 17.2 15 29 
histiocytosis 
X 
hGH-iCJD 15 m 1976-1982 3.8 19.1 9 37 IGHD 
hGH-iCJD 16 m 1978-1985 1.8 20 16 30 IGHD 
hGH-iCJD 17 f 1973-1983 6 23.7 22 41 IPHP 
hGH-iCJD 18 f 1977-1985 4.3 22.6 23 34 IGHD 
hGH-iCJD 19 f 1980-1985 1.5 22 32 29 IGHD 
hGH-iCJD 20 m 1980-1983 0.5 29.4 5 46 IGHD 
hGH-iCJD 21 m 1977-1985 3.3 31.7 8 42 CP 
hGH-iCJD 22 m 1974-1985 5.5 7.8 7 20 IGHD 
hGH-iCJD 23 f 1974-1985 8.2 10.5 2 20 IGHD 
hGH-iCJD 24 m 1976-1982 4.7 13.7 13 32 IGHD 
hGH-iCJD 25 m 1977-1985 2.3 12.5 16 30 IGHD 
hGH-iCJD 26 m 1977-1985 2 13.2 7 27 IGHD 
hGH-iCJD 27 m 1979-1985 1 12.8 7 24 IGHD 
hGH-iCJD 28 f 1972-1977 1.5 9.5 11 22 CP 
hGH-iCJD 29 m 1976-1985 3.8 9 5 20 CP 
hGH-iCJD 30 m 1980-1985 1 13.6 8 23 IGHD 
hGH-iCJD 31 m 1977-1979 2 19.1 5 28 IGHD 
hGH-iCJD 32 m 1972-1982 5 21.4 9 36 CP 
hGH-iCJD 33 m 1978-1985 3.8 18.1 20 31 IGHD 
hGH-iCJD 34 m 1973-1983 4.3 25.4 19 38 IGHD 
hGH-iCJD 35 f 1969-1978 3.5 32.3 6 45 RSS 
 
Abbreviations: CP: craniopharyngioma; f: female; GH: growth hormone; hGH: human growth 
hormone; HWP-hGH: human growth hormone produced using the Hartree modification of the 
Wilhelmi protocol; iCJD: iatrogenic Creutzfeldt-Jakob disease; IGHD: isolated growth hormone 
deficiency; IPHP: idiopathic hypopituitarism; m: male. RSS: Russell-Silver syndrome 
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Appendix 2. Details of hGH control cases from Dr Peter Adlard, Institute of Child 
Health 
 












Cause of GH deficiency 
hGH-control1 m 1981-1982 0 18 astrocytoma 
hGH-control2 f 1983-1985 0 18 craniopharyngioma 
hGH-control3 m 1984-1985 0 13 craniopharyngioma 
hGH-control4 m 1978-1981 3 28 craniopharyngioma 
hGH-control5 f 1975-1985 5.2 24 craniopharyngioma 
hGH-control6 f 1975-1981 6 31 Prader Willi syndrome 
hGH-control7 m 1978-1983 1.8 30 craniopharyngioma 
hGH-control8 m 1980-1985 0.5 33 mitochondrial cytopathy 
hGH-control9 m 1974-1981 3.2 42 
idiopathic 
panhypopituitarism 
hGH-control10 m 1982-1985 0.3 37 ependymoma 
hGH-control11 m 1969-1981 6.6 45 IGHD 




Abbreviations: f: female; GH: growth hormone; hGH: human growth hormone; HWP-hGH: human 
growth hormone produced using the Hartree modification of the Wilhelmi protocol; IGHD: isolated 
growth hormone deficiency; m: male. 
iv 
 
Appendix 3. Details of 108 sCJD cases according to the combination of CNS PrPres 
type and PRNP codon 129 genotype 
 




TC PC OC Th Consensus 
sCJD1 MM 2 1 1 1 1+2 
sCJD2 MM 1+2 1+2 1+2 0 1+2 
sCJD3 MM 1 1 1 1 1 
sCJD4 MM 0 1 0 0 1 
sCJD5 MM 1 1 1 0 1 
sCJD6 MV 2 2 2 1+2 1+2 
sCJD7 VV 2 2 2 2 2 
sCJD8 MM 1 1 1 1 1 
sCJD9 VV 1 1 1 1 1 
sCJD10 MM 1 1 1 1 1 
sCJD11 MM 1 1 1 1 1 
sCJD12 MV 1+2 1+2 2 1+2 1+2 
sCJD13 MM 0 1 1 0 1 
sCJD14 MM 1 1 1 1 1 
sCJD15 MM 1 1 1 0 1 
sCJD16 MM 1 1 1 1 1 
sCJD17 MM 1+2 1 1 1 1+2 
sCJD18 MM 1 1 1 1 1 
sCJD19 MM 1 1 1 1 1 
sCJD20 MM 2 2 2 0 2 
sCJD21 MM 2 2 2 2 2 
sCJD22 MM 1 1 1 1 1 
sCJD23 MV i+2 2 2 i+2 i+2 
sCJD24 VV 2 2 2 2 2 
sCJD25 MM 1 1+2 1 1+2 1+2 
sCJD26 MM 1 1 1 1 1 
sCJD27 MM 1 1 1 1 1 
sCJD28 MM 1 1 1 0 1 
sCJD29 MM 1+2 2 2 2 1+2 
sCJD30 MM 0 2 2 1+2 1+2 
sCJD31 MM 1 1 1 1 1 
sCJD32 VV 2 2 2 2 2 
sCJD33 MM 1 1 1 1 1 
sCJD34 MV 1 1 1 1 1 
sCJD35 MM 1 1 1 1 1 
sCJD36 VV 2 2 2 2 2 
v 
 
sCJD37 MM 1 1 1 0 1 
sCJD38 VV 2 2 2 2 2 
sCJD39 MV 2 2 2 i+2 i+2 
sCJD40 VV 2 2 2 2 2 
sCJD41 MM 1 1 1 1 1 
sCJD42 MM 1 1 1+2 1+2 1+2 
sCJD43 MV 2 2 2 2 2 
sCJD44 MM 1 1 1 1 1 
sCJD45 MV 1 1 1 1 1 
sCJD46 MM 1 1 1 1 1 
sCJD47 MM 1 1 1 1 1 
sCJD48 MM 1 1 1 0 1 
sCJD49 MM 1 1 1+2 1 1+2 
sCJD50 MM 1 1 1 1 1 
sCJD51 MM 1 1 1 1+2 1+2 
sCJD52 MM 1 1 1 1 1 
sCJD53 MM 1 1 1 1 1 
sCJD54 MM 1 1 1 1 1 
sCJD55 MV 2 2 2 i+2 i+2 
sCJD56 MM 1 1 1 1 1 
sCJD57 MM 1 1 1 1+2 1+2 
sCJD58 MV 2 1+2 1+2 1+2 1+2 
sCJD59 MM 1 1 1 0 1 
sCJD60 MM 1 1 1 1 1 
sCJD61 MM 1 1 1 1 1 
sCJD62 MM 1+2 1+2 1+2 1+2 1+2 
sCJD63 VV 2 2 2 2 2 
sCJD64 MM 1 1+2 1+2 1+2 1+2 
sCJD65 MV 0 0 0 1 1 
sCJD66 MV i+2 i+2 2 i+2 i+2 
sCJD67 MM 2 2 0 1+2 1+2 
sCJD68 MM 2 2 2 2 2 
sCJD69 MM 1 1+2 1+2 1 1+2 
sCJD70 MV 1+2 1 1+2 1+2 1+2 
sCJD71 MM 1+2 1+2 1+2 1+2 1+2 
sCJD72 MM 1 1 1 1 1 
sCJD73 MM 1 1 1 1 1 
sCJD74 MM 1 1 1 1 1 
sCJD75 MM 1 1 1 1 1 
sCJD76 MV 2 2 2 2 2 
sCJD77 VV 2 2 2 2 2 
sCJD78 VV 2 2 2 2 2 
sCJD79 VV 2 2 2 2 2 
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sCJD80 MV 2 2 2 2 2 
sCJD81 MM 1 1+2 1+2 1 1+2 
sCJD82 VV 0 2 2 2 2 
sCJD83 VV 0 0 0 2 2 
sCJD84 MV 0 0 0 2 2 
sCJD85 MV 1 1 1 0 1 
sCJD86 MM 1 1 1 1 1 
sCJD87 VV 2 2 2 2 2 
sCJD88 MM 1+2 1+2 1 1+2 1+2 
sCJD89 MM 1 1 1 1 1 
sCJD90 MM 1 1+2 1+2 1 1+2 
sCJD91 MV 1+2 1+2 1+2 1+2 1+2 
sCJD92 MM 1 1 1 1 1 
sCJD93 MM 1 1 1 1 1 
sCJD94 MM 1 1 1 0 1 
sCJD95 MV 2 2 2 2 2 
sCJD96 VV 1 1+2 0 1+2 1+2 
sCJD97 MM 1 1 1 1 1 
sCJD98 MM 1+2 1+2 1 1+2 1+2 
sCJD99 VV 2 2 0 2 2 
sCJD100 MV 2 2 2 0 2 
sCJD101 MM 1 1 0 1 1 
sCJD102 MM 1 1 1 1 1 
sCJD103 MM 1 1 1 1 1 
sCJD104 MM 1 1 0 0 1 
sCJD105 MM 1 1 1 1 1 
sCJD106 MM 1 1 1 1 1 
sCJD107 MM 2 1+2 1 1+2 1+2 
sCJD108 MM 1 1 1 1 1 
 
Abbreviations: Cb: cerebellum; M: methionine; OC: occipital cortex, PC: parietal 
cortex, PRNP: prion protein gene; sCJD: sporadic Creutzfeldt-Jakob disease; TC: 
temporal cortex, Th: thalamus; V: valine 
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Appendix 4. Tissue processing 
 
4.1. CNS tissue processing 
Using the Class 1 Cabinet, the 15% unbuffered formalin (GENTA MEDICAL, York, 
UK, catalogue F40050) from the trimmed tissue blocks and cassettes was drained and 
replaced with 96% formic acid (Fischer Scientific, Loughborough, UK, catalogue 
10478020), for 1h.  Following formic acid treatment, the tissue and cassettes were 
washed with 2 or 3 changes of tap water (5min each), and placed into stainless steel 
baskets for processing. The processing schedule for CNS tissue using the Tissue Tek 
VIP 6 (Sakura, Thatcham, UK, catalogue 6032) was as follows: 
 
Solution                     Time Temperature (C) Pressure/Vacuum 
      Cycle 
15% formaldehyde         2 h        35         YES 
80% alcohol                2 h        35          YES 
90% alcohol                2 h        35          YES 
74 IMS               2 h        35         YES 
Absolute alcohol (3 changes) 2 h       35         YES 
Xylene (3 changes)      2 h        35          NO 
Wax                   2 h        60          NO 
Wax (3 changes)          2 h       60         YES 
 
Total processing time = 28 h 
(h: hours, C: centigrade, IMS: Industrial methylated spirit) 
Once the cycle was completed the baskets were removed and the tissue placed into 
fresh wax (Tek III paraffin wax, Sakura, Thatcham, UK, catalogue 4509) in the Tissue-
Tek 5 Embedding Centre and coldplate (Sakura, Thatcham, UK, catalogue 5229).  
Processing fluids: Formaldehyde 40%, Ethanol solution (IDA 99%) and Xylene all 
from Genta Medical, York, UK, (catalogue numbers F40050, 199050 and XYL050), 
Ethanol 100% from Haymankimia, Witham, UK (catalogue DRA 00020001). 
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4.2. Non-CNS tissue processing 
 
Using the Class 1 Cabinet, the 15% unbuffered formalin (GENTA MEDICAL, York, 
UK, catalogue F40050) from the trimmed tissue blocks and cassettes was drained and 
replaced with 96% formic acid (Fischer Scientific, Loughborough, UK, catalogue 
10478020), for 1h.  Following formic acid treatment, the tissue and cassettes were 
washed with 2 or 3 changes of tap water (5min each), and placed into stainless steel 
baskets for processing. The processing schedule for CNS tissue using the Tissue Tek 
VIP 6 (Sakura, Thatcham, UK, catalogue 6032) was as follows: 
 
Solution                     Time Temperature (C) Pressure/Vacuum 
      Cycle 
15% formaldehyde         1 h        40         YES 
80% alcohol                1 h        40          YES 
90% alcohol                1 h        40          YES 
74 IMS               1 h        40         YES 
Absolute alcohol (3 changes) 1 h       40         YES 
Xylene (3 changes)      1 h        40         YES 
Paraffin wax (4 changes)        0.75 h       60         YES 
 
Total time = 13 h 
(h: hours, C: centigrade, IMS: Industrial methylated spirit) 
Once the cycle was completed the baskets were removed and the tissue placed into 
fresh wax (Tek III paraffin wax, Sakura, Thatcham, UK, catalogue 4509) in the Tissue-
Tek 5 Embedding Centre and coldplate (Sakura, Thatcham, UK, catalogue 5229).  








Appendix 5. Non-CNS tissues sampled for histology and biochemistry 
 
 
Case Fixed tissues Frozen tissues 
hGH-iCJD2 LN, SP, TG MU, LN, PN, SP 
hGH-iCJD3 DR, MU, PN, PI  
hGH-iCJD4 PI  
hGH-iCJD5 
AG, LN, MU, PI, PN, SP, SY, 
TG 
LN, MU, PI, PN, SP 
hGH-iCJD6 AG, MU, PI, PN, SP MU, PN, SP 
hGH-iCJD7  PI 
hGH-iCJD8 AG, LN, MU, SP  
hGH-iCJD9 PI  
hGH-iCJD10  PI 
hGH-iCJD11 LN, SP, TO  
hGH-iCJD12  PI 
hGH-iCJD13  KI, LU, LV, PA 
hGH-iCJD14 AP, LN, PI, SP, TO  
hGH-iCJD15 AG, AP, DR, DU, LI, LN, MU, 
PI, PN, SP, SY, TO 
AG, AP, BM, DR, HE, K, LN, LU, LV, 
MU, PA, PN, SG, SP, TY, TO 
hGH-iCJD19 AP, MU, PN, PI, SPL, TON SP 
hGH-iCJD20 PI PI 
hGH-iCJD24 PI  
hGH-iCJD27 AG, DR, MU, PN MU, SP 
hGH-iCJD28 PI  
hGH-iCJD29 MU, SI, SP  
hGH-iCJD30 PI  
hGH-iCJD34 SP  
hGH-iCJD35 AP, LN, PI, SP  
hGH-control8 AP, LI, LN, MU, SI, TO  
hGH-control10 AG, AP, PN, SP  
 
 
Abbreviations: AG: adrenal gland; AP: appendix; BM: bone marrow; DR: dorsal root ganglion; DU: 
duodenum: HE: heart; hGH: human growth hormone; KI: kidney; LI: large intestine; LN: lymph 
node; LU: Lung; LV: liver; MU: muscle; PA: pancreas; PI: pituitary; PN: peripheral nerve; SG: 
salivary gland; SI: small intestine; SP: spleen; SY: sympathetic chain; TG: trigeminal ganglion; TO: 





Appendix 6. Microtomy and histological stains 
 
Sections were cut from paraffin-embedded tissue blocks on a microtome (Leica 
Microystems, Milton Keynes, UK, catalogue RM2255) using Accu-Edge Low-
Profile microtome blades (Sakura, Thatcham, UK, catalogue 4689). Sections were 
floated onto a water bath (Section Floatation Bath, Fisher Scientific, Loughborough, 
UK, catalogue E65) at 38oC and picked up on SuperFrost plus microscope slides 
(Fisher Scientific, Loughborough, UK, catalogue 10149870). 
 
6.1. Haematoxylin and eosin staining  
Paraffin embedded tissue sections were deparaffinised in Xylene for 5min followed by 
stepwise re-hydration (5min incubations) in absolute alcohol, 74% industrial 
methylated spirits (IMS) and 70% IMS (see Appendix 1 for sources of Xylene and 
IMS). Sections were immersed in saturated picric acid solution (Sigma-Aldrich, Poole, 
UK, catalogue 197378) for 15min to remove residual formalin pigment and washed 
well in running water. Following removal of the picric acid solution, sections were 
immersed in haematoxylin solution (Leica Biosystems, Milton Keynes, UK, catalogue 
380154E) for 2min before a thorough wash in water. After a single dip in a 1% acid 
alcohol solution (999mls 70% alcohol; 1ml concentrated HCl (Fisher Scientific, 
Loughborough, UK, catalogue 12352301)), sections were dipped three times in lithium 
carbonate solution (300ml tap water; 5-10ml saturated aqueous lithium carbonate 
(Fisher Scientific, Loughborough, UK, catalogue L/2100/50)) and stained in eosin 
solution (Leica Microsystems, Milton Keynes, UK, catalogue 3801600E) for 5min. 
Following a final rinse in water, sections were dehydrated by immersing 
(approximately 10sec) in 70% IMS, 74% IMS and absolute alcohol. Sections were 
cleared in Xylene, cover slipped on a Coverslipper (Leica Microsystems, Milton 
Keynes, UK, catalogue CV 5030) using VHM coverslips number 1 (CellPath, 
Newtown, UK, catalogue SAJ-2450-03A) with Pertex mountant (CellPath Ltd, 
Newtown, UK, catalogue SEA 0100-00A) and left to harden overnight. In order to 
analyse the slides outside the laboratory, sections were immersed in 96% formic acid 
(Fisher Scientific, Loughborough, UK catalogue 10478020) for 5min, washed well in 
water and dried. 
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6.2. Luxol Fast Blue/Cresyl Violet staining  
Paraffin embedded sections were deparaffinised in Xylene for 5min followed by 
stepwise rehydration (5min incubations) in absolute alcohol, 74% industrial 
methylated spirits (IMS) and 70% IMS (see Appendix 1 for sources of Xylene and 
IMS). Tissue sections were immersed in saturated picric acid solution (Sigma-Aldrich, 
Poole, UK, catalogue 197378) for 15min and washed well in running water. Following 
removal of the picric acid solution, sections were immersed in Luxol Fast Blue solution 
(95% alcohol, 0.1% of 10% acetic acid, 0.1% Luxol Fast Blue (Fisher Scientific, 
Loughborough, UK, catalogue 11418356)) and incubated at 60oC for approximately 
3-4h. Tissue sections were differentiated in 0.1% lithium carbonate (Fisher Scientific, 
Loughborough, UK, catalogue L/2100/50) for a few seconds before continuing the 
differentiation in 70% alcohol for approximately 20-30sec. Sections were then rinsed 
well in water, examined under a staining microscope and the differentiation step 
repeated if required. Following the differentiation, tissue sections were washed in 
water and counterstained with Cresyl Violet solution (0.1% Cresyl Violet acetate 
solution (Fisher Scientific, Loughborough, UK, catalogue 10137180) in 1% acetic 
acid). Tissue sections were rinsed in water and further differentiated in 95% alcohol. 
Finally, tissue sections were dehydrated by immersing (for approximately 10sec) in 
70% IMS, 74% IMS and absolute alcohol. Sections were cleared in Xylene, cover 
slipped on a Coverslipper (Leica Microsystems, Milton Keynes, UK, catalogue CV 
5030) using VHM coverslips number 1 (CellPath, Newtown, UK, catalogue SAJ-
2450-03A) with Pertex mountant (CellPath Ltd, Newtown, UK, catalogue SEA 0100-
00A) and left to harden overnight. In order to analyse the slides outside the laboratory, 
sections were immersed in 96% formic acid (Fisher Scientific, Loughborough, UK 
catalogue 10478020) for 5min, washed well in water and dried. 
 
6.3. Bielschowsky silver staining 
Blocks were selected for Bielschowsky silver staining according to the National 
Institute on Aging-Alzheimer’s Association guidelines (Hyman et al., 2012). Paraffin 
embedded CNS sections were deparaffinised in Xylene for 5min followed by stepwise 
rehydration (5min incubations) in absolute alcohol, 74% industrial methylated spirits 
(IMS) and 70% IMS (see Appendix 1 for sources of Xylene and IMS). Tissue sections 
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were immersed in saturated picric acid solution (Sigma-Aldrich, Poole, UK, catalogue 
197378) for 15min and washed well in running water. Following removal of the picric 
acid solution, sections were immersed in filtered 20% silver nitrate (Scientific 
Laboratory Supplies, Nottingham, UK, catalogue CHE3224) solution for 10min before 
washing in distilled water (dH2O) produced using an ELIX 5 CT water purification 
system (Millipore (UK), Watford, UK, catalogue ZLXE0050WW). Sections were 
immersed in freshly prepared silver impregnating solution (ammonia hydroxide 
(Fisher Scientific, Loughborough, UK, catalogue 423305000), added dropwise to 20% 
silver nitrate solution (only adding enough drops to dissolve the dark precipitate that 
initially forms) for 15min. The silver impregnating solution was decanted from tissue 
sections before re-immersing in a solution comprising 20mls impregnating solution 
and 600µl of reducing solution (20ml of 10% formalin, 0.5g citric acid (VWR 
International, Lutterworth, UK, catalogue 20276.235), 50µl concentrated nitric acid 
(Fisher Scientific, Loughborough, UK, catalogue 10381313) , 100mls dH20). Tissue 
sections were stained in this solution for approximately 4-8min until they developed a 
dark brown colour. Following a wash in dH2O, sections were toned in 0.1% gold 
chloride (Scientific Laboratory Supplies, Nottingham, UK, catalogue G4022) for 
approximately 5sec, washed in dH2O and fixed in 5% sodium thiosulphate (Scientific 
Laboratory Supplies, Nottingham, UK, catalogue 217263) for 5min. Finally, sections 
were thoroughly washed in dH2O and counterstained with neutral red solution 
(Scientific Laboratory Supplies, Nottingham, UK, catalogue CHE2624) for 30sec. 
Following a final rinse in water, sections were de-hydrated by immersing 
(approximately 10sec) in 70% IMS, 74% IMS and absolute alcohol. Sections were 
cleared in Xylene, cover slipped on a Coverslipper (Leica Microsystems, Milton 
Keynes, UK, catalogue CV 5030) using VHM coverslips number 1 (CellPath, 
Newtown, UK, catalogue SAJ-2450-03A) with Pertex mountant (CellPath Ltd, 
Newtown, UK, catalogue SEA 0100-00A) and left to harden overnight. In order to 
analyse the slides outside the laboratory, sections were immersed in 96% formic acid 
(Fisher Scientific, Loughborough, UK catalogue 10478020) for 5min, washed well in 
water and dried. 
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Appendix 7. Antibodies used in this thesis  
Antibody 
clone 
Antigen Specificity Source Protocol 
















































AT8 Human PHF-tau Thermo Scientific, UK 
Product:MN1020B 
IHC 
11-9 Human phospho TDP-43 2BScientific, UK 
Product: TIP-PTD-M01 
IHC 
3F4 Human prion protein 
 (Epitope 109-112) 
Cambridge Bioscience, UK 
Product: SIG-39640 
IHC, PET blot 
3F4 Human prion protein 
 (Epitope 109-112) 




12F10 Human prion protein 
 (Epitope 142-160) 
Bertin pharma, UK 
Product: A03221 
IHC, PET blot 
KG9 Human prion protein 
(Epitope 140-180) 




12B2 Human prion protein 
(Epitope 89-93) 
Central Veterinary Institute 
of Wageningen UR, 
Lelystad, Netherlands 
WB 
PGM1 CD 68  
 
Dako, UK 
Product: M 0876 
IHC 
GFAP Glial fibrillary acidic 
protein (GFAP) 
Dako, UK 
Product: M 0876 
IHC 




Abbreviations: A: amyloid beta; apoE: apolipoprotein E; CD68: cluster of differentiation 68; CDI: 
conformation-dependent immunoassay; IHC: immunohistochemistry; NaPTA: western blotting 
following sodium phosphotungstic acid precipitation; PMCA: protein misfolding cyclic amplification; 
TDP-43: transactive response DNA binding protein 43; WB: western blotting 
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Appendix 8. Immunohistochemistry protocols  
 
8.1. Immunohistochemistry 
Paraffin embedded tissue sections were deparaffinised in Xylene for 5 min followed 
by stepwise re-hydration in absolute alcohol, 74% IMS and 70% IMS (5min 
incubations) (see Appendix 1 for sources of Xylene and IMS). Endogenous peroxidase 
activity was blocked by immersing sections in 1% hydrogen peroxidise (Fisher 
Scientific, Loughborough, UK, catalogue BP2633-500) in methanol (Fisher Scientific, 
Loughborough, UK, catalogue M/3950/17) for 30min. Following a thorough wash in 
water, various pre-treatment protocols were performed, specific for each antibody, as 
detailed in Appendix 4. Following the pre-treatment protocol, tissue sections were 
washed thoroughly in water and incubated for 5min in Tris-buffered saline (TBS) 
(50mmol Tris-HCl (VWR, Lutterworth, UK, catalogue 10354M); 150mmol NaCL 
(VWR International, Lutterworth UK, catalogue 27810295); pH 7.6) before incubating 
with the primary antibodies at the dilution and time detailed in Table 4.1. After 3 x 
5min washes in TBS, immunolabelling was completed using the NovolinkTM Polymer 
Detection System (Leica Microsystems, Milton Keynes, UK, catalogue RE7280-K) 
with 30min incubations in the post primary and NovolinkTM polymer reagents. Washes 
in TBS were carried out between each reagent. After a final wash, staining was 
visualised with 3, 3’ diaminobenzidine (DAB). The DAB was prepared immediately 
before use from NovolinkTM Polymer Detection Kit (1ml of NovolinkTM DAB 
substrate buffer (Polymer); 50µl DAB chromagen). Sections were washed well in 
water before lightly counterstained (immerse in haematoxylin solution for 20sec, wash 
in water, dip once in a 1% acid alcohol solution, rinse in water and dip four times in 
saturated aqueous lithium carbonate solution). After a wash in water sections were 
dehydrated by immersing (approximately 10sec) in 70% IMS, 74% IMS and absolute 
alcohol. After clearing in Xylene, sections were cover slipped on a Coverslipper (Leica 
Microsystems, Milton Keynes, UK, catalogue CV 5030) using VHM coverslips 
number 1 (CellPath, Newtown, UK, catalogue SAJ-2450-03A) with Pertex mountant 
(CellPath Ltd, Newtown, UK, catalogue SEA 0100-00A) and left to harden overnight. 
In order to analyse the slides outside the laboratory, sections were immersed in 96% 
xv 
 
formic acid (Fisher Scientific, Loughborough, UK, catalogue 10478020) for 5min, 
washed well in water and dried. 
 
8.2. Double immunohistochemistry 
To investigate the co-localisation of PrP, CD68, phospho-tau and GFAP with Aβ 
deposits, paraffin embedded tissue sections were deparaffinised in Xylene for 5min 
followed by stepwise re-hydration in absolute alcohol, 74% IMS and 70% IMS (5min 
incubations) (see Appendix 1 for sources of Xylene and IMS). Endogenous peroxidase 
activity was blocked by immersing sections in 1% hydrogen peroxidise (Fisher 
Scientific, Loughborough, UK, catalogue BP2633-500) in methanol (Fisher Scientific, 
Loughborough, UK, catalogue M/3950/17) for 30min.  
 
Following a thorough wash in water, the pre-treatment protocol required for the 12F10 
anti-PrP/6F3D anti-Aβ antibody (hydrated autoclaving, formic acid treatment and 
proteinase K digestion); PGM1 anti-CD68/6F3D anti-Aβ antibody (microwaving in 
citric acid and formic acid); AT8 anti-phospho-tau/6F3D anti-Aβ antibody 
(microwaving in citric acid and formic acid); or GFAP anti-GFAP/6F3D anti-Aβ 
antibody (formic acid)  was performed as detailed in Appendix 4. Following the pre-
treatment protocol, tissue sections were washed thoroughly in water and incubated for 
5min in Tris-buffered saline (TBS) (50mmol Tris-HCl (VWR, Lutterworth, UK, 
catalogue 10354M); 150mmol NaCL (VWR International, Lutterworth UK, catalogue 
27810295) ; pH7.6). 
 
Immunohistochemistry for the prion protein, CD68 and phospho-tau was performed 
first using in combination with the Vectastain Elite ABC HRP (Peroxidase, Mouse 
IgG) Kit (Vector Laboratories, Peterborough, UK, catalogue PK-6102). All reagents 
were prepared as per manufacturer’s instructions. All sections were blocked in normal 
horse serum for 20min before incubation in the primary antibody; 12F10 at a dilution 
of 1/800, PGM1 at a dilution of 1/50 and AT8 at a dilution of 1/100 in TBS for 1h. 
After 3 x 5min washes in TBS, sections were incubated in the anti-mouse IgG 
biotinylated antibody for 1h before a further 3 x 5min washes. Sections were then 
incubated in the Vectastain ABC reagent for 30min before a final 3x5min washes in 
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TBS. Staining was visualised with 3,3’ diaminobenzidine (DAB). The DAB was 
prepared immediately before use from NovolinkTM Polymer Detection Kit (1ml of 
NovolinkTM DAB substrate buffer (Polymer); 50µl DAB chromagen) (Leica 
Microsystems, Milton Keynes, UK, catalogue RE7280-K). Immunohistochemistry for 
GFAP was performed in combination with the Vectastain Elite ABC HRP (Peroxidase, 
Rabbit IgG) Kit (Vector Laboratories, Peterborough, UK, catalogue PK-6101). All 
reagents were prepared as per manufacturer’s instructions. All sections were blocked 
in normal goat serum for 20min before incubation in the primary antibody; GFAP at a 
dilution of 1/800 in TBS for 1h. After 3 x 5min washes in TBS, sections were incubated 
in the anti-rabbit IgG biotinylated antibody for 1h before a further 3 x 5min washes. 
Sections were then incubated in the Vectastain ABC reagent for 30min before a final 
3 x 5min washes in TBS. Staining was visualised with 3, 3’ diaminobenzidine (DAB). 
The DAB was prepared immediately before use from NovolinkTM Polymer Detection 
Kit (1ml of NovolinkTM DAB substrate buffer (Polymer); 50µl DAB chromagen) 
(Leica Microsystems, Milton Keynes, UK, catalogue RE7280-K). Sections were 
washed well in water before incubating in TBS for 5min.  
 
Staining was continued for Aβ protein. Sections were blocked in normal rabbit serum 
(Vector Laboratories, Peterborough, UK, catalogue S-5000) diluted 1/5 in TBS for 
20min before incubating in the primary antibody 6F/3D at a dilution of 1/250 overnight 
a room temperature. After 3 x 5min washes in TBS, sections were incubated in a biotin-
SP-conjugated affinity pure rabbit anti-mouse IgG antibody (Jackson Immunoresearch 
Laboratories Inc, Baltimore, USA, catalogue 315-065-003) at a dilution of 1/400 in 
TBS for 1h. Sections were further washed in TBS before a final incubation in 
Vectastain ABC alkaline phosphatase standard (Vector Laboratories, Peterborough, 
UK, catalogue AK-5000) prepared as per instructions ( 2 drops of reagent A and 2 
drops of reagent B in 10 mls of TBS) for 30min. Sections were washed in thoroughly 
in TBS before staining with Vector red alkaline phosphatase substrate kit (Vector 
Laboratories, Peterborough, UK, catalogue PK-SK-5100) prepared according to 
instructions (to 5ml of 200mmol Tris-HCL add 2 drops of reagent 1, 2 drops of reagent 
2 and 2 drops of reagent 3). Sections were washed well in water before lightly 
counterstained (immerse in haematoxylin solution for 20sec, wash in water, dip once 
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in a 1% acid alcohol solution, rinse in water and dip 4 times in saturated aqueous 
lithium carbonate solution). After a wash in water sections were dehydrated by 
immersing (approximately 10sec) in 70% IMS, 74% IMS and absolute alcohol. After 
clearing in Xylene, sections were cover slipped on a Coverslipper (Leica 
Microsystems, Milton Keynes, UK, catalogue CV 5030) using VHM coverslips 
number 1 (CellPath, Newtown, UK, catalogue SAJ-2450-03A) with Pertex mountant 
(CellPath Ltd, Newtown, UK, catalogue SEA 0100-00A) and left to harden overnight. 
In order to analyse the slides outside the laboratory, sections were immersed in 96% 
formic acid (Fisher Scientific, Loughborough, UK, catalogue 10478020) for 5min, 
washed well in water and dried. 
 
Abbreviations: A: amyloid beta; CD68: cluster of differentiation 68; PrP: prion protein 
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Appendix 9. PET blot protocol 
 
5µm formalin fixed, paraffin embedded tissue sections were blotted onto a 0.45µm 
nitrocellulose membrane (Bio-Rad, Hemel Hempstead, UK, catalogue 9004700) and 
dried at 55oC overnight. The tissue sections were deparaffinised in Xylene for 10min 
followed by re-hydration with 5min incubations in 95%, 85% and 70% propan-1-ol 
(Scientific Laboratory Supplies, Nottingham, UK, catalogue CHE3104). Following re-
hydration, the membranes were air-dried before a thorough wash in TBST (10mmol 
Tris HCl (VWR International, Lutterworth UK, catalogue 10354M) pH 7.8, 100mmol 
NaCl (VWR International, Lutterworth UK, catalogue 27810295), 0.05% Tween 20 
(Sigma-Aldrich, Poole, UK, catalogue P9416)) until membranes were fully saturated. 
Membranes were incubated at 55oC overnight in 25µg/ml proteinase K (Roche 
Diagnostics, West Burgess, UK, catalogue 03115 836 001) in digestion buffer 
(10mmol Tris HCl (VWR International, Lutterworth UK, catalogue 10354M) pH 7.8, 
100mmol NaCl (VWR International, Lutterworth, UK, catalogue 27810295), 0.1% 
Brij (Sigma-Aldrich, Poole, UK; catalogue B4184)), a step which ensures the complete 
digestion of PrPC in the tissue sections, leaving only PrPres.  
 
Following protease digestion, membranes were washed in TBST before treating with 
3M guanadine isothiocynate (Sigma-Aldrich, Poole, UK, catalogue  G6639) for 
10min. After a further three washes in TBST, membrane bound tissues were blocked 
in casein (Vector Laboratories, Peterborough, UK, catalogue SP5020) for 30min 
before incubated for 1h with the primary antibodies (12F10, 1/22 000; 3F4, 1/500) 
diluted in casein. After 3 x 5min washes in TBST, immunolabelling was completed 
using the Vectastain ABC-AmP kit (Vector Laboratories, Peterborough, UK, 
catalogue AK-6400), with a 1h incubation in reagent A (streptavidin solution) and a 
30min incubation in reagent B (biotinylated alkaline phosphatase). Washes in TBST 
were carried out between each reagent. After a final wash, staining was visualised with 
5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (NBT/BCIP) (Vector 
Laboratories, Peterborough, UK, catalogue SK-5400). Membrane bound sections were 
washed thoroughly in water, air dried and mounted for analysis. 
Abbreviations: PrPC: cellular prion protein; PrPres: protease-resistant prion protein. 
xix 
 
Appendix 10. DNA Extraction protocols and PRNP codon 129 analysis 
 
10.1. DNA extraction from frozen tissues 
DNA was extracted from unfixed grey matter-enriched frozen brain tissue samples 
(20-30mg) of the cerebellar cortex or frontal cortex using the Qiagen DNeasy Blood 
and Tissue kit (Qiagen, Hilden, Germany, catalogue number 69504; www.qiagen.com 
for Handbook). Unless referenced, all reagents and consumables used in the following 
DNA extraction protocol are from this Qiagen DNeasy Blood and Tissue kit.  To lyse 
the tissue, each sample was placed into a 1.5ml microcentrifuge tube (Sarstedt, Cat# 
72.607.772) in 180μl of ATL buffer and 20μl of Proteinase K, and incubated overnight 
at 56 °C. 200l of AL buffer was added to each lysate and briefly vortexed before a 
further incubation at 70oC for 10min. 200l of ethanol was added to the sample and 
vortexed again. To bind the DNA, each lysate was pipetted into a DNeasy Minispin 
column (complete with 2ml collection tube) and this spin column was centrifuged at 
8,000 rpm for 1min. The flow-through and collection tube were discarded and the 
DNeasy Minispin column was placed in a new 2ml collection tube. To wash the DNA, 
500l of buffer AW1 was added to the column and was again centrifuged at 8,000 rpm 
for 1min. The flow-through and collection tube were again discarded, the collection 
tube replaced and 500l of buffer AW2 was added. The column was then centrifuged 
for 3min at 1,4000 rpm to complete the wash and to dry the DNeasy membrane. 
 
10.2. DNA extraction from paraffin-embedded tissues 
A similar protocol to Appendix 5 was followed after these pre-treatment steps: Up to 
25mg of paraffin-embedded tissue were cut as 10m sections and placed in a 2ml 
microcentrifuge tube. 1200l Xylene (Genta Medical, York, UK, catalogue XYL050) 
was added. The tube was vortexed vigorously, centrifuged for 5min at 1,4000 rpm and 
without disturbing the pellet, the supernatant was decanted.  To remove any residual 
xylene from the remaining pellet, 1200l ethanol (96-100%) (Haymankimia, Witham, 
UK, catalogue DRA 00020001) was added to the tube. The tube was vortexed, 
centrifuged for 5min at 1,4000 rpm and the ethanol was decanted. The ethanol wash 
step was repeated and after the third period of centrifuging, the microcentifuge tube 
was opened, the ethanol decanted and the tube incubated at 37°C for 10-15min, or until 
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the ethanol had evaporated. The tissue pellet was then ready to be re-suspended in 
180μl of ATL buffer and treated to the same protocol as above in  Appendix 7.1 ‘DNA 
extraction from frozen tissues’ using the Qiagen DNeasy Blood and Tissue kit 
(Qiagen, Hilden, Germany, catalogue 69504). 
 
The method of Nicoll et al. (Nicoll et al., 1997) was also used in an attempt to extract 
DNA from paraffin-embedded tissues. Briefly, 1ml Xylene (Genta Medical, York, 
UK, catalogue XYL050) was added to a reaction tube containing 1-5 10m tissue 
sections of cerebellar cortex from each case. The tubes were vortexed for 1min and 
centrifuged for 3min at 13,000 rpm, and the Xylene was decanted. 1ml ethanol 
(Haymankimia, Witham, UK, catalogue DRA 00020001) was added to each tube. The 
tubes were vortexed for 1min, centrifuged for 3min and the ethanol was decanted. The 
ethanol wash was repeated and residual ethanol was removed by overnight 
evaporation. 50l of proteinase K (800g/ml) (Roche Diagnostic, West Burgess, UK, 
catalogue 03 115 828 001), 20l 10x PCR buffer (Qiagen, Hilden, Germany, catalogue 
203203) and 130l Analar water (VWR International, Lutterworth, UK, catalogue 
10292) were added to each sample. The solutions were overlaid with 100l mineral 
oil and incubated at 37 °C overnight. The samples were then heated to 95°C to 
inactivate the proteinases; the resulting solution was used for DNA analysis. 
 
10.3. PCR of the prion protein gene for codon 129 analysis 
Using a PCR cabinet, a PCR reaction mix was prepared in a sterile 1.5ml 
microcentrifuge tube. The following reagents were used and the volumes were 









Reagent             Final concentration
        
10x PCR Buffer (+ 15mmol MgCl2)          1x PCR Buffer 
(Qiagen, Hilden, Germany, catalogue 203203)     
PCR Nucleotide Mix         0.2mmol 
(Promega, Southampton, UK, catalogue C1141).     
Primer Pair (A2/A3)           5pmol 
Primer A2 (forward): TGA TAC CAT TGC TAT GCA CTC ATT C 
Primer A3 (reverse): GAC ACC ACC ACT AAA AGG GCT GCA G 
HotStarTaq DNA Polymerase            1 Unit 
(Qiagen, Hilden, Germany, catalogue 203203)      
dH20 (Sigma-Aldrich, Poole, UK, catalogue W3513)          81.8µl per reaction. 
 
The PCR reaction mix was inverted to ensure homogeneity and 97µl was aliquoted 
into each 0.5ml PCR tube (Axygen, Loughborough, UK, catalogue AX-PCR-05-C). 
The tubes were transferred to a Class II Cabinet where 3µl of DNA template, acquired 
from the previous DNA extraction method, was added to each PCR tube bringing the 
total volume to 100µl. A negative control was included by adding 3µl of dH20 (Sigma-
Aldrich, Poole, UK, catalogue W3513) to one of the PCR tubes, and the positive 
controls were included by adding 3µl of known DNA templates (MM, MV and VV) 
to a further three PCR tubes. After the addition of the DNA template, the tubes were 
placed on the T3000 Thermocycler (Biometra, Gottingen, Germany, catalogue 050-












PCR Programme (PRPA2A3)  
1. 95C 15min 
2. 94C 1min 
3. 65C 1min (decrease 0.5C per cycle) 
4. 72C 2min 
5. Go to step 2 - 10 times 
6. 94C 45sec 
7. 60C 30sec 
8. 72C 1min 
9. Go to step 6 - 30 times 
10. 72C 15min 
11. 4C Held until completion 
12. END 
 
10.4. NspI restriction fragment length polymorphism digest for codon 129 analysis 
The digest reaction mix was prepared in a 0.5ml PCR tube (Axygen, Loughborough, 
UK, catalogue AX-PCR-05-C) using the following reagents, the total volumes were 
calculated by multiplying by the number of reactions required. 
 
Reagent                       Volume per  
    reaction tube 
CutSmart® Buffer (New England Biolabs, Hitchin, UK, catalogue B7204S)  1.0µl 
dH20 (Sigma-Aldrich, Poole, UK, catalogue W3513)       5.6µl   
NspI (5U/µl) (New England Biolabs, Hitchin, UK, catalogue R0602S)     0.4µl 
 
The digest reaction mix was inverted to ensure homogeneity and 7µl was aliquoted 
into each 0.2ml PCR tube (Axygen, Loughborough, UK, catalogue AX-PCR-02-C). 
For each digest, 3µl of the PCR reaction was added to the tube bringing the total 
volume to 10µl. The tubes were placed on the T3000 Thermocycler, using the Digest 
Program 37DEGDIG (37C, 8 h). On completion, the digest products were stored in 
the fridge at 4C until required. 
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10.5. Agarose gel electrophoresis of amplified PCR products and restriction digest 
products for codon 129 analysis 
Ultrapure Agarose (Invitrogen, Loughborough, UK, catalogue 16500100) was 
weighed out and combined with 1 x UltraPure™ TBE Buffer (Invitrogen, 
Loughborough, UK, catalogue 15581044) to make a 1.5% agarose gel. The solution 
was heated in the microwave until the agarose had melted completely and was clear of 
small bubbles. The solution was cooled under running water until hand hot, SYBR® 
Safe DNA Gel Stain 10000X (Invitrogen, Loughborough, UK, catalogue S33102) was 
added at a final concentration of 1:10000 and the bottle agitated gently until mixed. 
Using the Mini-Sub Cell GT Horizontal Electropheresis System (Bio-Rad, Hemel 
Hempstead, UK, catalogue 1704467), the melted agarose solution was poured into the 
casting try, the combs were inserted and the gel was left to set for 45min. The gel was 
transferred to the electrophoresis tank, the wash tank was filled with 1 x UltraPure™ 
TBE Buffer (Invitrogen, Loughborough, UK, catalogue 15581044) to submerge the 
gel and the combs were removed. 5µl of Gel Loading Buffer (Sigma-Aldrich, Poole, 
UK, catalogue G2526) was added to each sample before being loaded onto the gel with 
1µl of 100bp Ladder (Life Technologies, Paisley, UK, catalogue 15628019) being 
loaded at the beginning of each comb. Electrophoresis was performed at 100V for 1h 
so that the dye front has migrated ~5cm. Once complete, an image of the gel was 
captured using the UV setting on the ChemiDoc XRS+ system (Bio-Rad, Hemel 
Hempstead, UK, catalogue 1708256). 
 
Abbreviations: A:adenine; bp: base pair; C:cytosine; G; guanine; PCR: polymerase chain reaction;  
PRNP: prion protein gene; T: thymine; UV ultraviolet light; V: volts 
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Appendix 11. Western blot analysis for PrPres 
 
11.1. Preparation of PrPres from frozen brain tissue 
Preparation of tissue for Western blot analysis was carried out in a Class 1 
Microbiological Safety Cabinet within the High Risk Laboratory of NCJDRSU. A 
small piece (approximately 100mg) of frozen grey matter enriched brain tissue was 
sampled and placed in a sterile 2ml Eppendorf tube (Fisher Scientific, Loughborough, 
UK, catalogue 10038760) on ice. The precise weight of each brain sample was 
recorded and sufficient lysis buffer with high buffer capacity (LB100) (100mmol Tris 
(Sigma-Aldrich, Poole, UK, catalogue TRIS-OR) pH6.9 at 37oC; 100mmol NaCL 
(VWR International, Lutterworth, UK, catalogue 27810295), 10mmol 
ethylenediamine tetra-acetic acid (EDTA) (Sigma-Aldrich, Poole, UK, catalogue E-
4884), 0.5% Nonident P-40 (Fisher Scientific, Loughborough, UK, catalogue 19628); 
0.5% sodium deoxycholate (Sigma-Aldrich, Poole, UK, catalogue 30970) added to 
give a 10% mass per volume brain homogenate. Tissues were then homogenised in the 
LB100 using a disposable micropestle. Insoluble material was pelleted by spinning at 
2,000 rpm for 5min at 4oC using a microcentrifuge (Eppendorf AG, Stevenage, UK, 
catalogue 5417R) with a fixed angle motor (Eppendorf AG, Stevenage, UK, catalogue 
F-45-30-11). The supernatant was aspirated using an aerosol resistant tip into a fresh 
1.5ml Eppendorf tube (VWR International, Lutterworth, UK; 2112139) and the 
remaining pellet frozen at -20oC. A 0.2ml volume of the supernatant was then aspirated 
into a fresh Eppendorf tube and proteinase K (PK) (Roche Diagnostics, West Burgess, 
UK, catalogue 03 115 828 001) added to a final specific activity of 10U/ml. PK treated 
samples were then incubated at 37oC for 1h before stopping the reaction with the 
addition of Pefabloc™ (Roche Diagnostics, Burgess Hill, UK, catalogue 
11429868001) to a final concentration of 1mmol. The PK treated sample along with 
any residual supernatant were frozen at -20oC until required. 
 
11.2. SDS-PAGE and Western blot transfer  
PK treated samples were thawed and given a brief vortex before removing a 5µl 
volume and adding to 2.5µl of 4X NuPAGE LDS sample buffer (Fisher Scientific, 
Loughborough, UK, catalogue NP0007), supplemented with 2.5µl of LB100 buffer. 
After a brief vortex, samples were denatured by boiling at 100oC for 10min before a 
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brief spin at 14,000 rpm. In addition to the human diagnostic reference standards, 
protein molecular weight markers were included in each run (1µl Magic MarkerTM XP 
(Fisher Scientific, Loughborough, UK, catalogue LC5602); 5µl Benchmark (Fisher 
Scientific, Loughborough, UK, catalogue 10748-010); 1.5µl of LB100 buffer; 2.5µl of 
NuPAGE LDS sample buffer). Molecular weight markers were not boiled. Samples 
were electrophoretically separated on NuPAGETM NovexTM 10% Bis-Tris Protein Gels 
(Fisher Scientific, Loughborough, UK  catalogue NP0301BOX) by running at 200V 
(constant current) for 55min in 1X NuPAGE MES running buffer (50mls 20X running 
buffer (Fisher Scientific, Loughborough, UK, catalogue NP0002-02); 950ml dH2O) 
within a Western blot running tank. Proteins separated by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) were electrotransferred onto 
polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hemel Hempstead, UK, 
catalogue 1620177) at 30V (constant current) for 1h using the NuPAGE transfer 
system. Transfers were carried out in 1X NuPAGE transfer buffer (25ml 20X 
NuPAGE transfer buffer (Fisher Scientific, Loughborough, UK, catalogue NP0006-
1); 375ml dH2O, 100ml methanol). 
 
11.3. Detection of PrPres bound to PDVF membrane  
Membranes were rinsed in TBS-T (100mls 10X TBS (Sigma-Aldrich, Poole, UK, 
catalogue T5912); 900ml dH2O; 0.1% Tween 20 (Sigma-Aldrich, Poole, UK, 
catalogue P2287)) before incubating in 5% powdered milk (from a supermarket)/TBS-
T for 45min at room temperature or overnight at 4oC to block non-specific binding 
sites. Membranes were then washed (3 x 5min) in TBS-T prior to incubating in the 
primary anti-PrP antibody 3F4 (Millipore, Watford, UK, catalogue MAB1562) at a 
final concentration of 75ng/mL, or the monoclonal antibody 12B2 (Central Veterinary 
Institute of Wageningen UR, Lelystad, The Netherlands) at a final concentration of 
200ng/ml for 1h at room temperature. After a further wash, immunolabelling was 
completed by incubating the membrane in the Amersham ECL Mouse IgG, HRP-
linked F(ab')₂ fragment (from sheep)  (GE Healthcare Life Sciences, Little Chalfont, 
UK, catalogue NA9310-1ML) diluted 1:25,000 in TBS-T for 1h at room temperature. 
Immunodetection was carried out by incubating the membrane with the 
chemiluminescent substrate ECL 2 (50µl of reagent B per 2 ml of reagent A (Fisher 
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Scientific, Loughborough, UK, catalogue 80196)). After draining off the excess ECL 
plus, membranes were exposed to Hyperfilm ECL (GE Healthcare, Little Chalfont, 
UK, catalogue 28-9068-37) for 30sec, 3min and 30min before the films were 
developed in an automatic film hyperprocessor (Konica Minolta SRX-101A medical 
film processor).   
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Appendix 12. Western blotting with NaPTA precipitation 
 
Samples of frozen non-CNS tissues were weighed and placed into Lysing matrix D 
tubes (Fisher Scientific, Loughborough, UK, catalogue MB116913050). These 
samples were homogenised in ice-cold 2% sarkosyl/phosphate buffered saline pH 7.4 
(PBS) (Sigma Aldrich, Poole, UK, catalogue 11666789001) containing 2% N-
Laurosarcosine, (Sigma Aldrich, Poole, UK, catalogue 61745). An appropriate volume 
of homogenisation buffer was used to give a final tissue concentration of 10% (mass 
per volume). The tissue was homogenised in a Fastprep-24 homogeniser (MP 
Biomedicals, Santa Ana, CA, USA, catalogue 116004500) at room temperature using 
three cycles of 45sec at a speed of 6ms-1. Cellular debris was cleared from the 
homogenates by centrifugation at 5200g at 4°C for 5min using a microcentrifuge 
(Eppendorf AG, Stevenage, UK, catalogue 5417R) with a fixed angle motor 
(Eppendorf AG, Stevenage, UK, catalogue F-45-30-11). The cleared homogenate was 
transferred to a fresh tube and either stored at -80ºC, or immediately subjected to 
sodium phosphotungstic acid (NaPTA) precipitation.  
 
12.1. NaPTA precipitation 
The cleared 10% homogenates of the non-CNS tissues were each diluted to 5% with 
2% N-Laurosarcosine/PBS. Cleared spleen tissue homogenate (5%) from a patient 
proven not to have any form of human prion disease was used as a non-CJD 
neurological negative control. In addition, iCJD or sCJD brain tissue homogenate 
(10%, 10l, corresponding to 100g brain) was diluted and mixed into 1ml of 5% 
cleared non-CJD spleen tissue homogenate, for use as positive control. The 5% cleared 
peripheral tissue homogenates (each 1ml) and the abovementioned positive and 
negative controls were incubated at 37ºC for 10min. To degrade nucleic acids, the 
samples were incubated with 50 Units of benzonaseTM nuclease (Sigma-Aldrich, 
Poole, UK, catalogue E1014) and 1mmol MgCl2 (Sigma-Aldrich, Poole, UK, 
catalogue UKM8266) as a cofactor.  To effect the precipitation of any PrPSc, the 
samples were mixed with 81l of a pH7.4 solution of 4% (mass per volume) NaPTA 
(Sigma-Aldrich, Poole, UK, catalogue 31648) and 170mmol MgCl2 to give final 
concentrations of 0.3% NaPTA and 13.62mmol MgCl2 (including the MgCl2 added in 
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the benzonase step). The samples were incubated at 37ºC for 30min. Precipitated 
protein was pelleted by centrifugation at 21,000 rpm for 30 at 37oC. The pellets were 
resuspended in 20µl of 0.1% N-Laurosarcosine/PBS by breaking the pellets into pieces 
with the pipette tip, and then pipetting up and down repeatedly. Protease sensitive 
protein was eliated from the resuspensions by incubation with 2l of 550g/ml 
proteinase K (PK) (Roche Diagnostics, West Burgess, UK, catalogue 03 115 828 001) 
for 30 at 37C (final PK concentration of 50g/ml). Protease digestion was terminated 
by the addition of 1l of 23mmol PefaBloc SCTM (Sigma-Aldrich, Poole, UK, 
catalogue 76307, final concentration of 1mmol). The proteins in the sample were then 
denatured prior to their electrophoretic separation by mixing with 8l of NuPAGETM 
LDS sample buffer (4x) (Fisher Scientific, Loughborough, UK, catalogue NP0007) 
and incubating at 100C for 10.  
  
12.2. SDS-PAGE and Western blot transfer  following NaPTA precipitation 
Samples were electrophoretically separated on NuPAGETM NovexTM 10% Bis-Tris 
Protein Gels (Fisher Scientific, Loughborough, UK catalogue NP0301BOX) in 1X 
NuPAGE MES running buffer (50mls 20X running buffer (Fisher Scientific, 
Loughborough, UK, catalogue NP0002-02) using the method described above in 
Appendix 8. A sample of brain homogenate prepared in 2% N-Laurosarcosine/PBS 
and digested with 50g/ml PK at 37ºC for 1h, was separated alongside the NaPTA 
precipitated peripheral tissue samples and the NaPTA precipitated positive and 
negative controls.  After electrophoresis, the separated proteins were electrotransferred 
onto Immun-Blot PVDFTM membrane, (Bio-Rad, Hemel Hempstread, UK 1620177) 
using the method described above in Appendix 8.  
 
12.3. Immunoblotting for PrPres following NaPTA precipitation 
To block non-specific binding sites the PVDF membrane was incubated overnight at 
4°C in 5% non-fat dried milk powder (from a supermarket) made up in Tris Buffered 
Saline (Sigma-Aldrich, Poole, UK, catalogue T5912) containing 0.1% 
(volume/volume) Tween 20 (Sigma-Aldrich, Poole, UK, catalogue P2287). The latter 
is referred to here as TBS-T. Since non-CNS tissues from CJD patients contain only 
low levels of PrPSc, the immunoblotting technique was designed to maximise 
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sensitivity. All wash steps were 5min using TBS-T. All washing and antibody 
incubation steps were performed on a shaking platform set at 100 rpm. After blocking, 
the membranes were washed three times and probed for 1h with a 1:10,000 dilution of 
anti-PrP antibody 3F4 (Millipore, Watford, UK, catalogue MAB1562, final 
concentration: 200ng/ml). After a further three washes the membrane was probed with 
a 1:25,000 dilution of Amersham ECL Mouse IgG, HRP-linked F(ab')₂ fragment (from 
sheep) (GE Healthcare Life Sciences, Little Chalfont, UK, catalogue NA9310-1ML) 
for 1h at room temperature. The membrane was then washed five times and treated 
with SuperSignal™ West Femto Maximum Sensitivity Substrate (Fisher Scientific, 
Loughborough, UK, catalogue 34095) according to the manufacturer’s instructions. 
The membrane was then developed by exposure to Amersham Hyperfilm ECL (GE 
Healthcare, Little Chalfont, UK, catalogue 28906835), for periods of time up to 3min. 
Alternatively, the images from the membrane were recorded using the ChemiDoc™ 
XRS+ System with Image LabTM Software (Bio-Rad, Hemel Hempstead, UK, 
catalogue 170-8265), for periods of time up to 30min.   





Appendix 13. RT-QuIC protocols 
 
13.1. Preparation of brain homogenates for use as seeds in RT-QuIC 
Samples of frozen grey matter enriched cerebral cortex samples were weighed and 
placed into Lysing matrix D tubes (Fisher Scientific, Loughborough, UK, catalogue 
MB116913050). These samples were homogenised in phosphate buffered saline (PBS) 
(Sigma-Aldrich, Poole, UK, catalogue 11666789001) containing 1mmol  EDTA 
(Sigma Aldrich, Poole, UK, catalogue 03690-100ML), 150mmol NaCl (SAFC 
Biosciences, Irvine, U, catalogue 59222C) 0.5 % Triton X-100 (Sigma-Aldrich, Poole, 
UK, catalogue X100) and cOmpleteTM Mini EDTA-free protease inhibitor cocktail 
(Roche Diagnostics, West Burgess, UK, catalogue 05892791001). An appropriate 
volume of homogenisation buffer was used to give a final tissue concentration of 10% 
(mass per volume). The tissue was homogenised in a Fastprep-24 homogeniser (MP 
Biomedicals, Santa Ana, CA, USA, catalogue 116005500) at room temperature using 
one cycle of 45sec at a speed of 6ms-1. Cellular debris was cleared from the 
homogenates by centrifugation at 5200g at 4°C using a microcentrifuge (Eppendorf 
AG, Stevenage, UK, catalogue 5417R) with a fixed angle motor (Eppendorf AG, 
Stevenage, UK, catalogue F-45-30-11).  Prior to the use of these samples as seeds in 
RT-QuIC, further serial ten-fold dilutions of the cleared homogenates were made using 
PBS. The equivalent masses of brain contained within these ten-fold dilutions are 
shown in the Table below.  
 




Equivalent wet mass of brain (g) 
per microlitre (l) 
1 10-1 10-4 
10-1 10-2 10-5 
10-2 10-3 10-6 
10-3 10-4 10-7 
10-4 10-5 10-8 
10-5 10-6 10-7 




13.2. RT-QuIC reaction setup 
The method used for the RT-QuIC was the one described previously by Peden et al. 
(Peden et al., 2012, 2014) with minor modifications. Full length hamster (Meocricetus 
auratus) recombinant PrP (recPrP, amino acids 23–231; GenBank accession no. 
K02234) was used as a substrate for seeded conversion. Hamster recPrP was used as 
this substrate has been shown to detect brain PrPSc from CJD patients with greater 
sensitivity and specificity compared with human recPrP substrate (Peden et al., 2012). 
This recPrP was obtained from the Bristol Institute of Transfusion Sciences, Bristol, 
UK. The method used by Bristol for the expression and purification of recPrP in 
Escherichia coli was as described previous by Wilham et al. (Wilham et al., 2010). 
Aliquots of frozen recPrP were thawed at room temperature and then 500µl batches 
were filtered through a 100kDa Nanosep centrifugal concentrator (VWR International, 
Lutterworth, UK) at 3000g for 20min. The concentration of recPrP was determined by 
diluting samples 1:10 in PBS containing 0.1% sodium dodecyl sulphate (SDS). The 
absorbance was measured at 280nm in an Ultraspec 3000 (GE Healthcare, Little 
Chalfont, UK, catalogue 80-2116-30). After multiplying by the dilution factor, the 
concentration of recPrP was calculated using an extinction coefficient of 2.6 l/g cm-1. 
 
The 100l RT-QuIC reactions were set up in quadruplicate in the wells of a clear-
bottomed black 96-well microplate (Fisher Scientific, Loughborough, UK, catalogue 
15142799). Stock solutions containing the reaction components were filtered through 
0.22M MillexTM PES filters (Millipore, Watford, UK, catalogue SLGP033NB). A 
master mix containing all reaction components except the brain seed was prepared, 
with recPrP being added last. The recPrP was the final addition to the master mix, 
which was mixed by gently inversion of the container tube. This master mix was then 
dispensed into the wells of the 96-well plate as 98l volumes. The RT-QuIC reactions 
were initiated by the addition of 2l of a dilution of 10% (w/v) homogenate. For the 
determination of lag times as a measure of seeding potential 2l of a 10-3 fold dilution 
of the 10% (mass per volume) homogenate was added to the wells (see Lag time as a 
measure of seeding below). This amount is equivalent to 2x10-7g brain (wet mass) per 
100l reaction (Table 4.5). After adding this volume of diluted brain homogenate, the 
final reactions contained PBS, 324mmol NaCl (including the NaCl present in PBS), 
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1mmol EDTA, 10mmol ThT, 1x10-7% TritonTM X-100 and 0.1 mg/ml recPrP. In 
contrast to the method given in Peden et al. (Peden et al., 2012), no SDS or N-2 
Supplement was added, as improved specificity can be achieved when these 
components are omitted. 
 
13.3. Quaking conditions and real-time fluorescence readings  
The plates were sealed with film. The sealed 96-well plates were incubated at 42◦C 
and shaken intermittently (87sec of shaking at 900 rpm in a double orbital 
configuration followed by 33sec of rest) using a FLUOstar Omega microplate reader 
(BMG Labtech Ltd, Bucks, UK, catalogue 1524782). Fluorescence readings were 
taken at 480 nm every 15min from the clear bottoms of the wells after excitation of 
each well with 20 flashes at 450nm.  
 
13.4. Lag time as a measure of seeding 
In order to quantify prion seeding efficiency we used a method based on the one 
described by Shi et al (Shi et al, 2013). In this method, the lag time to conversion is 
used as an inverse measure of seeding potential, (i.e. a shorter lag time to conversion 
corresponds to greater seeding efficiency). The lag period to the start of conversion 
was defined as the time (in hours (h)) from the start of the assay to when the RT-QuIC 
fluorescence reading was three times the baseline. The baseline for each RT-QuIC 
reaction was taken to be the mean reading (for at least four replicate reactions) at 0.5h. 
A lag period was thus obtained for each replicate reaction and a mean lag period for 
each patient sample was calculated.  
 
A preliminary analysis was conducted to determine the relationship between seed 
dilution and lag period. Brain homogenates (10%) from sCJD and iCJD patients were 
serially diluted in PBS by factors of 10-2, 10-3, 10-4, 10-5 and 10-6 (see below). Samples 
(2l) of these serial dilutions were introduced into the RT-QuIC reactions. Analysis of 
these RT-QuIC reactions concluded that differences in seeding efficiency between 
iCJD and sCJD subgroups could best be discriminated by seeding RT-QuIC reactions 
with 2l of a 10-3 dilution of 10% brain homogenate.  
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Appendix 14. PMCA protocol 
 
14.1. Sample preparation 
Normal brain homogenates from humanised transgenic mice (HuTg) of the PRNP 
codon 129 methionine homozygous (129MM), valine homozygous (129VV) and 
methionine/valine heterozygous (129MV) genotypes (Bishop et al., 2006) were 
prepared using a manual homogeniser (KONTES Potter-Elvehjem Tissue Grinder 
17ml, VWR International, Lutterworth, UK, catalogue 885500-0023) and conversion 
buffer composed of phosphate-buffered saline 1X (Sigma-Aldrich, Poole, UK, 
catalogue D8537), 150mmol NaCl (Sigma-Aldrich, Poole, UK, catalogue S3014-
500G), 1% Triton X-100 (Sigma-Aldrich, Poole, UK, catalogue T9284-100ml) and 1X 
protease inhibitors ((Roche Diagnostics, West Burgess, UK, catalogue 11697498001), 
to obtain a final 10%  mass per volume solution (termed a PMCA “substrate”). The 
homogenised tissue was cleared by centrifugation at 2000 rpm for 40sec in a 
refrigerated centrifuge (4°C), and the supernatant was aliquoted and stored at −80°C. 
The sCJD and iCJD brain homogenates (termed PMCA “seeds”) were prepared 
following the same method used for substrate preparation 
  
14.2. PMCA method 
Aliquots of 10% brain homogenate substrate were mixed with 10% CJD brain 
homogenate seeds in PCR tubes. Low molecular weight heparin (Heparin Sodium, 
Cambridge Bioscience, Cambridge, UK, catalogue H1658) was added at 100μg/ml for 
all PMCA reactions. Prior to the amplification procedure, 19μl of the PMCA reaction 
mixture was taken (from the final volume of 120μl) for each reaction (referred to as 
the “frozen” sample) for comparison with the sonicated samples (referred to as the 
“sonicated” sample). Amplification employed cycles of sonication and incubation in a 
programmable sonicator (Qsonica, Newtown, USA, model Q-700) at 37°C. A total of 
96 PMCA cycles were performed comprising 20sec of sonication (at an amplitude of 
38%, wattage: 275-300) followed by 29min 40sec of incubation for each cycle. Frozen 
and sonicated samples were digested with proteinase K (Roche Diagnostics, West 
Burgess, UK, catalogue 03115828001), in a final concentration of 50µg/ml at 37˚C for 
1h and analysed by Western blotting using the anti-PrP monoclonal antibody 3F4 
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(Millipore, Watford, UK; Product: MAB1562). Amplification efficiency was 
expressed as the increase in PrPres signal in the sonicated compared to the frozen 
sample. 
 
14.3. Western blotting analysis – PMCA products 
Samples were boiled at 100°C for 10min and centrifuged at 2000 rpm for 10sec 
(Eppendorf AG, Stevenage, UK, catalogue 5417R). The samples were loaded into the 
wells of a NuPAGE Novex 10% Bis-Tris Gel 1.0mm, 10 well (Fisher Scientific, 
Loughborough, UK, catalogue NP0301BOX) and electrophoresed at 200V for 55min 
in NuPAGE MES SDS Running Buffer (Fisher Scientific, Loughborough, UK, 
catalogue NP000202). 
 
Proteins were transferred to a polyvinylidene difluoride membrane (PVDF) (Bio-Rad, 
Hemel Hempstead, UK, catalogue 1620177) using 800 mA (constant) for 1h. The 
PVDF membranes were blocked with 2% milk for 1h followed by incubation with the 
anti-PrP monoclonal antibody 3F4 (Millipore, Watford, UK, catalogue MAB1562) 
diluted in 1X Tris-buffered saline with 0.05% Tween 20 (Sigma-Aldrich, Poole, UK, 
catalogue P9416) (TBS-T) in a dilution 1:10,000. Blots were rinsed 3 times (10min 
each time) with 1X PBST (washing buffer). Amersham ECL Anti-mouse IgG, 
peroxidase-linked species specific F(ab')2 fragment (from sheep) (GE Healthcare Life 
Sciences, Little Chalfont UK, catalogue NA9310-1ML) was used as a secondary 
antibody diluted 1:25,000 in washing buffer and incubated for 1h. Finally, blots were 
rinsed 3 times for 10min each with washing buffer to eliminate any excess of 
secondary antibody. Membranes were developed using the Amersham ECL-Prime 
luminescent peroxidase detection reagent (GE, Little Chalfont, UK, catalogue 
RPN2232). Image of the WB were acquired using the XRS digital CCD camera system 
(Bio-Rad, Hemel Hempstead, UK, catalogue 1708265SP). 
 
14.4. PMCA normalisation and quantification 
To estimate the PMCA amplification efficiency, PrPres densitometric signals (after PK 
treatment and Western blotting) were calculated using the Image Lab software 2.0.1 
(Bio-Rad, Hemel Hemptsead, UK, catalogue 1709692). The densitometric value of the 
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intensity of PrP immunoreactive bands was calculated for the samples before and after 
PMCA measuring an equal designated area (number of pixels). To obtain a better 
comparison between samples, background subtraction was performed. The 
densitometric values of “sonicated” samples were divided by the “frozen” measures. 
The increase in signal (the ratio between the detectable levels of PrPres before and after 
PMCA) was designated as the amplification efficiency of the in vitro PMCA 
conversion. 
 
14.5. Densitometric Analysis 
Densitometric analyses were performed using Image Lab software version 2.01 (Bio-
Rad, Hemel Hempstead, UK, catalogue 1709692). All images were captured using a 
charge-coupled device (CCD camera HQ2, Bio-Rad, Hemel Hempstead, UK, 
catalogue 1708255) and saved in TIFF format for further analysis. Densitometric 
analysis of relative band intensity was performed assuming a linear range for the PrP 
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